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Abstract
Background
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune 
disease. It has protean clinical manifestations making it difficult to diagnose. 
This thesis is an investigation of the utflity of the General Practice Research 
Database (GPRD) for the study of SLE epidemiology and management.
Methods
A number of studies have been conducted to describe the epidemiology of 
SLE in the UK between 1992 and 1998 as well as a case-control study of its 
presentation and a descriptive analysis of its management.
Results
Cases of SLE can be identified from the GPRD population based on a 
diagnosis of SLE with evidence of treatment in hospital and/ or long term 
therapy consistent with SLE. Incidence was 3.8/100,000/year and highest in 
women aged 30-69 years, challenging the traditional description of SLE as a 
disease of 'women of childbearing age'. Prevalence increased from 1992 to 
1998 which was an artefact resulting from the relapsing-remitting nature of 
this disease. The SMR for SLE was 1.83. Women aged 20-29 had a 17-fold 
risk of death compared with the general population. SLE patients had more
m
musculoskeletal and cutaneous symptoms than individuals in the general 
population for five years before diagnosis. A model has been developed that 
might be useful for the earher recognition of SLE. Management of SLE was 
consistent with previous studies other than the use of combined oral 
contraceptives, which did not change following diagnosis as would be 
expected from the prescribing guidelines.
Conclusions
The GPRD is more reHable for the identification of incident than prevalent 
cases of SLE. SLE remains a disease that is difficult to diagnose in primary 
care; general practitioners should be made more aware of the insidious onset 
of SLE and its frequency in women of peri- and postmenopausal age.
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Introduction to the Thesis
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1 Introduction to the thesis
I first became interested in systemic lupus erythematosus (SLE) ten years ago 
when my partner at the time, who was a senior house officer in Liverpool, 
came home and proudly announced that he had diagnosed a patient of his 
with SLE. He went on to tell me about how difficult SLE was to recognise 
and diagnose and 1 found this fascinating.
When 1 joined the Department of Pharmacoepidemiology at the 
University of Surrey 1 was involved in conducting studies of the risk of 
stroke and venous thrombosis in women using combined oral contraceptives 
(COCs). It was at this time that 1 once again came across SLE. In these 
projects, we excluded women who had SLE because of their increased risk of 
stroke and VTE and because SLE is listed as a contraindication to the use of 
COCs in the British National Formulary. When 1 started to develop the 
protocol for my PhD appHcation, 1 was interested in assessing whether or not 
women with SLE used COCs to determine whether or not the prescribing 
guidelines were adhered to. It became clear from discussions with clinicians 
that in fact women with stable SLE were commonly prescribed COCs. When 
this study was conducted (Chapter 11), 1 found that women with SLE did not 
stop using COCs at time of diagnosis and had utiHsation rates similar to that 
of women in the general population of the UK. This was not consistent with 
reports of COC utilisation in the USA and continental Europe. 1 had 
originally planned to conduct a study to investigate the safety of oral
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contraceptives in terms of whether the risk of SLE flare and thrombotic 
events was higher among women using COCs compared with those not 
using COCs. For this study 1 planned to develop a methodology of 
identifying exacerbations ('flares') using the General Practice Research 
Database (GPRD) and then compare the incidence rates of flare in women 
with SLE using COCs with that of women not using COCs. After some 
initial investigations and a preliminary review of the Hterature 1 concluded 
that that this proposed study would not only be inaccurate based on the data 
that were available in the GPRD (see chapters 4 and 12) in terms of the 
identification of flares but that the study would be superseded by a 
randomised controUed clinical trial that was being conducted to address this 
issue of the safety of oestrogens in women with SLE in the USA, SELENA 
(Safety of Estrogens in Lupus Erythematosus; National Assessment). For 
these reasons, 1 decided not to proceed with this study.
Whilst conducting the study of the use of systemic hormonal 
contraceptives in women with SLE 1 made two observations of SLE patients 
using GPRD data that merited further investigation. The first observation 
was that there was an apparent increase in the prevalence of SLE between 
1992 and 1998 (Chapter 8). This observation was surprising and not 
consistent with any of the published studies of the epidemiology of SLE. 
Increasing prevalence of disease is caused by increasing incidence or 
survival, or a combination of both. In order to investigate the increasing 
prevalence 1 calculated the annual incidence and mortahty rates of SLE in the
16
GPRD population (Chapters 7 and 9). 1 found that incidence and mortahty 
rates did not change over the time period and that the apparent increase in 
prevalence was an artefact caused by the way in which it had been necessary 
to identify and confirm the cases of SLE from the GPRD. The importance of 
this finding is that this artefact would occur in any study of chronic 
relapsing-remitting disease using longitudinal databases of medical records. 
When 1 calculated the mortahty rates of patients with SLE compared with the 
general population of the GPRD, the standardised mortahty rate (SMR) was 
1.5. This was consistent with recent studies of mortahty in SLE. In most 
studies of mortahty in SLE, the SMR is presented without further data 
regarding age-specific mortahty rate ratios. 1 found that although the overall 
SMR was 1.5, this summary of mortahty obscured a finding that younger 
patients with SLE were 17 times more likely to die than those in the general 
population of the same age and that this risk decreased with increasing age 
(Chapter 9).
The second observation was made during the process of case 
identification which involved detailed review of the medical records of each 
potential case of SLE. It seemed that in many cases, there were numerous 
symptoms that might be attributable to SLE for months or years before their 
diagnosis (Chapter 6). It was at this time that 1 had a telephone conversation 
with Brian Hanner, who was the Director of Lupus UK (a patient support 
charity) regarding our finding of increasing prevalence. During this 
conversation he said that although the management of SLE was improving
17
rapidly, the main problem with the treatment of SLE was in the early 
recognition disease by general practitioners. Early recognition of SLE might 
lead to earher treatment of the disease process rather than symptom 
management which should decrease irreversible organ damage. We 
hypothesised that using primary care data we would be able to describe the 
presentation of SLE in general practice and to develop age- and sex-specific 
symptom profiles of the presentation of SLE that might help to guide GPs to 
earlier referral of these patients. SLE is a disease that is managed in 
secondary care and therefore nearly all studies of patients with SLE are 
conducted at specialist centres rather than in general practice (Chapter 10).
In Chapter 2,1 have given a brief overview of SLE. SLE is a complex 
disease with many clinical and immunological features. Its aetiology is 
unknown but many causes and risk factors have been investigated. This 
thesis is an investigation of the epidemiology of SLE in primary care in the 
UK and for this reason; 1 have limited my overview to the epidemiology of 
SLE rather than its aetiopathology.
Appendix 1 contains a list of my pubHcations since 1 was registered on 
my PhD in January 2000 and reprints of published papers and conference 
abstracts from the thesis.
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Chapter 2
Overview of Systemic Lupus Erythematosus
19
2 Overview of systemic lupus erythematosus
The first sentence of virtually all papers reporting clinical research into SLE 
begins with a description of the disease that is a permutation of the following 
description: Systemic lupus erythematosus is a chronic, inflammatory, multi­
system autoimmune disease of unknown aetiology. Its clinical manifestations are 
protean and it has a relapsing-remitting course of disease activity. It affects mainly 
women of childbearing age and is more common in those of non-Caucasian ethnic 
origin.
In this chapter 1 wiQ expand on this description. The chapter is not 
intended to be an in-depth review of aU aspects of SLE as this is a complex 
disease that spans many scientific disciplines. The thesis is a epidemiological 
investigation of the presentation and management of SLE in primary care 
and therefore, 1 wiU describe the clinical aspects of SLE that are of relevance 
to these studies.
2.1 The history of SLE diagnosis
The term lupus (Latin for "wolf") was first used to describe the cutaneous 
lesions of SLE in the 12^  ^Century by Rogerius Frugardi, who described lupus 
as an ulcer-hke condition. Later, in the 16*^  Century Paracelsus (1493-1541) 
documented the skin disease lupus and recognised it as different from 
herpes, fistulae and from cancer (Wallace 1999a).
20
Figure 2.1. Lupus Erythematosus from Von Hebra "Atlas of Skin Diseases" 
1856 (source: Wikipedia)
The cutaneous lesions of lupus were 
described by Thomas Bateman (1778 -  1821), 
Pierre Cazenave (1795-1877) and Moriz 
Kaposi (1837 -1902). Kaposi was the son-in- 
law of dermatologist Ferdinand von Hebra 
(1816-1880) (Smith 1988). It was Von Hebra 
who first published illustrations of the 
characteristic malar rash and who introduced the term ^butterfly rash.'
$4
The recognition of systemic disease associated with the lupus rash is usually 
credited to Moriz Kaposi who, in 1872 described the two distinct forms of 
lupus erythematosus (LE): discoid LE and disseminated LE (Lahita 1999a). 
However, in their paper reviewing the work of Cazenave, Wallace and Lyon 
(Wallace 1999a) translated Cazenave's report that he published in 1856. In 
this, Cazenave observed that the skin lesions were also associated with fever, 
hypertension, pain, photosensitivity and hair loss. It was also at this time 
that the female predominance of SLE was noted and the hormonal aspects of 
SEE development were first suspected (Wallace 1999a). Cazenave observed 
that lupus was most common in young women leading to the traditional 
depiction of SLE as a disease of 'women of childbearing age'. He also noted 
that it frequently occurred after pregnancy and was exacerbated by poor
21
hygiene. He also proposed a hereditary component to SLE and in 1850 gave 
the name Tupus érythémateux' to the disease (Wallace 1999). Further and 
more detailed observations on the systemic nature of lupus were made by 
William Osier (1849-1919) between 1895 and 1903. He described many 
aspects of SLE that are consistent with current knowledge of the disease 
(Benedek 1997).
The most important findings with regards to the recognition of 
autoimmunity as a mechanism for SLE were in 1910 when Hauck 
documented that the test for syphilis was positive in patients with SLE and 
by Malcolm Hargreaves, Robert Morton and Helen Richmond in 1948 who 
described the LE cell phenomenon (Hepburn 2001). The LE cell phenomenon 
was later reported to be caused by a serum factor that reacted with the 
nuclear material in the leucocytes, the antinuclear factor (Hepburn 2002).
2.2 SLE: an inflammatory autoimmune disease of unknown 
aetiology
The immune system is comprised of a number of physical, mechanical, 
cellular and chemical factors that act together to ensure that the body is 
protected against infection and disease (Kumar 1998). Within the body's 
ability to recognise 'non-self' so that an immune response can be triggered 
against foreign antigens lies the inherent need to recognise and not react 
against 'self'. This is known as 'self tolerance' and is achieved through the
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expression of Human Leucocyte Antigens (HLA) on the surface of each cell 
of the body. HLA haplotypes are specific to each individual and are 
generated by the genes of the Major Histocompatibility Complex (MHC) 
(Kumar 1998). In autoimmune diseases, self-tolerance is broken and the 
immune system mounts and autoimmune response. In SLE, autoantibodies, 
cytokines and circulating immune complexes are formed as part of this 
response causing tissue damage either by direct action on tissues or as a 
result of the inflammatory response to their presence (Amital 1999). 
Autoimmune diseases are characterised by the presence of autoantibodies 
and can be limited either to a particular organ system such as Grave's disease 
which is isolated to the thyroid and Type 1 diabetes meUitus which is 
isolated to the pancreas, or multi-system where many organs can be involved 
such as SLE, rheumatoid arthritis and Sjogren's syndrome (Amital 1999). The 
clinical manifestations of SLE are discussed in detail throughout the thesis. 
Rheumatoid arthritis affects the joints, lungs, skin and pericardium; Sjogren's 
syndrome affects the exocrine glands most often resulting in dry eyes and /  
or dry mouth (Amital 1999).
Although the exact aetiology of SLE is unknown, it is known that it is 
multi-factorial and complex, and is influenced by genetic, environmental and 
hormonal factors (Mason 1998, Amital 1999, Cooper 2000a). Alaron-Sergovia 
(1999) used the Troika analogy to describe the way in which different 
mechanisms interact to result in SLE. This analogy is summarised briefly in 
section 2.2.1.
23
2.2.1 Troika analogy (Alaron-Sergovia 1999)
The "Troika is a three-horse Russian carriage, where each horse pulls 
independently but concertedly to make it go" (Alaron-Sergovia 1999 p55). 
The first Troika is aetiology, the second aetiopathogenesis and the third 
pathogenesis (Alaron-Sergovia 1999). Figure 2.2 is a diagrammatic sununary 
of this analogy.
2.2.1.1 The first troika: aetiology
The first troika, aetiology has genetic, environmental and hormonal factors. 
Evidence of genetic susceptibility to SLE comes from epidemiological and 
genetic studies of SLE. Epidemiological factors indicating genetic 
susceptibility include the increased risk of SLE in women and in those of 
non-Caucasian ethnicity, particularly those of Afro-Caribbean origin (Mason 
1998, Cooper 1998, Petri 2002). In twin concordance studies of SLE, 
monozygotic twins have been reported to have between 24% and 58% 
disease concordance and in dizygotic twins it is between 2% and 5% (Tsao 
2003). In Caucasians, SLE has been associated with the expression of HLA- 
A l, HLA-B8, HLA-DR2 and DR3 (Fronek 1990, Mason 1998, Tsao 2003) but 
these associations are less well established in other ethnic groups (Tsao 2003).
The genes that have been associated with increased susceptibility to 
SLE are those associated with the production of complement; those that 
control the thresholds at which the B and T lymphocytes are activated and
24
those that control the way in which the inflammatory process is expressed in 
different organs (Robson 2001).
The role of endogenous oestrogens in SLE is illustrated most 
pertinently by the predominance of the disease in females (see Chapters 5, 7 
and 8). There is little evidence, however, that duration of oestrogen exposure 
is responsible for the development of SLE as there is little evidence of 
association between SLE and early menarche or late menopause (Cooper 
1998). Other indicators to the role of oestrogens in SLE come from the 
increased incidence of SLE in males with Klinefelter's syndrome (Talal 1981) 
and from evidence of abnormal oestrogen and androgen metabolism in 
patients with SLE (Lahita 1992). It is known that oestrogens act to enhance 
many aspects of the immune response (Lahita 1992). AbnormaHties in the 
metabolism of oestrogens and androgens in women with SLE lead to 
decreased androgen levels and increased levels of the more femimsing 
metabolites of oestrogen (Lahita 1999b). The combination of these 
abnormities results in higher levels of circulating unopposed oestrogen in 
women with SLE compared to women without SLE. Current theories suggest 
that these abnormahties in SLE patients lead to an increase in T and B cell 
activity which might lead to autoimmunity (Kyttaris 2005). In murine 
models of SLE, female Fi hybrid New Zealand (NZ) black (B) x NZ White 
(W) mice are shown to be adversely affected by oestrogens and protected by 
androgens (Walker 1997).
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Figure 2.2 Diagrammatic representation of the 'Tale of three troikas' (Alaron- 
Sergovia 1999)
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There have been a number of case reports of the onset of SLE shortly after 
starting combined oral contraceptives (COCs) (Travers 1978, Garovich 1980, 
Todd 1985, Julkxmen 1991) although most case-control studies of the risk 
factors for SLE have not demonstrated an association with the use of COCs 
or postmenopausal hormone replacement therapy (Strom 1994, Sanchez- 
Curerreo 1995, Sanchez-Cuerrero 1997, Meier 1998, Cooper 2002b). I have 
conducted a study of the utilisation of systemic hormonal contraceptives in 
women with SLE and this is reported in Chapter 11.
Environmental factors that influence the aetiology of SLE have been 
the subject of much discussion and investigation. Ultraviolet light 
undoubtedly has a role in the onset and exacerbation of SLE, with 
photosensitivity being a symptom that is included in the American College 
of Rheumatology (ACR) classification criteria for SLE (Tan 1982, see section 
2.3, Mason 1998, Mok 2003). Occupational and environmental risk factors 
that have been reported to be associated with an increased risk of developing 
SLE include crystalline silica (quartz), solvents, pesticides, smoking and the 
use of hair dye (Cooper 2004). Exposure to silica dust has been strongly 
associated with the development of SLE in a number of studies and a dose- 
response relationship has been demonstrated (Cooper 2004). Other exposures 
that have been associated with the onset of SLE or that lead to lupus-like 
syndromes are alfalfa spouts and over 70 drugs (Yung 1999) including some 
antihypertensives, antibiotics containing sulpha, anticonvulsants and anti­
inflammatory agents such as sulfasalazine and gold.
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It should be noted here that there is a difference between SLE as an 
autoimmune disease that has been triggered by environmental or drug 
exposures and lupus-like syndromes associated with drug exposure. Drug- 
induced lupus (DIL) is an aetiologically different disease to SLE. Although 
many symptoms are similar to SLE, they tend to be mild and always resolve 
on removal of the particular exposure (Lunec 2000).
2.2.1.2 The second troika: aetiopathogenesis
Several abnormalities of the immune system occur which lead to the 
production of autoantibodies, immune complexes and result in tissue 
damage (Amital 1999). Firstly, there are decreased levels of complement 
proteins which are responsible for the mechanisms by which foreign 
organisms and antibodies are removed. This deficiency occurs either by the 
binding of complement proteins to immune complexes or because of 
hereditary or congenital abnormalities of the complement cascade (Cook 
1999). Secondly, there are abnormalities in the production of B and T 
lymphocytes. B lymphocytes are over activated, leading to an increased 
release of autoantibodies. At the same time there is under activity of T 
lymphocytes in suppressing the activity of the B lymphocytes and an 
increase in the T lymphocyte helper functions to B lymphocytes (Mok 2003). 
Cytokines are responsible for the regulation of the immune system and are 
released by T lymphocytes. Cytokine production is abnormal, which leads to 
abnormalities of the regulation of the immune system. In SLE, cytokines are
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typically elevated, which increases the activity of the immune cells (Amital 
1999). Thirdly, there is an increased or decreased rate of apoptosis, which is 
programmed cell death. Increased apoptosis leads to decreased circulating 
lymphocytes, platelets and monocytes whilst decreased apoptosis leads to a 
an accumulation of immune complexes (Tsokos 1999). It also results in 
increased presence of nuclear materials which can act as antigens to the 
stimulation of autoantibody production by B lymphocytes (Tsokos 1999). The 
net effect results in the presence of high levels of autoantibodies, many of 
which are reactive with nuclear material, which cannot be cleared from the 
body due to deficiencies in the complement pathways that are responsible 
for moderation of abnormal cell clearance.
2.2.1.3 The third troika: pathogenesis
As a result of the dysregulation of the immune system and under the 
influence of genetic, hormonal or environmental factors, a large number of 
autoantibodies are produced by patients with SLE (Tsokos 1999). These 
autoantibodies act in a number of ways to cause organ damage leading to the 
clinical symptoms of active SLE. For reasons not yet fully understood, 
specific autoantibodies (e.g. anti-dsDNA) result in different clinical 
symptoms in different individuals. Organ damage in SLE is caused by three 
main mechanisms: immune-complex mediated damage and damage caused 
directly or indirectly by the autoantibodies (Alarôn-Segovia 1999).
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Circulating immune complexes are formed in patients with SLE consisting of 
antigens and antibodies. Immune-complex mediated damage leads to 
nephritis, vasculitis, pulmonary haemorrhage, and central nervous system 
involvement (Alaron-Segovia 1999). Many of the haematological features of 
SLE such as haemolytic anaemia, thrombocytopaenia and neutropaenia are 
due to the direct action of the autoantibodies on the cells of the circulatory 
system. An example of indirect, or functional, damage caused by 
autoantibodies is that the presence of antiphosphoHpid antibodies leads to a 
thrombophihc state in around 50% of patients with SLE (Alaron-Segovia
1999).
2.3 SLE: a multi-system disease with protean manifestations
The clinical presentation of SLE varies from patient to patient and 
subsequently, it is a disease that is difficult to diagnose. It has been referred 
to as 'the great mimic' (Chng 2001) because its symptoms overlap with those 
of many other autoimmune diseases such as rheumatoid arthritis, Sjogren's 
syndrome, fibromyalgia and mixed connective tissue disease (Lahita 1999c). 
SLE can affect any organ system of the body. Damage to organs is caused by 
the deposition of immune-complexes and by the direct or indirect action of 
autoantibodies and inflammation (see section 2.2, Amital 1999, Alarcon- 
Sergovia 1999). In this section I will briefly discuss the clinical 
manifestations, diagnosis and classification of SLE and its initial 
presentation. This discussion is of importance as it relates to the method in
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which cases of SLE have been identified and defined using the General 
Practice Research Database for aU studies within this thesis (see Chapter 5 for 
case identification).
2.3.1 Clinical manifestations of SLE
SLE can affect any organ system of the body but the most common clinical 
manifestations are constitutional, cutaneous and musculoskeletal (Lahita 
1999c). Table 2.1 shows the main clinical manifestations of SLE (Lahita 1999c, 
Haq 2002, DaU'Era 2003, Gill 2006). Figure 2.3 shows the characteristic malar 
(butterfly) rash of acute cutaneous SLE, Figure 2.4 shows discoid LE lesions.
Figure 2.3 Malar rash (source Medscape.com 408846-6)
Figure 2.4 Discoid lupus erythematosus rash (source: health-pictures.com)
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2.3.2 Diagnosis of SLE
The fact that SLE has such varied manifestations that mimic and overlap 
with other diseases often leads to misdiagnosis of diseases such as 
rheumatoid arthritis and fibromyalgia, and the labelling of the patient as a 
hypochondriac or as needing psychiatric treatment (Lahita 1999c, Hughes
2000). The time from first symptom of SLE to diagnosis has been reported in 
a number of studies (Maddison 1987, Hopkinson 1994, Jacobsen 1998a, 
Thumboo 2001, Ozbek 2003) and ranges from 10 weeks (Thumboo 2001) to 
11.9 years (Thumboo 2001). Studies that calculate the time from symptom 
onset are complicated as they are not consistent in the way in which 
'symptom onset' is defined. Some studies define symptom onset as the time 
that the first American College of Rheumatology (ACR) classification criteria 
for SLE (Tan 1982, Hochberg 1997, see section 2.3.3) is experienced (Thumboo
2001) whereas others define symptom onset as any symptom that could be 
attributable to SLE (Hopkinson 1994). Moreover, date of diagnosis is usually 
defined as the date on which the 4* ACR criterion manifests (Hopkinson 
1994, Costallat 1994, Thumboo 2001). A full discussion of the ACR criteria 
for the classification of SLE (Tan 1982, Hochberg 1997) follows in section 2.3.3 
but it is clear that the time of clinical diagnosis of SLE and fulfilment of the 
ACR criteria are different. It can take a patient many months or years from 
the time of their clinical diagnosis of SLE to fulfil at least 4 of the 11 criteria
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(Petri 2004). Therefore, it is possible that the time from first symptom to 
'diagnosis' as reported in most of these studies is not representative of the 
time it actually takes for the patient to be given a clinical diagnosis of SLE 
and commence therapy. Delay in diagnosis in SLE appears to be greatest in 
adults over the age of 50 (Maddison 1987, Antolin 1995, Ozbek 2003) and it 
has been suggested that this may result from the more insidious onset in 
older adults and the fact that SLE is almost always described as a 'disease of 
women of childbearing age'. (Maddison 2002).
The diagnosis of SLE is based on clinical features, physical 
examination and is supported through the use of blood and urine analysis 
(Hughes 2000, ACR Committee 1999). Patients with multi-systemic 
manifestations consistent with SLE (see section 2.4) with raised titres of 
antinuclear antibodies (ANA) (above 1:40) are referred to a rheumatologist 
who confirms or excludes a diagnosis of SLE (GUI 2003). Symptoms of SLE 
are discussed in section 2.3.3.
2.3.3 Classification of SLE
The ACR criteria for the classification of SLE were first pubHshed in 1971 
(Cohen 1971) and were revised in 1982 (Tan 1982). They were updated in 
1997 at which time two changes were made to the immunological disorder 
criterion (Hochberg 1997). These criteria were principally developed for use 
in a research rather than a clinical setting although they provide useful
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guidelines for rheumatologists by which to distinguish SLE from other 
connective tissue diseases (Hughes 2000). The current criteria are shown in 
Table 2.2. In order to be classified as a case of SLE, patients must fulfil at least 
4 of the 11 criteria. Table 2.3 shows a summary of the prevalence of the ACR 
criteria in various SLE populations; all defined using the ACR criteria. 
Patients who do not fulfil 4 criteria are normally referred to as having 'latent' 
or 'incomplete' lupus, and approximately one third will eventually become 
cases of SLE (Petri 2004). The 1982 criteria were found to be 96% sensitive 
and specific in classifying SLE (Tan 1982).
The classification criteria were developed for use in research rather 
than in the clinical setting. They were designed to ensure that SLE patients 
recruited to clinical studies were a homogenous group in terms of clinical 
disease and therefore the results of such studies could be compared directly 
(Petri 2004). However, the criteria have also been criticised (Smith 1999, Petri 
2004) for being biased towards cutaneous disease and excluding mild or 
early disease and severe disease that is limited to one organ system, e.g. 
lupus nephritis. The criteria were developed on a set of patients who had 
long-standing disease, and who were mainly Caucasians (Tan 1982). Bearing 
in mind that the prevalence of SLE is higher, with disease manifestations also 
tending to be more severe in those of Afro-Caribbean (Petri 1991), and to a 
lesser extent, Asian origin (Samanta 1991) when compared with Caucasians, 
the validity in developing a classification tool on a mainly Caucasian 
population could be questioned. Once a clinical diagnosis of SLE has been
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made, it might take many years for a patient to fulfil four or more of the ACR 
criteria (Petri 2002). This has impHcations in terms of the definition of 
'incident' disease, and the interpretation of studies that report time from first 
symptom to diagnosis. The time from first symptom to clinical diagnosis 
may be considerably shorter than the time from first symptom to fulfilment 
of the ACR criteria.
Although to date the majority of studies of the epidemiology of SLE 
have used the ACR criteria to define their cases, of particular interest is a 
recently published international multi-centre cohort study of mortaHty in 
SLE (Bernatsky 2006). This study was conducted in 20 centres from the USA, 
Canada, the UK, Sweden, Iceland and South Korea and consisted of 9546 
patients with SLE. The study was conducted by many high-profile 
researchers in SLE. The inclusion criteria for this study was either the 
fulfilment of 4 or 11 or a clinical diagnosis of SLE "whether or not 4 ACR 
criteria had been met" (Bernatsky 2006).
A number of alternative methods of classifying patients with SLE have 
been developed since the 1982 criteria were published (Tan 1982). Clough 
(1984) and Costenbader (2002) developed weighted criteria for SLE. These 
criteria allow patients with severe manifestations without evidence of 
extensive multisystem disease (e.g. patients with lupus nephritis) to be 
classified as 'cases' of SLE. Additionally, two classification trees for SLE were 
developed by Edworthy (1988). Firstly, a simple tree based on the presence 
or absence of immunologic disorder (as defined in the ACR criteria, table 2.2)
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and the presence or absence of malar rash; these items were found to be the 
most accurate criteria in the classification of SLE. The simple tree was found 
to have 92% sensitivity and specificity in the classification of SLE. The 
second (full) tree is shown in Figure 2.2. The sensitivity of the full tree was 
97% and the specificity was 95%.
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Table 2-2. The American College of Rheumatology criteria for the
classification of SLE (Reproduced from Lahita 1999 c)
Criterion Description
Malar rash
Discoid rash
Photosensitivity
Oral ulcers 
Arthritis
Serositis 
Renal disorder
Neurological
disorder
Haematological
disorder
Immunologic
disorder
ANA
Fixed erythema, flat or raised, over the malar eminence, tending to spare the 
nasolabial folds
Erythematous raised patches with adherent keratotoic scaling and follicular 
plugging; atrophic scarring may occur in older lesions
Skin rash as a result of unusual reaction to sunlight by patient history or 
physician observation
Oral or nasopharyngeal ulceration, usually painless, observed by a physician
Nonerosive arthritis involving two or more peripheral joints, characterised by 
tenderness, swelling or effusion
(a) Pleuritic: convincing history of pleuritic pain or rub heard by 
physician or evidence of pleural effusion OR
(b) Pericarditis: documented by ECG or rub or evidence of pericardial 
effusion
(a) Persistent proteinuria greater than 0.5g per day or greater than 3+ if 
quantifications are not performed OR
(b) Cellular casts : may be red cell, haemaglobin, granular, tubular or 
mixed
(a) Seizures in the absence of offending drugs or known metabolic 
derangement; e.g uremia, ketoacidosis, or electrolyte imbalance OR
(b) Psychosis: in the absence of offending drugs or known metabolic 
derangement; e.g uremia, ketoacidosis, or electrolyte imbalance OR
(a) Haemolytic anaemia: with reticulocytosis OR
(b) Leucopaenia: less than 4,000/mm3 total on two or more occasions OR
(c) Lymphopaenia: less than 1,500/mm  ^on two or more occasions OR
(d) Thrombocytopaenia: less tiian 100,000/mm  ^in the absence of 
offending drugs
(a) Anti-DNA: antibody to native DNA in abnormal titre OR
(b) Anti-SM: presence of antibody to SM nuclear antigen OR
(c) Positive findmg of antiphospholipid antibodies based on (1) an 
abnormal serum level of IgG or IgM anticardiolipin antibodies, or (2) a 
positive test for lupus anticoagulant antibodies using a standardised 
test, or (3) a false positive serological test for syphilis known to be 
positive for at least 6 months and confirmed by Treponema pallidum 
immobilisation or florescent treponemal antibody absorption test
An abnormal titre of ANA by immunofluorescence or by an equivalent assay 
at any point in time and in the absence of drugs known to be associated with 
'drug-induced' lupus syndrome_____________________________  ■______
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Table 2-3. Reported prevalence of ACR criteria in different populations
Study Tan H opkinson Cervera Alamanos G udm undsson Voss
1982 1994 2003 2003 1990 1998
Country USA England Europe Greece Iceland Denmark
Cases (n) 177 147 1000 178 76 127
Percentage (%) of cases
Malar rash 57 30 31.1 66.3 48 43
D iscoid  rash 18 10 7.8 N R f 10 12
Photosensitivity 43 51 22.9 51.1 40 46
Oral ulcers 27 37 12.5 NR 35 7
Arthritis 86 91 48.1 50.0 92 50
Serositis 56 27 16.0 11.2 36 43
Renal disorder 51 22 27.9 15.2 20 29
N eurological
disorder
20 7 19.4 NR 14 11
H aematatological
disorder
59 80 13.4/4.8* NR 65 56
Im m unological
disorder
85 54 NR 44.4 68 87
Antinuclear
antibodies
99 97 NR 86.0 100 100
*Thrombocytopaenia /  haemolytic anaemia 
fNR, not reported
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2.3.4 Initial presentation of SLE
The initial presentation of SLE varies from patient to patient and has been 
shown by some studies to have an association with age, gender and 
ethnicity. All studies of the initial presentation have been conducted in 
hospital settings, using medical record review or patient interview. Accurate 
recall of symptoms of the onset of SLE wlQ be dependent on how long ago 
they first appeared and whether or not the patients associate those symptoms 
with their current disease status. Moreover, this association of past illness or 
symptoms to their SLE will be dependent on their level of understanding and 
knowledge of the disease and all its potential clinical manifestations. Bearing 
in mind the limitations of these studies, some clear patterns of the initial 
presentation of SLE have emerged. In the vast majority of patients, 
constitutional, cutaneous and musculoskeletal symptoms are the first 
manifestations of SLE (Maddison 1987, Hopkinson 1994, Jacobsen 1998, 
Lahita 1999c, Ozbek 2003). Constitutional symptoms that are reported 
include weight loss, fatigue and fever. Arthralgia and arthritis frequently 
affect the knees, wrists and the proximal and distal interphalangeal joints of 
the hand, and they are generally mild and non-deforming (Lahita 1999c, 
Ozbek 2003). The early cutaneous manifestations are malar rash, discoid rash 
and photosensitivity (Hopkinson 1994, Jacobsen 1998a).
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Studies investigating the presentation of early- and late-onset SLE have 
identified some symptoms that are more frequent in these groups compared 
with adult-onset SLE. No studies have identified patterns of onset in adult 
patients. In children, onset tends to be severe (Bader-Meunier 2005) with 
malar rash, arthritis, haematological, neurological and renal involvement 
occurring more frequently than in adult-onset SLE (Jacobsen 1998). During 
the course of their disease, approximately 50% of children will develop 
clinically apparent renal disease (Ansell 1987) and they suffer more seizures 
and psychosis than patients with adult-onset disease (Antolin 1995, Costallat 
1994, Font 1998, Bader-Meunier 2005). Patients who develop SLE at an older 
age (>50years) tend to have an insidious onset, with severe manifestations, 
such as clinically significant renal disease, being infrequent (Ward 1989, 
Ward 1990a, Costallat 1994, Antolin 1995, Formiga 1999). Jacobsen (1998a) 
also reported that pulmonary involvement was more common in late-onset 
SLE. Patients with late-onset SLE also tend to be Caucasian whereas SLE 
patients from other ethnic groups are more usually younger age at onset 
(Maddison 1987, Hopkinson 1995, Alarcon 1999). Additionally, during the 
evolution of their disease, Caucasians tend to have less severe disease 
manifestations than Afro-Caribbeans, Hispanics, and Asians (Samanta 1991, 
Alarcôn 1999). The main differences in SLE between male and females at 
onset are that males tend to be older at first onset (Ward 1990b, Jacobsen 1998 
and chapters 4, 6, 7) and are more likely to have serositis and discoid rashes 
than females (Font 1992, Voulgari 2002).
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The initial presentation of SLE usually occurs whilst a patient is under the 
care of a general practitioner who would make a differential diagnosis and 
refer the patient to a rheumatologist. However, to date I have not been able 
to identify any studies of the presentation of SLE that have been conducted 
using observational data from primary care. In Chapter 101 report on a study 
of the presentation of SLE using prospectively collected data from primary
care.
2.4 SLE: affects women of childbearing age
Studies of the epidemiology of SLE have shown that SLE is more common in
females, with the female: male ratio of onset highest during the 
"childbearing' years. The ratios of female: male cases vary from 4 to 13:1 
(Petri 2002). In this section I review the epidemiological studies of the 
incidence and prevalence of SLE. 1 have conducted a systematic Hterature 
review of the incidence and prevalence of SLE in the UK population in 
Chapter 5. In summary, in the UK, incidence rates for SLE have been 
reported to be between 3.8 and 4.0/100,000/year with rates being higher in 
females (6.5 to 6.8/100,000/year) than in males (0.5 to 1.5/100,000/year) 
(Hopkinson 1993, Johnson 1995). Age and ethnicity are associated with 
incidence of SLE. Afro-Caribbeans, and to a lesser extent, Asians, have higher 
incidence rates of SLE than Caucasians (Hopkinson 1993, Johnson 1995). 
Prevalence of SLE in the UK population has been estimated to be between
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24.6 and 27.7/100,100 (Hopkinson 1993, Johnson 1995). Prevalence is higher 
in females (Samanta 1992, Hopkinson 1993, Johnson 1995, Gourley 1997) and 
in those of Afro-Caribbean, and to a lesser extent, Asian origin (Samanta 
1992, Hopkinson 1993, Johnson 1995).
The incidence and prevalence of systemic lupus erythematosus (SLE) 
from population-based studies outside the UK vary according to study 
period, country of study, case definition and ethnicity of the population. 
Incidence and prevalence of SLE are higher in women and in those of non- 
Caucasian origin (Gudmundsson 1990, Jonsson 1990, McCarty 1995, Voss 
1998, Uramoto 1999, Stahl-Hallengren 2000, Ward 2004). In the last 25 years, 
studies of the epidemiology of SLE in continental Europe have reported the 
overall prevalence to be between 21.7/100,000 (Voss 1998) and 68/100,000 
(Stahl-Hallengren 2000). Prevalence has been reported to be between 
4.7/100,000 (Voss 1998) and 7.2/100,000 (Gudmundsson 1990) in males and 
37.9/100,000 (Voss 1998) and 62/100,000 (Gudmundsson 1990) in females, 
Incidence for Denmark (Voss 1998), Sweden (Jonsson 1990) and Iceland 
(Gudmundsson 1990) has been reported to be 3.6/100,000/year, 
4.0/100,000/year and 3.3/100,000/year respectively. Most studies of SLE 
epidemiology define cases using the ACR classification criteria for SLE (Tan 
1982, Hochberg 1997).
Reflecting on the traditional depiction that "SLE affects women of 
childbearing age", this is likely to influence the chances of diagnosis of SLE in 
older women and in males. It is a widely publicised fact that might explain,
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along with the more insidious onset of SLE in older adults, the increased 
delay in diagnosis in those over the age of 50 (Maddison 2002). There is 
undeniable epidemiological evidence that the claim of 'childbearing' age at 
onset it true for Black Americans and those of Afro-Caribbean ethnic origin 
(Petri 2002) but in Caucasians, the age of diagnosis is consistently reported to 
be as high in women between the ages of 50 and 59 who would be 
considered to be peri- or post-menopausal. In Chapters 7 and 8 I have 
reported on studies of the incidence and prevalence of SLE in the UK 
population using data from the General Practice Research Database (GPRD).
2.5 SLE: life-threatening manifestations
The major causes of death in patients with systemic lupus erythematosus 
(SLE) have been reported to be active disease, severe infection and 
cardiovascular disease (Jacobsen 1999, Cervera 2003, Schattner 2003, Borchers 
2004, Bernatsky 2006). Early death is usually from active disease whereas 
those surviving longer are more Hkely to suffer from the effects of accelerated 
atherosclerotic cardiovascular and cerebrovascular disease (Urowitz 1999, 
Bernatsky 2006).
There is little doubt that survival in patients with SLE has improved 
considerably in the last 50 years. This improvement has been attributed to 
earher diagnosis, significant improvements in the management of SLE and 
lower toxicity from medical treatment (Borchers 2004). Studies investigating 
survival amongst patients with SLE have varied in their diagnostic or
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classification criteria, length of follow-up and demographic characteristics of 
participants (Borchers 2004). Five-year survival from inception cohort studies 
has improved from 65% in Caucasians in 1955-66 (Seigel 1969) to 96.8% in 
1982-2001 (Alamanos 2003b). Recently pubHshed studies of SLE mortality 
have reported ten-year survival rates to be over 90% (Manger 2002, Cervera 
2003, Alamanos 2003b).
Five and ten-year survival estimates have limited value when 
examining the effects of SLE on absolute survival compared with that of the 
general population. Few studies have calculated the standardised mortaÜty 
ratio (SMR) for SLE patients. This is the ratio of the number of observed 
deaths in a cohort of SLE patients to the number of expected deaths in the 
same age group in a standard population (e.g. the National, European or 
World Population). Urowitz (Urowitz 1997) calculated the SMR in three 
cohorts of SLE patients in Toronto to be 10.1 (95% confidence interval (CI95) 
6.5,15.0) in 1970-77, meaning that SLE patients had a 10-fold increased risk of 
dying compared with individuals of the same age in the general population. 
In the 1978-85 cohort the SMR was 4.8 (CI95 3.2, 7.0) and in the 1986-94 cohort 
it was 3.3 (CI9 51.8,5.7). This decrease in SMR over time was not attributed to 
earlier diagnosis or new treatments but to better use of conventional 
treatments and prompt management of treatment-related toxicity (Urowitz 
1997). In Germany the SMR for Caucasian SLE patients was 2.7 in 1982-97 
(Manger 2002). A study of mortality in SLE in Northwest Greece (1981-2001) 
calculated the SMR of patients with SLE to be 1.5 (CI95 1.3, 1.8). (Alamanos
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2003). A recently published international multicentre cohort study of 
mortahty in systemic lupus erythematosus reported an SMR of 2.4 for SLE 
patients. The SMR for patients under the age of 40 was 10.7 (CI95 9.5, 11.9) 
whereas in those aged 60 and over the SMR was 1.4 (CI9 5 13,1.5). SMR was 
also higher in females than males and in those who were in their first year 
after diagnosis (SMR 5.4 (CI95 4.7, 6.3)) compared with those whose disease 
duration was greater than 1 year (Bernatsky 2006).
The reasons for the differences in SMR in Toronto, Germany and 
Greece are not entirely clear and are likely to be due to an interacting number 
of differences in the SLE itself and general populations. Although all three 
studies classified their cases according to the 1982 revised American College 
of Rheumatology (ACR) criteria for the classification of SLE (Tan 1982, 
Hochberg 1997), it is possible that disease severity differed between 
populations. For example, although the prevalence of lupus nephritis was 
similar in the Toronto and Germany studies, neurological disorder was more 
common in Toronto (41.5% in 1970-77, 42.8% in 1978-85 and 33.2% in 1986- 
94) than in Germany (21% of cases). In Greece, 15.2% of cases had lupus 
nephritis at time of diagnosis. This is probably owing to the fact that the 
Greek study included only newly diagnosed patients with SLE whereas the 
Toronto and Germany studies included cases that had been diagnosed some 
years before their recruitment. Although data on socioeconomic status of the 
cases and of the general populations they were compared with were not 
given, it is possible that any differences in the three study populations with
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regard to socioeconomic status may have affected the estimate of the SMR. It 
has been shown that low socioeconomic status is associated with higher 
mortality in SLE (Petri 1991). Finally, it is possible that mortahty rates in the 
general population of Ontario, Germany and Northwest Greece vary. 
Underlying differences in the mortahty rates, health and healthcare provision 
in these populations might lead to differences in the SMR for the SLE 
populations.
The recently published international multi-centre cohort study of 
mortahty in SLE (Bernatsky 2006) reported an overah SMR of 2.4 (CI95 2.3, 
2.5). They found that SLE patients were more hkely to die from heart disease, 
haematological cancers (especiahy non-Hodgkins lymphoma), lung cancer, 
infections, respiratory causes and renal disease. They also found that the 
SMR for SLE was significantly higher in Canada (RR 1.8 (CI95 1.6, 2.1)) 
England (RR 1.6 (CI95 1.2, 2.2) and Scotland (RR 1.3 (CI95 1.1,1.5) compared 
with the SMR in the USA. Mortahty was lower in Sweden (RR 0.8 (CI95 0.5, 
1.4)) and South Korea (RR 0.7 (CI95 0.3, 2.0)), but not significantly so. When I 
was conducting the studies for this thesis, there had been no reports of age- 
specific mortahty rate ratios or age-specific SMRs in SLE populations. In the 
study by Bernatsky et al (2006), increased risk of mortahty was associated 
with female gender, age < 40 years compared with >60 years and Disease 
duration of less than 19 years compared with 20 years or more, with a 
particularly high risk of death during the first year after diagnosis (RR 7.7 
(CI95 5.9, 10.2)). There was a statisticaUy insignificant decrease in the
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standardised mortality rates from 1970 to 2001.1 have conducted a study of 
mortahty in the UK using the GPRD and this is reported in Chapter 9.
2.6 SLE: a chronic relapsing-remitting disease
Currently there is no cure for SLE; it is a chronic condition that is
characterised by periods of quiescence, which can last for weeks, months or 
years (Barr 1999), and exacerbations ('flares') of disease activity. When flares 
occur there is an increase in disease activity and in the case of clinicahy 
apparent flares, a patient wih experience worsening of existing symptoms or 
new symptoms that they have not previously experienced (Petri 1991b, 
Lahita 1999c). The incidence of flare in patients with SLE has been calculated 
to be 0.65/person/year (Petri 1991b). Barr et al (1999) conducted a study to 
identify patterns of disease activity in the Hopkins lupus cohort. They 
identified three patterns of activity. The most common was 'chronic active' 
disease. The mean length of the chronic active period was 2.8 years (SD 1.4); 
activity during this period was generally mild or moderate with moderate to 
severe flares. Tlie second pattern was relapsing-remitting disease in which 
patients had flares but in between times, were symptom-free. Exacerbations 
were mild to moderate. The third pattern was long-quiescent with a mean 
duration of 2.3 years (SD 1.1). During the long-quiescent periods, around 
50% of patients had serologically active disease despite being symptom-free 
(Barr 1999).
50
2.7 Management of SLE
After the diagnosis of SLE, the rheumatologist monitors disease activity and 
severity and develops a treatment plan for the patient. Individuals with mild 
or stable disease can be managed in primary care with guidance from lupus 
specialists in secondary care. Those with severe or active disease will be 
managed in specialist centres (ACR 1999). The purpose of the treatment of 
SLE is to alleviate symptoms, and minimise or prevent long-term organ 
damage and premature mortality. The drug treatment for SLE depends on 
the severity of disease and the clinical manifestations but is usually with a 
combination of non-steroidal anti-inflammatory drugs (NSAIDS), topical and 
systemic corticosteroids, antimalarial drugs and inununosuppressive /  
cytotoxic agents.
Mild to moderate disease activity without major organ involvement is 
treated using systemic corticosteroids (<10mg/ day of prednisolone) and 
hydroxychloroquine. Severe disease and major organ involvement is treated 
with high dose or pulse systemic corticosteroids and immunosuppression 
with azathioprine, methotrexate, myocophenelate mofetil and for very severe 
renal disease, cyclophosphamide (Petri 1998, Dall'Era 2003).
2.7.1 Non-steroidal anti-inflammatory drugs
NSAIDs are used to treat serositis, fever, polyarthralgia and arthritis (Petri 
1998, Dall-Era 2003). The main side effects of NSAID use are gastrointestinal, 
and in combination with corticosteroids, the risk of peptic ulcer is increased
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(Kimberley 1999). Commonly used NSAIDs are ibuprofen, diclofenac and 
naproxen.
2.7.2 Corticosteroids
Corticosteroids are immunosuppressive and anti-inflammatory. Their 
potency is related to their biologic activity and duration of action (Kimberly 
1999). Topical corticosteroids are used to treat cutaneous manifestations of 
SLE. Systemic corticosteroids are a mainstay of treatment for all clinical 
manifestations of SLE. High oral doses or pulse therapy can be used to treat 
flares but only for short periods of time. In the LUMINA cohort, nearly 90% 
of the patients had past or current treatment with systemic corticosteroids at 
a mean dose of 19 mg /  day (SD 17.8), median dose 11 m g/ day (range 0.3 -  
80mg/day). (Alarcon 1999). Side effects from long-term steroid use can be 
significant and include infections, osteonecrosis, osteoporosis (which is 
reversible), and myopathy (Kimberley 1999). Petri (1998) reconunends that if 
a maintenance dose of greater than lOmg/day is needed that azathioprine or 
methotrexate should be added to prevent the long-term toxicity associated 
with high dose corticosteroid use.
2.7.3 Antimalarials
Antimalarials are used for all mild to moderate manifestations of SLE 
including arthritis, serositis, constitutional symptoms and cutaneous lesions; 
they are anti-inflammatory and immunomodulatory (Kimberley 1999).
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Hydroxychloroquine (200-400 mg/day) stimulates apoptosis in lymphocytes 
(Davis 1999) and is the favoured antimalarial because it is not associated with 
as high risk of ocular toxicity as chloroquine. Quinicrine can be added to 
hydroxycholorquine if needed (Petri 1998). In the LUMINA cohort, 
approximately 50% of patients had past or current treatment with 
hydroxychloroquine (Alarcon 1999). Antimalarials are generally well- 
tolerated by the majority of patients but side effects include malaise, 
gastrointestinal side effects, rashes and alopecia (Davis 1999). Occular 
toxicity is more commonly seen with chloroquine use but patients should be 
monitored for retinal damage (Davis 1999).
2.7.4 Immunosuppressants I cytotoxics
The immunosuppressive and cytotoxic agents are used to treat moderate to 
severe manifestations. They are added when high doses of corticosteroids are 
required to control disease activity (Petri 1998). Azathioprine and 
methotrexate are both used as steroid-sparing therapies. Azathioprine is 
especially useful for neprhitis whereas methotrexate is effective in the 
treatment of arthritis, arthralgia and serositis (Davis 1999 Ch 46). In the 
LUMINA cohort, 8% of patients had or were being treated with azathioprine. 
Mycophenelate mofetil is a suppressor of T and B cell proliferation and has 
been used with success in patients with SLE (Smolen 2002). 
Cyclophosphamide is used for major organ involvement such as nephritis.
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life-threatening thrombocytopaenia and CNS symptoms (Davis 1999). In the 
LUMINA cohort, 16% of patients had been treated with pulse 
cyclophosphamide. Cyclosporin is used only for severe lupus nephritis 
(membranous glomerulonephritis) or for refractory disease activity (Ruiz- 
Irastorza 2001). The major side effects of treatment with these agents are 
gastrointestinal, bone marrow toxicity, hair loss and increases susceptibility 
to infection (Davis 1999).
2.7.5 Other treatments
Patients with cutaneous involvement and photosensitivity need to use sun 
block and sometimes require prescription for camouflage make-up for 
scarring caused by cutaneous lesions. ThaUdomide has been found to be very 
effective in the treatment of discoid lupus (Petri 1998, Ruiz-Irastorza 2001) 
but its use is limited due to its well documented teratogenic side effects. 
Dapsone an the systemic retinoids (usually used to treat severe acne) can be 
used if antimalarials are not well tolerated (Petri 1998).
Seizures in SLE are treated using anticonvulants; psychosis is treated 
using antipsychotics (Petri 1998). Cardiovascular involvement in SLE can be 
treated using anticoagulants such as warfarin and heparin (Petri 1998).
Intravenous (IV) immunoglobulin has been used for severe or life- 
threatening disease activity along with danazol and vincristine (Petri 1998).
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IV immunoglobulin has been found to be effective in the treatment of 
arthritis, fever and thrombocytopaenia (Ruiz-Irastorza 2001).
I have conducted a study of the management of SLE in primary care in the 
UK using the GPRD and a case study of the use of hormonal contraceptives 
in women before and after their diagnosis of SLE. This is presented in 
Chapter 11.
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Chapter 3
Aims and Objectives
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3 Aims and Objectives
Research into SLE epidemiology has traditionally been conducted in 
secondary care and in specialist tertiary centres because SLE is a disease that 
is generally managed in these settings. However, in the UK, in order to 
receive treatment from secondary or tertiary care centres, patients must be 
referred to specialists by their general practitioners. This has the inherent 
impHcation that in order to be diagnosed with SLE, a patient's GP must first 
recognise the varied symptoms of SLE, conclude that they are in some way 
related and refer the patient to a rheumatologist for investigation and 
confirmation of diagnosis. The presentation of SLE has been shown to vary 
substantially (Chapter 2) and can be insidious, especially in older patients, in 
whom the suspicion of diagnosis may be lower due to the fact that they do 
not fall into the classical profile of being a 'woman of childbearing age' 
(Maddison 2002). Early recognition of SLE is important to enable treatment 
with appropriate medications that will provide symptom control and disease 
activity in order to prevent irreversible organ damage and minimise the 
effects of accelerated atherosclerosis (D'Cruz 2006). In order to raise 
awareness of SLE amongst GPs, it is necessary to identify the way in which 
patients with SLE present clinically in this setting. Although this could be 
conducted using retrospective surveys of those patients who have been 
referred to rheumatologists, this type of methodology is limited by recall 
issues that might be differential between patients with SLE and patients
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without SLE. Moreover, in 1992, the way in which health care trusts paid for 
medical treatments changed from a provision of prescribing in hospital 
outpatient clinics for diseases that were primarily managed in secondary or 
tertiary centres to prescribing being the responsibility and at the cost of 
general practice (primary care). Although SLE remains a disease that is 
primarily managed by rheumatologists, the medical therapies to control SLE 
are prescribed by GPs under the instruction of rheumatologists.
The aim of this thesis was to describe the clinical presentation, morbidity, 
mortality and subsequent management of SLE in primary care in the UK 
using the General Practice Research Database. I formulated the following 
hypotheses:
(a) That it would be possible to identify cases of SLE from the GPRD 
population.
(b) That the incidence and prevalence of SLE in the GPRD population 
would be consistent with previous estimates for the UK population.
(c) That SLE patients would be significantly different from members of 
the general population without SLE in terms of their reported 
symptoms, use of medication and GP consultation rates for at least 12 
months before their date of clinical diagnosis and probably for up to 
three years before diagnosis and that it would be possible to develop 
age- and sex-specific profiles of the clinical presentation of SLE in 
primary care
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(d) That management of SLE in primary care would be consistent with the 
estabhshed prescribing patterns for SLE from hospital-based studies.
(e) That, as a case study of adherence to oral contraceptives prescribing 
guidelines, the use of combined oral contraceptives would decline in 
women after their date of SLE diagnosis and that their overall use 
would be significantly lower than that of the female population of the 
same age who did not have a diagnosis of SLE.
In order to test these hypotheses, I carried out a number of studies using the 
General Practice Research Database (GPRD). Chapter 4 describes the 
structure, quality, generalisabüity, strengths and weaknesses of the GPRD. 
Chapter 5 is a systematic Hterature review of the incidence and prevalence of 
SLE in the UK population. This review was restricted to UK studies because 
the objective was to determine the number of cases of SLE that we would 
expect to identify from the GPRD population. We used this as the method of 
validating our case identification algorithm.
Chapter 6 describes the way in which cases of SLE were identified 
from the GPRD. Once the cases of SLE were identified I calculated the 
incidence (Chapter 7) and prevalence (Chapter 8) of SLE in the GPRD 
population. To investigate the questions arising from the results of my study 
of the prevalence of SLE I calculated the age- and sex-specific mortahty rate 
ratios for the SLE population compared with the general population of the 
GRPD (Chapter 9).
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Chapter 10 describes my study of the presentation of SLE in primary 
care. Chapter 11 describes the management of SLE using prescribing data 
from the General Practice Research Database firstly with a description of 
prescribing patterns for drugs used to manage disease activity in SLE and 
secondly in a case study of the adherence to prescribing guidelines for 
combined oral contraceptives to women with SLE.
Chapter 12 is an overall discussion of the important findings, clinical 
implications, strengths and weaknesses of this thesis.
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Chapter 4
The General Practice Research Database and
its Utility for the Study of Systemic Lupus
Erythematosus
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4 The General Practice Research Database (GPRD)
The aims of this thesis were to determine the incidence, prevalence and 
mortality rates of SLE in the UK population, and to investigate the clinical 
presentation and management of SLE in primary care. As SLE is a relatively 
rare disease (see Chapters 2 and 5) I decided to use the General Practice 
Research Database to conduct these studies.
The GPRD contains the anonymous primary care diagnostic, 
prescribing and preventative medicine records for between 4% and 6% of the 
UK population. It has been used extensively for studies of disease 
epidemiology (Walley 1997, HoUoweU 1997, Garcia Rodriguez 1998, Garcia 
Rodriguez 2000) including two studies of risk factors for the development of 
SLE (Meier 1998, Sturkenboom 2000). Automated data are recorded by 
general practitioners (GPs) as part of their routine clinical practice and 
anonymised for the purposes of research. In this chapter I wiU discuss the 
GPRD and its utility for conducting longitudinal observational studies.
4.1 History of the GPRD
The General Practice Research Database (GPRD) was set up by VAMP (Value 
Added Medical Products) in May 1987. The database set up to collect 
longitudinal primary care data for four million patients, representative of the 
UK general practice population that could be used for post-marketing drug 
safety and surveillance (Walley 1997, ONS Information for Researchers). The
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VAMP software enabled GPs to record and keep electronic records on the 
routine clinical management of their patients and to submit these data to the 
central VAMP research database. Data were then anonymised for the 
purposes of research. Reuter's Health took over VAMP and the ownership of 
the database in 1993 and donated it to the Department of Health (DoH) in 
1994. The Office of National Statistics (ONS) managed the database for nearly 
five years until it was transferred to the Medicines Control Agency, now the 
Medicines and Health care products Regulatory Agency (MHRA) (Anon 
(Lancet) 2001). In 1995 In Practice Systems (InPS) developed a Windows 
based version of the VAMP software called Vision. The software used by the 
DoH for collating the VAMP data did not support the Vision software. 
Although Vision data were collected, they were not included in the database 
until the 2002 version of the database was compiled.
4.2 Structure of the GPRD
The GPRD is made up of a number of tables that contain different data about 
individuals registered with contributing GPs. Each individual registered 
with a contributing practice has a unique patient identifier. I have used two 
versions of the GPRD in this thesis. The majority of the investigations were 
conducted using data collected up to January 1999, known from this point on 
as the '1998 version'; the studies of the presentation and management of SLE 
were conducted using data collected to April 2002, known from this point on
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as tiie '2002 version'. The major differences between the two versions of the 
were that the data from the Vision practices were included in the 2002 
version of the database and the free text 'comments' field of the medical 
records were unavailable in the 2002 version.
I will describe the content and structure of the tables that comprise the 
GPRD as this is important for the reader's understanding of some of the 
methodological issues discussed within the thesis.
4.2.1 General Practice Information
The 'Practice' table of the GPRD contains information about the date upon 
which each general practice started to contribute data that were deemed to 
be of a standard adequate for the purposes of research; it also contains the 
date on which the practice last contributed data to the GPRD. Table 4.1 
shows an example of data from the Practice table. The criteria used to assess 
the quality of the data are summarised in section 4.3. The first practice was 
recruited to the database in June 1987 and peak recruitment took place 
between 1988 and 1989. Figure 4.1 shows the number of practices entering 
and leaving the 1999 and 2002 versions of the GPRD from 1987 to 2002. The 
total number of practices contributing to the GPRD declined from 1991 to 
2002 (Figure 4.2). One of the reasons for this decline was the change from 
VAMP to Vision software. The GPRD was growing rapidly in size from 1987 
to 1990 and most practices were providing up-to-standard data from mid-
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1991. For this reason I decided to conduct the studies in this thesis using data 
from 1992 onwards.
Table 4-1. Example of the 'practice' table from the 2002 version of the GPRD.
ENCPRACEXT
000
VMPRACID
0000
NEWPRACID
00000
OLDNEW
1
START_UTS
Ol-May-89
END.UTS
18-Dec-Ol
002 0002 00002 2 Ol-Oct-87 Ol-Jun-96
003 0003 00003 2 Ol-Jan-92 Ol-Jul-93
004 0004 00004 1 Ol-Mar-90 22-Mar-02
005 0005 00005 2 Ol-Mar-88 22-No v-98
The first three columns of this table give information about the practice 
identifier. The OLDNEW column indicates whether the practice was a new 
practice in the 2002 version of the GPRD. The START_UTS (up to standard) 
is the date on which the practice started to contribute data of research 
standard and the END UTS is the date of last data collection.
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Figure 4-1. Number of practices entering and leaving the GPRD between 
1987 and 2002
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Figure 4-2. Total number of practices contributing to the GPRD in each year 
between 1989 and 2002
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4.2.2 Patient information table
The Tatienf table of the GPRD contains demographic data such as year of 
birth, sex and date of registration with the GP. Table 4.2 shows an example of 
the data available from this table. Patients are given a date for which their 
data are considered to be Teft-censored' (i.e. the records before this date are 
incomplete and are not reliable for use for the purposes of research) and the 
date on which the records are Tight-censored'. The left-censoring date is the 
later of the patient's registration date with the GP or the date on which the 
GP first contributed data of research standard. The right-censoring date is the 
earlier date of a patient's date of leaving the general practice (by moving 
practice or through death) or the last date on which the GP contributed data.
All individuals registered with contributing GPs have a registration 
status assigned. For all of the studies in this thesis, I used records from 
individuals with the following registration status: permanent, left practice, 
death. We did not include individuals with other registrations statuses as the 
records for these patients were more likely to be incomplete. Demographic 
data relating to employment, socioeconomic status and ethnicity are not 
routinely recorded on the GPRD.
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4.2.3 Medical records
The medical records table contains information on diagnoses and symptoms 
along with the date of their presentation to the GP (date of consultation). 
Diagnoses are entered using standardised OXMIS (Oxford Medical 
Information System) (Lis 1995) and Read Codes (Robinson 1997). These codes 
are organised in a hierarchical manner within the medical dictionary. When 
the GP enters the patient's diagnosis onto the computer system, the 
dictionary is searched automatically and a list of matching terms is produced 
from which the GP can select the most appropriate term. This is then entered 
into the medical record. It is possible for the GP to create new diagnostic 
codes if none of the available codes are suitable for use. It is using these 
codes that the GPRD can be searched for patients with particular medical 
diagnoses in their record. An example of OXMIS and Read codes is shown in 
Table 4.3.
Each medical record has an 'outcome' field in which the GP can record 
a number of predefined outcomes to the consultation. Examples of possible 
outcomes are: hospital letter, inpatient discharge summary, referral to 
outpatients, referral to accident and emergency. In addition to the outcome 
field of the medical record, hospital attendance can be recorded within the 
medical record using an OXMIS or Read code. These codes can allow the GP 
to be more specific about the referral, for example, 'seen in rheumatology 
cHnic'.
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Table 4-3. Example of OXMIS and Read Codes for rheumatoid arthritis
CODE DESCRIPTION CODE DESCRIPTION
7120A RHEUMATOID ARTHRITIS 
JUVENILE
N040500 RHEUMATOID ARTHRITIS OF 
ELBOW
7123 RHEUMATOID ARTHRITIS N040700 RHEUMATOID ARTHRITIS OF 
WRIST
7123A RHEUMATOID DISEASE N040800 RHEUMATOID ARTHRITIS OF 
MCP JOINT
7123AN RHEUMATOID NODULES N040900 RHEUMATOID ARTHRITIS OF PIP 
JOINT OF FINGER
1211.00 FH: RHEUMATOID ARTHRHIS N040A00 RHEUMATOID ARTHRITIS OF 
DIP JOINT OF FINGER
14G1.00 H/O: RHEUMATOID ARTHRITIS N040B00 RHEUMATOID ARTHRITIS OF 
HIP
43F..00 RHEUMATOID FACTOR N040D00 RHEUMATOID ARTHRITIS OF 
KNEE
43F1.00 RHEUMATOID FACTOR POSITIVE N040E00 RHEUMATOID ARTHRITIS OF 
TIBIO-FIBULAR JOINT
43F2.00 RHEUMATOID FACTOR 
NEGATIVE
N040F00 RHEUMATOID ARTHRITIS OF 
ANKLE
43F8.00 SERUM RHEUMATOID 
ANTIBODY LEVEL
NO40G00 RHEUMATOID ARTHRITIS OF 
SUBTALAR JOINT
43FZ.00 RHEUMATOID FACTOR NOS N040H00 RHEUMATOID ARTHRITIS OF 
TALONAVICULAR JOINT
N040.00 RHEUMATOID ARTHRITIS N040K00 RHEUMATOID ARTHRITIS OF 
1ST MTP JOINT
In the 1998 version of the GPRD the free text comments field of the medical 
record was available for use at the time that this thesis was started. 
Subsequently this field was removed from the database because some of the 
comments were deemed to compromise anonymity. The comments are now 
available in an anonymised format for an additional fee but were unavailable 
at the time I conducted the studies for this thesis. The usefulness of the 
comments field, particularly in respect to the ability to confirm or exclude a
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diagnosis that has been entered onto the GPRD cannot be overstated. Within 
the comments field of the OXMIS or Read Code entry, GPs can record blood 
test results, referral to hospital, symptoms of chronic diseases, blood pressure 
readings, urine analysis results and comments such as "excluded' (i.e. the 
recorded diagnosis had been investigated and excluded). Table 4.4 is an 
example of the patient record table.
The EVNTDATE is the date on which the medical diagnosis has been 
entered into the patients record, oxmscode is the OXMIS or Read Code that 
has been used to record the medical diagnosis, text is the text description of 
the code (this is not present in the medical record table), comment_txt is the 
free text comments field and outcome describes the outcome of the 
consultation: O = other, L = hospital letter, D = inpatient discharge summary, 
R = referral to outpatients, A = referral to accident and emergency.
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4.2.4 Therapy records
The majority of prescriptions are generated using the GPs' computers and 
consequently, recording of prescribing is approximately 95% complete 
(Walley 1997). Prescriptions are product specific and are entered onto the 
database using Prescription Pricing Authority (PPA) codes. The PPA codes 
are stored in the therapy records, with linkage to a drug dictionary that gives 
further details of the product including its generic name and dose 
information. The dose and duration of each prescription is recorded and this 
means that periods of continuous coverage of prescriptions can be mapped 
for individual patients. In diseases such as SLE, it is likely that the 
responsibihty for changes in medication would be with the rheumatologist 
rather than with the GP (ACR 1999, Glazier 2002). However, prescriptions 
are issued by the GP rather than by the hospital consultant on the advice of 
the rheumatologist meaning that prescriptions for the treatment of SLE will 
be recorded in the therapy records. Table 4.5 is an example of the therapy 
records from the 2002 database.
4.2.5 Prevention records
The 'prevention records' are named as such because they contain information 
about immunisations and other data related to preventative medicine such as 
height, weight, smoking, cervical screening records, urinanalysis and
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contraceptive use. Most of these can also be recorded within the medical 
records table.
4.3 Reviewing patient records from the GPRD
Software has been developed by Annie Hutchison in the department of 
Pharmacoepidemiology at the Postgraduate Medical School, University of 
Surrey that combines all of the data for each patient into one, chronological 
medical record. An example of a complete medical record can be seen in 
Appendix 2.
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4.4 Population
When the GPRD was set up it aimed to collect the longitudinal primary care 
data for four million people from general practices that were representative 
of practices throughout the UK. Figure 4.3 shows the number of males and 
females contributing to the GPRD between 1989 and 2002. Tables 4.6 and 4.7 
show the age-specific number of males and females respectively contributing 
to the 2002 version of the GPRD and the proportion (%) of the UK population 
covered by the GRPD. This was calculated using the annual population data 
for the UK published by the Office of National Statistics (ONS online).
Figure 4-3. Number of males and females contributing data to the GPRD 
between 1989 and 2002.
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Table 4-6. Annual male population of the 2002 version of the GPRD between 
1989 and 2002, stratified 10 year age group and the annual proportion of the 
UK male population covered the GPRD.
GPRD Population (1000s) by 10 year age band
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80 + Total
1989 54.5 48.1 65.2 60.3 54.8 40.9 38.0 24.0 10.4 396.2
1990 200.4 181.7 244.7 225.2 212.7 155.1 137.5 89.7 38.1 1485.2
1991 304.8 272.7 378.8 348.5 326.7 237.0 206.6 139.6 61.1 2275.7
1992 304.2 266.9 374.3 352.7 326.2 238.5 204.5 140.7 63.3 2271.3
1993 298.0 261.1 360.6 351.4 320.2 239.2 198.4 139.3 64.3 2232.5
1994 279.4 244.3 327.6 335.7 296.7 229.6 185.2 130.1 61.2 2089.9
1995 273.2 244.3 312.3 338.8 294.5 231.0 183.2 130.4 61.2 2068.9
1996 256.2 236.3 286.1 325.3 278.3 229.1 175.1 126.1 58.8 1971.2
1997 234.2 222.1 252.4 301.5 252.4 220.6 161.8 117.4 53.4 1815.8
1998 216.8 214.0 231.8 285.3 237.4 213.5 153.9 112.7 50.8 1716.1
1999 203.7 207.5 216.5 275.4 228.8 209.3 149.2 108.8 49.9 1649.1
2000 174.9 183.4 184.5 242.3 203.4 186.9 132.0 94.7 46.8 1449.0
2001 147.7 161.7 158.7 211.5 182.0 166.3 115.4 83.0 43.1 1269.6
2002 59.2 71.7 63.8 88.6 81.6 73.1 51.7 37.4 19.8 546.9
% of the UK Population covered by the GPRD by 10 year age band
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80 + Total
1989 1.4 1.3 1.4 1.6 1.5 1.4 1.4 1.5 1.7 1.4
1990 5.3 4.9 5.3 5.8 5.7 5.2 5.1 5.4 6.2 5.3
1991 7.9 7.4 8.3 8.8 8.5 8.0 7.7 8.2 9.7 8.2
1992 7.8 7.4 8.3 8.7 8.4 8.0 7.7 8.1 9.7 8.1
1993 7.6 7.3 8.1 8.5 8.2 7.9 7.5 7.9 9.5 8.0
1994 7.1 6.8 7.5 8.0 7.6 7.4 7.1 7.4 8.8 7.4
1995 7.0 6.8 7.4 7.9 7.6 7.3 7.0 7.3 8.6 7.3
1996 6.6 6.5 6.9 7.4 7.1 7.1 6.7 7.0 8.2 7.0
1997 6.0 6.0 6.3 6.8 6.6 6.6 6.2 6.4 7.4 6.4
1998 5.6 5.7 6.0 6.3 6.2 6.2 5.9 6.0 7.1 6.0
1999 5.3 5.5 5.7 6.1 6.0 5.9 5.6 5.8 7.0 5.8
2000 4.6 4.8 4.9 5.3 5.3 5.2 5.0 5.0 6.2 5.1
2001 4.0 4.2 4.2 4.6 4.6 4.5 4.3 4.4 5.4 4.4
2002 1.6 1.8 1.7 1.9 2.0 2.0 1.9 2.0 2.4 1.9
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Table 4-7 Annual female population of the 2002 version of the GPRD 
between 1989 and 2002, stratified by 10 year age group and the annual 
proportion of the UK female population covered the GPRD.
GPRD Population (1000s) by 10 year age band
0 -9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80 + Total
1989 51.4 47.5 72.4 61.9 54.0 41.8 43.5 34.1 23.2 429.9
1990 190.7 174.8 262.5 226.4 209.1 155.3 153.8 125.7 85.1 1583.4
1991 290.7 259.2 403.6 344.1 318.2 234.1 227.3 194.5 134.3 2405.8
1992 290.4 253.0 398.0 346.8 316.9 234.6 222.4 193.4 138.4 2393.9
1993 284.5 247.8 381.3 345.5 310.7 235.0 213.4 189.3 138.1 2345.5
1994 265.8 232.4 346.2 328.7 287.6 224.8 197.1 175.4 130.8 2188.8
1995 259.7 233.3 329.3 331.0 285.1 226.2 193.2 173.2 130.2 2161.2
1996 243.7 226.1 299.1 318.1 269.6 224.4 184.4 165.5 124.4 2055.2
1997 223.0 213.2 262.5 295.2 244.0 215.9 169.9 152.8 112.6 1889.2
1998 206.9 205.0 240.5 279.5 228.4 208.4 160.4 145.1 105.3 1779.5
1999 193.8 198.9 224.7 269.9 220.0 204.5 154.3 139.5 102.1 1707.6
2000 166.4 176.8 192.4 237.5 194.5 182,6 135.4 120.4 93.6 1499.6
2001 140.1 156.7 165.0 206.8 173.5 161.8 117.7 103.4 83.8 1308.8
2002 56.2 69.2 64.4 87.1 77.3 71.3 52.6 45.4 38.0 561.5
% of the UK Population covered by the GPRD by 10 year age band
0 -9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80 + Total
1989 1.4 1.3 1.6 1.6 1.5 1.4 1.4 1.5 1.6 1.5
1990 5.2 4.9 5.7 5.8 5.6 5.1 5.0 5.2 5.8 5.4
1991 7.9 7.4 8.8 8.6 8.3 7.8 7.6 8.0 9.0 8.1
1992 7.8 7.3 8.8 8.5 8.2 7.8 7.5 7.9 9.1 8.1
1993 7.6 7.2 8.6 8.3 7.9 7.7 7.3 7.7 8.9 7.9
1994 7.1 6.7 8.0 7.7 7.3 7.2 6.9 7.2 8.3 7.4
1995 7.0 6.7 7.8 7.6 7.2 7.1 6.8 7.1 8.1 7.2
1996 6.6 6.4 7.3 7.1 6.8 6.9 6.5 6.8 7.7 6.9
1997 6.0 6.0 6.6 6.5 6.3 6.3 6.0 6.2 7.1 6.3
1998 5.6 5.7 6.2 6.1 5.9 5.9 5.7 5.8 6.7 5.9
1999 5.3 5.4 5.9 5.9 5.7 5.7 5.4 5.6 6.6 5.7
2000 4.6 4.8 5.1 5.1 4.9 5.0 4.8 4.9 5.8 5.0
2001 4.0 4.2 4.4 4.4 4.3 4.3 4.2 4.3 5.1 4.3
2002 1.6 1.9 1.7 1.9 1.9 1.9 1.9 1.9 2.2 1.8
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The age- and sex- distribution of individuals registered on the GPRD was 
similar to that of the population of England and Wales during the same time 
period. In terms of representation of each area of the NHS (defined by the 
pre-1994 Regional Health Authority boundaries), in 1996 there was a relative 
under-representation of the population from Yorkshire, and from Scotland 
and a relative over-representation of the Trent population (Lawson 1998, 
ONS Info for researchers). There was also a sHght over-representation of 
large general practices (with more than four partners) and an under­
representation of single-handed general practices (Lawson 1998). It is 
possible that practices that stopped contributing data because of changing 
from VAMP to Vision software may be different, for example, in terms of 
their size or location, from those that remained using the VAMP software 
and therefore continued to contributed to the GPRD, but this has not been 
quantified.
4.5 Quality of the data
The quahty of the data was monitored until 1997 and was based on 
(reproduced from ONS Information to researchers):
■ Completeness of recording of demographic /registration data
■ The percentage of acute and repeat prescriptions that have appropriate 
indications recorded
■ Referrals
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■ Recording of the fact and cause of death
■ Recording of pregnancy outcome on maternal and child records
■ Completeness of recording of contraception
■ Monitoring trends in rates of consultations, prescriptions etc
In order to meet the requirements to contribute data of 'research standard'
GPs must have recorded the indication for all new drug therapies, hospital 
referrals, the diagnoses made by hospital in- or out-patient episodes and 
significant test results (Garcia-Rodriguez 2000).
A number of studies have been undertaken to verify diagnoses and 
recording completeness on the GPRD. Studies that have compared the 
accuracy of diagnostic code use compared with diagnoses from hospital 
letters have found that accuracy is approximately 90% for major medical 
diagnoses (Jick 1991, Jick 1992, van Staa 1994, Hansell 1999, Jick 2003). 
Inpatient episodes and referrals to outpatient clinics have been shown to be 
between 10% and 30% under-recorded (Lawrenson 2000, Lewis 2002).
The GPRD is comprised of the medical records of patients derived 
from GPs' day-to-day patient management. In terms of completeness of data, 
this can mean that GPs will not record every symptom or mild illness that a 
patient presents unless it is of importance to their clinical management of the 
patient. However, in order that the database contains records that are of a 
standard that can be used for research, the guidelines to general practitioners
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contributing to the GPRD in terms of data that should be recorded are as
follows (reproduced from 'Nine Golden Nuggets', MHRA 2003).
■ Prescriptions: details of every prescription issued by the practice should be 
entered whether the drug was prescribed at a surgery or at any other 
time.
■ Events resulting in a prescription: A  computer record should be made of all 
events resulting in a prescription or withdrawal of a drug or other 
treatment.
■ Other significant events: In addition to events which result in a 
prescription, a record should be made of all other significant morbidity 
findings (e.g. hospital referrals, test results, unplanned withdrawal of a 
drug, childhood diseases and pregnancy).
■ Chronic and recurrent illnesses: the date of the original onset of a chronic or 
recurrent condition should be recorded.
■ Contraception and immunisations: A  record of contraceptives (oral, lUD, 
other) and immunisation should be recorded whether these are 
prescribed or administered in the surgery or elsewhere.
■ Pregnancy outcomes and childbirth: the outcome of pregnancy should be 
entered in the mother's clinical record and the condition of the newborn 
should be recorded in the child's own record.
■ Deaths: where a patient has died, a record of the death, and when known, 
the cause of death should be entered.
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Lifestyle: current smoking status, alcohol intake and height /  weight 
should be recorded for adults approximately every 3-5 years.
Registrations: registration details of all patients should be accurately 
maintained including date of birth, sex, registered GP, and registration 
status.
4.6 Potential strengths and limitations of the GPRD in 
studying SLE
Although SLE is a disease where a firm diagnosis is made by a 
rheumatologist, who will also manage most of the patients care, it is a 
disease that will present in general practice, and all prescriptions for its 
management will be issued by the GP under the guidance of the 
rheumatologist (Glazier 2002). The aims of this thesis were to determine the 
epidemiology of SLE in the UK population and to investigate and describe its 
initial presentation in primary care, and its management in primary care.
The GPRD is a large, observational, longitudinal population-based 
database of medical records. Although SLE may not be considered to be 
/rare' in terms of its prevalence, it is certainly rare with regards to its 
incidence. If a study of the presentation of SLE were to be conducted using 
recruitment from general practices in the UK, it would be necessary to 
involve hundreds of practices in order to have a sufficient sample size for 
such a study. In terms of population size and the availability of the data, the 
GPRD is suitable for the study of SLE.
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Data contained in the GPRD are collected prospectively by GPs in the 
day-to-day management of their patients. There are advantages and 
disadvantages to this characteristic of the database. The strengths are that 
the data are truly observational and free from recall bias; it is possible to 
draw conclusions about the presentation of disease as it occurs and before 
the diagnosis has been made. However, GPs will only record symptoms and 
diagnoses that they consider to be of importance to the clinical management 
of their patients. In Chapter 3 I reviewed the published studies of the initial 
presentation of SLE and it is clear that although arthritis and arthralgia are 
common, there are also many constitutional symptoms that are important in 
the prodromal period of SLE. Whilst it might be assumed that GPs would 
record arthritis and arthralgia in children and in adults, it cannot be assumed 
that they will do so for older patients, who might be expected to have some 
aches and pains, associated with, for example, normal 'wear and tear' or 
menopause. Equally, the recording of constitutional symptoms will be 
dependent on whether the GP perceives them to be of importance or not. 
Moreover, the recording of any symptoms is entirely dependent on the 
patient reporting them to the GP. It is not possible to request that specific 
data are collected for the purposes of a particular study, and therefore the 
GPRD is limited by the GPs decision whether or not to record certain clinical 
information. In the study of SLE, especially with reference to the ACR 
classification criteria (Tan 1982), full details of all symptoms reported by 
patients would be of benefit. An additional consideration in the
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identification of cases is that GPs are, as a requirement for the quahty of their 
data coUection, not obhged to record every consultation or symptom of a 
chronic disease once it has been diagnosed.
SLE is a chronic relapsing-remitting disease that, to date, has no cure. 
IdeaUy, in the study of SLE presentation and management, it would be useful 
to have access to the patient's entire medical record. However, the GPRD is a 
dynamic cohort, patients and practices enter and leave the database at 
different times, some contributing many years of data whilst others 
contribute only a few months. This issue is somewhat exacerbated in the 
1998 database by the loss of the Vision practices from 1995 onwards. The 
data from the GPRD are censored; they are essentiaUy a snap-shot in time, of 
varying lengths, for each patient's medical records. Data before the left- 
censoring date are likely to be incomplete and cannot be considered to be 
complete or reliable for the purposes of research. Data after the right- 
censoring date are unavailable. This issue of censoring is important with 
regards to not only to methods of case identification, ensuring that a case is 
truly incident, but also to the investigation of presentation. If the mean time 
from symptom onset to diagnosis in the UK is 61 months (Hopkinson 1994), 
there are methodological considerations to be made for studies of its onset 
using censored data.
It is clear from the studies of the presentation, incidence, prevalence 
and prognosis of SLE that ethnicity is an important factor, with Afro- 
Caribbeans being more likely to suffer from SLE, with more aggressive
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disease and worse prognosis (Petri 2002). Although there is the facility to 
record ethnicity on the GPRD it is not routinely collected. A weakness of all 
of the studies presented in this thesis is the lack of data on ethnicity.
Prescribing data are approximately 95% complete (WaUey 1997) and 
since the early 1990s, GPs have been responsible for issuing all prescriptions 
including those managed by hospital specialists. For the investigation of the 
management of SLE, the GRPD is a rich data source. However, it is not 
possible to determine whether or not a patient has filled their prescription 
and there are no data regarding compliance or use of over-the-counter 
medications. Many of the drugs used in the management of SLE are 
potentially toxic and are not available over the counter. Therefore the 
potential information errors introduced by the analysis of prescribing data 
are likely to be minimal. I have not addressed the issue of treatment 
compliance in any of the investigations in this thesis. Chapter 6 reports the 
method of case identification for SLE that was used for all of the studies in 
the thesis.
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Chapter 5
Systematic Literature Review of the Incidence 
and Prevalence of Systemic Lupus 
Erythematosus in the United Kingdom
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5 Systematic Literature Review of the Incidence and 
Prevalence of Systemic Lupus Erythematosus in the 
UK
5.1 Background
The aim of this review was to determine the reported incidence and prevalence 
of SLE in the UK population and from that, to estimate the age- and sex- 
specific number of cases of SLE we should expect to identify from the 
population of the GPRD.
5.2 Methods
A systematic review of the literature was conducted of studies of the incidence 
and prevalence of SLE in the UK population.
5.2.1 Types of studies and study participants
Population-based cohort or cross-sectional studies designed to estimate the 
incidence and /  or prevalence of clinically diagnosed SLE or SLE defined using 
the ACR classification criteria (Tan 1982, Hochberg 1997) in any specific 
population within the United Kingdom were included in the review.
5.2.2 Outcome measures
1. Unadjusted, age- and sex-specific, age-adjusted incidence rates of SLE with 
95% confidence intervals
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2. Unadjusted, age- and sex-specific, age-adjusted prevalence of SLE with 95% 
confidence intervals
3. Race-specific incidence and prevalence of SLE
4. Mean age at diagnosis for incident cases of SLE
5.2.3 Search Strategy
Medline (1966 to November 2005) and Embase (1974 to November 2005) were 
searched to identify studies that fulfilled the inclusion criteria using the 
following search strategy.
Exp Systemic Lupus Erythematosus /  All subheadings 
And
Incidence /  All subheadings or Incidence (text)
Prevalence /  All subheadings or Prevalence (text)
Cross-sectional studies /  AU subheadings 
And
Exp Great Britain /  AU subheadings 
UK (text)
England /  All subheadings or England (text)
Exp Ireland /  All subheadings or Ireland (text)
Scotland /  AU subheadings or Scotland (text)
Wales /  All subheadings or Wales (text)
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In addition to the search of the electronic databases, citation Hsts of all included 
papers and relevant literature reviews and book chapters were searched for 
further studies.
5.2.4 Methods of the review
The abstracts of all papers identified from the search strategy were assessed for 
inclusion or exclusion into the review. The reasons for exclusion were 
recorded. After all abstracts had been assessed, the full text of aU papers that 
had been included at this stage were obtained and assessed for inclusion or 
exclusion. AH included papers were critically appraised using an adapted 
version (Appendix 4a) of Crombie's cohort and survey appraisal checktists 
(Crombie 1996). Data extraction was carried out using a standardised data 
extraction form (Appendix 4b).
5.3 Results
Fifty-nine papers were identified from the searches of Medline and Embase. 
There were no relevant additional papers identified from citation lists. Figure 
5.1 shows the number of papers included and excluded from the review. Seven 
papers were included in the review, reporting the results from 6 studies of the 
incidence and prevalence of SLE in the UK. The studies that were described in 
these papers were; the GP Morbidity Study (Hochberg 1987), the Leicester 
study (Samanta 1992), the Nottingham study (Hopkinson 1993, Hopkinson
1994), the Birmingham Study (Johnson 1995), the Northern Ireland study
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(Gourley 1997) and the South London study (Molokhia 2001). Table 5.1 is a 
summary of the included studies. A list of all excluded papers is provided in 
Appendix 2c and 2d.
Figure 5-1. Papers identified from the search strategy
7 papers included in the review 
(see Table 5.1)
59 papers identified: 
Abstracts assessed
14 fuU text papers assessed
45 papers excluded 
(Appendix 2c)
7 papers excluded 
(Appendix 2d)
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5.3.1 Critical appraisal of included studies
From critically appraising the included papers, the two main issues in terms of 
assessing the reported accuracy of the incidence and prevalence of SLE and in 
applying the results to the UK as a whole were (a) the method, and 
consequently completeness of case ascertainment used and (b) the 
generalisability of the study populations to the UK population.
5.3.1.1 Case ascertainment
The Nottingham (Hopkinson 1993, Hopkinson 1994) and Birmingham (Johnson
1995) studies were population-based and cases were defined using the ACR 
criteria. Both studies were well designed and used multiple sources of retrieval 
for their case ascertainment. It is possible that a few cases of SLE were not 
identified. Case identification occurred over a period of time using a 
combination of hospital and primary care sources along with contacts to local 
support groups and patient registers that had been collated over several years. 
It is unlikely that many cases would have been missed due to the relapsing- 
remitting nature of SLE (i.e. patients not seeing a doctor during periods of 
quiescence). Using the capture-recapture technique, Johnson (1995) calculated 
that 18 cases of SLE may have been missed. Hopkinson (1993) stated that 83% 
of cases were identified from more than one source and this was suggestive of 
a high level of case ascertainment.
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The Leicester study (Samanta 1992) was designed to determine the prevalence 
of SLE amongst Asian immigrants and excluded cases other than those of 
Asian or Caucasian origin. They used multiple sources of retrieval for case 
ascertainment which was carried out using three years of data from two of the 
sources. None of the cases were identified solely from one source. With the 
exception of contacting the local lupus support group, all of the sources used 
for case identification were hospital based. The authors recognised that 
patients with SLE not attending hospital during the study period would not 
have been identified and state that the prevalence estimates should be regarded 
as the "minimum' rather than true estimate for the study population. It should 
be noted that the crude prevalence of SLE reported in this study is an 
underestimate of the "true' population prevalence as ethnic groups other than 
Asian and Caucasian were not included in the study population.
The Northern Ireland study (Gourley 1997) was population-based and 
used multiple sources of retrieval, but did not classify all cases according to the 
ACR criteria. It had a complex design that aimed to adjust for non­
ascertainment of cases and for the specificity of diagnosis of SLE. They 
classified a proportion (20.9%) of cases that were included in another study of 
familial SLE using the ACR criteria. Of this proportion of cases classified using 
the ACR criteria, 14 did not fulfil the criteria. The authors used the capture- 
recapture technique to estimate the number of cases that had not been 
identified during case ascertainment. They adjusted the actual number of cases 
identified (n=422) for non-ascertainment (n=493) and then carried out a further
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adjustment of this number for diagnostic specificity (n=415). It is possible that 
cases not seeing their doctor for SLE during the one year period of case 
ascertainment might not have been identified and that this could have led to an 
underestimate of the prevalence even after adjustment for non-ascertainment 
of cases.
The South London study (Molokhia 2001) was designed to determine 
whether the prevalence of SLE was higher in those of West African origin 
compared with those of Afro-Caribbean origin. This study used hospital clinics 
as the only source of case ascertainment and it is highly probable that patients 
with SLE who were not attending hospital clinics for the management of their 
disease would not have been identified.
The study by Hochberg (1987) was conducted using data from the 3^  ^
National Study of Morbidity Statistics from General Practice. Prevalence of SLE 
in this study was certainly underestimated as only patients with SLE who had 
consulted their GP in 1981-82, and whose GP had recorded that consultation 
using the lCD-9 Rubic 710.10 (SLE) would have been identified. This study 
would not have identified any cases of quiescent disease or cases where the 
consultation had been recorded using a symptom code (e.g. arthritis or renal 
disease). There were no male cases of SLE identified during the study period.
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5.3.1.2 Generalisability
The South London (Molokhia 2001) study was conducted in a unique 
population within the UK with the objective of assessing the prevalence of SLE 
in West African migrants compared with that in West Africans originating 
from the Caribbean. Therefore, this study is not generalisable to the general 
population of the UK. The study by Samanta (1992) estimated the prevalence of 
SLE in the Caucasian and Asian populations of Leicester. Although overall 
prevalence estimates were calculated, these would have excluded any other 
ethnic group and cannot be seen as representative of Leicester, or of the UK as 
a whole. To a lesser extent, the populations in Nottingham and Birmingham 
have a higher proportion of Asians and Afro-Caribbeans than the population of 
England and Wales (ONS Online). Incidence and prevalence estimates might 
be marginally higher than that of the UK population, of which 92% are 
Caucasian. The study in Northern Ireland is representative of a Caucasian 
population. The true prevalence of SLE in the UK is probably somewhere in the 
range of the point estimates and their 95% confidence intervals from the 
Nottingham, Birmingham and Northern Ireland studies and would be affected 
by the ethnic mix of the population. The study by Hochberg presents a 
substantial underestimate of the prevalence of SLE and should not be used to 
estimate prevalence in the UK population as a whole.
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5.3.1.3 Incidence of systemic lupus erythematosus
The Birmingham (Johnson 1995) and Nottingham (Hopkinson 1993) studies 
reported the incidence of SLE. Johnson (1995) excluded males and females 
under 18 years of age and therefore, the only incidence data available for the 
UK in children is for Nottingham (Hopkinson 1993). The investigators in these 
studies included consultant rheumatologists. Incident cases were defined as 
patients without a previous diagnosis of SLE and who fulfilled at least four of 
the ACR criteria during the study periods. There were 33 incident cases of SLE 
in the Birmingham study and 23 in the Nottingham study.
The overall age-standardised incidence rates were 3.8/100,000/year 
(CI95 2.5, 5.1) in Birmingham and 4.0/100,00/year (2.3, 5.6) in Nottingham. In 
the Birmingham study, the incidence rates were directly standardised to the 
population of the West Midlands whereas in the Nottingham study the 
European population was used as the standard. It would seem that for the 
immediate area, the West Midlands population was a more appropriate 
population to use as a standard. Bearing in mind the strong association 
between non-Caucasian ethnicity and SLE, the use of the European population 
as a standard could be questioned, and it might have been more appropriate to 
standardise the rates to the UK population. If, in Europe, the proportion of the 
population that is of non-Caucasian origin is lower than that for Nottingham 
and the UK. Standardisation to the European population would produce an 
overestimate of the incidence of SLE.
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Table 5.2 shows the age- and sex-specific incidence rates for the Nottingham 
and Birmingham studies. Incidence rates of SLE were consistently higher in 
females than in males. In Nottingham, the peak incidence rate of 
18.4/100,000/year was in females aged 50-59 years whereas the Birmingham 
investigators reported the peak incidence rate to be amongst females aged 18- 
19. However, it could be debated whether this is a true peak incidence rates 
because it is not significantly different from the incidence rates in the older age 
groups, the confidence intervals are wide and the lower age for inclusion of 
cases in this study was 18 years. In Birmingham, the median age of the 
incident female cases was 37 years (range 17-72), whereas in Nottingham it was 
47 years. There were two incident male cases in Birmingham, aged 23 and 65, 
and four in Nottingham, with a median age of 55.5 years.
The race-specific incidence rates of SLE are shown in Table 5.3. 
Although Hopkinson (1994) reported age- and race-specific incidence rates, the 
numbers in each stratum were very small. For this reason, we have presented 
overall and age-standardised race-specific incidence rates only. Incidence rates 
were higher in those of Afro-Caribbean and Asian origin than those in the 
Caucasian population. The proportion of Afro-Caribbeans in Nottingham and 
Birmingham were similar, but there was a higher proportion of Asians and 
lower proportion of Caucasians in Birmingham.
Johnson (1995) reported the median ages at disease onset by ethnicity. In 
Afro-Caribbean females, the median age at disease onset was significantly 
lower at 26 years (range 16-57) in Asian females it was 32.5 years (range 9-70)
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and in Caucasian females it was 33 years (range 5-72). The difference in age at 
onset in Afro-Caribbean females was significantly lower than that in Asian and 
Caucasian females (p < 0.05).
98
'S
bO
G\(S
S'o
s .
m
ON
G .
VO mo
N
ON
I
00
VO
d
VOoo
CO
+o OVuS
VO
I cvlK o
ON
R GCO CN
CM
vd
Im CM VO VOCMCO VO 00r - l
I VOCM % ino
I
CO
00
CM
00
o
N
I KCMin o Zn ONin
Q)
G G
00
s?
00
c6
L0)
2I I
00
M o
I à I "5 COtI I 1 II
y ,
'd
ON
00r4
I
Ii ON
ON
Table 5-3. Race-specific incidence rates of SLE
Caucasian Asian Afro-Caribbean
NOTTINGHAM (Hopkinson 1994) n=23
Cases 19 1 3
Proportion of all cases (%) 82.6 4.4 13.0
Incidence rate /  100,000/year (aU) 3.3 6.1 21.0
Age-standardised incidence rate (CI95) 3.4 (1.8,4.9) 4.1(0,12.0) 31.9 (0,69.8)
BIRMINGHAM (Johnson 1995) n=33
Cases 18 8 7
Proportion of all cases 54.6 24.2 21.2
Incidence rate /100,000/year (females)* 4.3 20.7 25.8
Age-standardised incidence rate (CI95)* 4.5 (2.7,7.2) 29.2 (14.2,51.0) 22.8 (6.9,50.2)
* female cases only
5.3.1.4 Prevalence of systemic lupus erythematosus
Prevalence of SLE was reported in six studies included in the review. Overall 
prevalence estimates varied from 12.5/100,000 (Hochberg 1987) to 27.7/100,000 
(Johnson 1995). Tables 5.4 and 5.5 show the age-specific prevalence in males 
and females respectively. Prevalence of SLE was higher in females in aU 
studies. In Nottingham (1993) the peak prevalence of 92.0/100,000 was in 
females aged 50-59 years. Similarly, in Northern and Ireland (Gourley 1997) 
and Birmingham (Johnson 1995) peak prevalence was found in females aged 
45-59 years (87.7/100,000) and 40-49 years (83.2/100,000) respectively. In 
Leicester (Samanta 1992), peak prevalence in Caucasian females was in those
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aged 45-59 years and in Asian females, peak prevalence was in those aged 60- 
69 years.
The capture-recapture technique was used to estimate the number of 
missing cases in the Birmingham (Johnson 1995) and Northern Ireland 
(Gourley 1997) studies. In Birmingham, it was estimated that 18 cases may 
have been undetected, and the prevalence of SLE adjusted for non­
ascertainment of cases was 29.8/100,000 (CI95 26.2,33.4). In Northern Ireland, it 
was estimated that 71 cases may have been missed. Additionally, the 
investigators calculated that of the 422 cases identified, 67 might not have 
fulfilled the ACR classification criteria. The prevalence of SLE adjusted for non- 
ascertainment of cases and for inclusion of cases that may not have fulfilled the 
ACR criteria was 25.4/100,000 (CI95 22.1,28.7) (n=415).
Race- specific prevalence of SLE was reported in the Birmingham (14), 
Nottingham (16) and Leicester (17) studies. Although age- and race-specific 
prevalence point estimates were reported for the Nottingham and Leicester 
studies, with the exception of the Caucasian group, numbers of cases were very 
small, making the point estimates of the prevalence unstable. We have 
summarised the overall and age-standardised race-specific prevalence, by 
gender where available (Table 5.6). As previously discussed for the calculations 
of the age-standardised incidence rates, the standard populations for these 
studies were the European population for the Nottingham study and the West 
Midlands population for the Birmingham study. In the Leicester study they 
calculated the age-standardised prevalence of SLE in the Asian population
101
standardised to the Caucasian population in the study area. In the South 
London study, prevalence was directly standardised to the total population of 
the study area.
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5.4 Discussion
There were two studies reporting the incidence of SLE in Nottingham 
(Hopkinson 1993, Hopkinson 1994) and Birmingham (Johnson 1995) and six 
studies (Hochberg 1987, Johnson 1995, Hopkinson 1993, Hopkinson 1994, 
Samanta 1992, Gourley 1997, Molokhia 2001) reporting the prevalence of SLE 
in other selected populations with in the UK. With the exception of the USA, 
no other country has had more studies of the epidemiology of SLE 
published. There have been no country-wide studies of the incidence or 
prevalence of SLE in England, Scotland or Wales UK. The quaUty of the 
studies identified varied, however overall the studies were rigorously 
conducted and were of high quatity. The studies that are of timited use in 
terms of applying their results to the population of the General Practice 
Research Database are those by Samanta (1992) Molokhia (2001) and 
Hochberg (1987). These studies had methods of case ascertainment that 
would have missed cases of SLE and therefore prevalence estimates are 
underestimated. Additionally, Molokhia (2001) selected the specific 
population in South London for a study that did not aim to calculate the 
prevalence of SLE in the general population but in those of West African or 
Afro-Caribbean origin. The study by Samanta (1992) cannot be generalised 
to the UK population as a whole because it included only Asian and 
Caucasian cases.
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Summarising the results of this review, the incidence of ACR defined SLE in 
the UK amongst females is between 6.5/100,000/year (CI95 3.5, 9.4) and 
6.8/100,000/year (CI95 4.4, 9.2) whereas it is between 0.5/100,000/year (CI95 
0.1, 1.7) and 1.5/100,000/year (CI95 0.02, 2.9) in males. Prevalence of ACR 
defined SLE is likely to be between 3.6/100,000 (CI95 2.0, 6.0) and 4.3/100,000 
in males and 45.4/100,000 (CI95 37.6,53.1) and 49.6/100,000 (Cl9s43.2, 56.1) in 
females. The incidence and prevalence of clinically diagnosed and treated 
SLE is likely to be higher than that of SLE classified using the ACR criteria 
and lower than that of undiagnosed SLE in the community. Johnson (1996) 
conducted a pilot survey of undiagnosed SLE in Birmingham. They had a 
low response rate to the survey and identified only 3 cases of undiagnosed 
SLE in the study population; however the effect of these cases on the 
prevalence of SLE in Birmingham was that it increased from 54/100,000 (CI95 
47,62) in women aged 18-65 years to 200/100,000 (CI95 80,412). The 
prevalence of clinically diagnosed SLE in the UK population will He 
somewhere in this range.
The incidence and prevalence of SLE in the UK population is similar 
to that reported for mainly Caucasian populations in Europe (Jonsson 1990, 
Gudmundsson 1990, Voss 1998, Stahl-Hallengren 2000) but lower than that 
reported (122/100,000 ( C I 9 5  97,147)) for a primarily Caucasian population in 
Minnesota, US in 1993 (Uramoto 1999). Incidence and prevalence are highest 
in the UK in women aged 40-59 years, and this is consistent with findings in 
Europe (Gudmundsson 1990, Jonsson 1990, Voss 1998, Stahl-Hallengren
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2000). Incidence and prevalence of SLE is also significantly higher in Afro- 
Caribbeans compared with Caucasians, and to a lesser extent, in Asians. 
Average age at disease onset and diagnosis is lower in Afro-Caribbeans than 
in Caucasians and Asians (Johnson 1995).
This systematic review was designed to identify aU pubHshed studies 
of the incidence and prevalence of SLE in the UK. I found no further studies 
from searching citation Hsts of included studies and relevant Hterature 
reviews and beheve that all pubHshed studies were identified by the search 
strategy. The main weaknesses of this review were the lack of attempt to 
identify unpubHshed studies of the incidence or prevalence of SLE in the UK 
population and that, for practical reasons, assessment of studies for inclusion 
or exclusion into the review and data extraction was not carried out by more 
than one reviewer. The issues that these methodological weaknesses present 
are the presence of potential publication bias in the selection of included 
studies, selection bias and data extraction bias caused by the lack of a second 
reviewer in the review. I have not identified any further studies of the 
epidemiology of SLE in the UK population that should have been included in 
this review from any other source and therefore the likelihood a significant 
role of pubHcation and selection bias in the review is minimal. Data 
extraction for the review has been carried out on several occasions since the 
start of this thesis and therefore, although it has not been carried out by two 
independent reviewers, it has been checked more than once. This does not 
exclude the possibility of error during data extraction but it does mmimise
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the chances of this bias existing in the review. I decided not to conduct a 
pooled analysis of the incidence and prevalence as the study populations 
differed in terms of case identification and ethnic mix.
The aim of this review was to determine an accurately estimated range 
of incidence and prevalence of SLE in the UK population in order to 
determine the number of cases we would expect to identify from the 
population of the GPRD. The population of the GPRD has been described in 
detail in Chapter 4. Table 5.7 is a summary of the population of the GPRD for 
those contributing at least 3 years of research standard data to the database 
for 1992,1994,1996 and 1998. I have appHed the confidence intervals of the 
sex-specific prevalence estimates from this review to determine the number 
of cases of SLE (defined using the ACR criteria) that might be identified from 
the GPRD population. Table 5.8 is a summary of the number of person-years 
of observation in the same population of the GPRD for 1992-1998 and an 
estimation of the number of incident cases that should be identified from the 
GPRD during this period.
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Chapter 6
Identifying Cases of Systemic Lupus 
Erythematosus from the General Practice
Research Database
112
6 Identifying Cases of SLE from the GPRD
6.1 Introduction
The GPRD comprises the records of the day-to-day clinical management of 
patients in primary care. Therefore, it is not unusual for GPs to record a 
suspected diagnosis, which is then investigated and either confirmed or 
excluded. As a consequence, when using the GPRD it is important that when 
cases have not only got a record of diagnosis but also some evidence in their 
medical record to support that diagnosis. This supporting evidence helps to 
distinguish between those that are a 'real' case of that disease and those 
where the GP has suspected the presence of disease or a disease process, and 
this is under investigation or it has been excluded following investigation. 
For example, patients presenting with inflammatory connective tissue 
diseases (e.g. mixed connective tissue disease or undifferentiated connective 
tissue disease) may be monitored by a rheumatologist for the development of 
SLE at some time in the future. It is possible that this is reflected in the 
records that the GP makes for their clinical management of their patients 
leading to issues with separating cases of 'suspected' and 'confirmed' cases 
of SLE. The availability of the free text 'comments' field of the medical 
records in the 1998 version of the GPRD was helpful in this process because 
GPs would record the presence of symptoms, test results and whether the 
diagnosis had been confirmed or excluded.
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This chapter reports on the methods of case identification used for SLE and is 
a discussion of the issues in identifying cases of SLE from the GPRD and in 
their classification using the ACR criteria. It also contains a summary of the 
clinical and demographic characteristics of all cases identified from the 1998 
and 2002 versions of the database.
6.2 Methods
The initial phase of identifying cases of SLE was conducted using the 1998 
version of the GPRD; the methods developed during this phase were then 
apphed to the 2002 database to identify cases for my study of the 
presentation of SLE in primary care (Chapter 10). The medical records of all 
potential cases were reviewed in detail using our Coding Browser software 
(as described in Chapter 4).
6.2.1 Identifying potential cases
The 1998 version of the GPRD was searched for all patients with a diagnosis 
of SLE at any time in their medical record, including diagnoses recorded 
before the left-censoring date. Table 6.1 is a list of the OXMIS and Read 
Codes that were used to search the GPRD. The record of each potential case 
was reviewed manually in detail to determine whether or not they had a 
confirmed diagnosis of SLE. This method of case identification was 
approved by the Scientific Advisory and Ethical Group (SEAG) to the GPRD
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within the approvals for the incidence and prevalence study protocol 
(Appendix 3).
6.2.2 Classification of cases
I had aimed to classify aU cases of SLE according to the 1982 Revised ACR 
criteria for the classification of SLE (Tan 1982, Hochberg 1997) to enable the 
comparison of our study with the results of the majority of epidemiological 
studies of SLE conducted elsewhere. As specific codes relating to each 
criterion were not available, I mapped each criterion to a number of OXMIS 
and Read Codes used in the GPRD and extracted data manually on blood 
and urine analysis and on presenting symptoms from the free text 
'comments' field of the medical records and from prevention records of 
blood test results.
The specific OXMIS and Read Codes used for the classification of 
cases of SLE can be found in Appendix 4. Codes that were used to identify 
relevant blood test results, symptoms and urine analyses are in Table 1, 
Appendix 4. Cases were classified using the adapted definitions of the ACR 
criteria (Table 6.2).
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Table 6-1. OXMIS and Read Codes used to search for cases of SLE in the 
GPRD population
Code Description
6954 Systemic Lupus Erythematosus
6954ED Lupus Erythematosus Discoid
6954EL Lupus Erythematosus Local
6954ND Discoid Lupus
7341 Lupus Erythematosus Disseminated
7341A Systemic Lupus Erythematosus with Renal Involvement
7341AA Lupus Erythematosus Systemic
7341AB Lupus Nephritis
7341AC Acute Systemic Lupus Erythematosus
7341AD Lupus Erythematosus Acute
F371000 Polyneuropathy in Disseminated Lupus Erythematosus
F396100 Myopathy due to Disseminated Lupus Erythematosus
H57y400 Lung Disease with Systemic Lupus Erythematosus
K01x400 Nephrotic syndrome in systemic lupus erythematosus
K01x411 Lupus Nephritis
M154.00 Lupus Erythematosus
M154100 Discoid Lupus Erythematosus
M154700 Sub acute Cutaneous Lupus Erythematosus
M154z00 Lupus Erythematosus NOS
Myu7800 [X] Other Local Lupus Erythematosus
NOOO.OO Systemic Lupus Erythematosus
NOOOOO Disseminated Lupus Erythematosus
N000300 Systemic Lupus Erythematosus with Organ or Systemic
Involvement
N000400 Systemic Lupus Erythematosus with Pericarditis
NOOzOO Systemic Lupus Erythematosus NOS
Nyu4300 [X] Other Forms of Systemic Lupus Erythematosus
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Table 6.2. Adapted definitions of the ACR criteria used for potential SLE 
cases from the GPRD
Criterion and 
location of 
OXMIS and Read 
Codes
ACR definition Adapted GPRD definition
Malar rash 
Appendix 4 
Table 2
Fixed erythema, flat or raised, over the malar 
eminence, tending to spare the nasolabial 
folds
Record of malar or butterfly rash.
Discoid rash 
Appendix 4 
Table 3
Erythematous raised patches with adherent 
keratotic scaling and follicular plugging; 
atrophic scaring may occur in older lesions
Record of discoid lupus or discoid rash 
with lupus in the comments
Photosensitivity 
Appendix 4 
Table 4
Skin rash as a result of unusual reaction to 
sunhght by patient history or physician 
observation
Record of photosensitivity, adverse effect 
of sunlight, rash light eruption or allergy 
or sensitivity to the sun
Oral ulcers 
Appendix 4 
Table 5
Oral or nasopharyngeal ulceration, usually 
painless, observed by a physician
Record of mouth, palate, tongue, nose or 
throat ulceration
Arthritis 
Appendix 4 
Table 6
Non-erosive arthritis involving two or more 
peripheral joints, characterised by tenderness, 
swelling or effusion
Record of arthritis or arthropathy in the 
absence of a diagnosis of osteoarthritis or 
record of arthralgia plus joint swelling or 
effusion
Serositis 
Appendix 4 
Table 7
Pleuritis: convincing history of pleuritic pain 
or rub heard by physician or pleural effusion 
or
Pericarditis: documented by EGG or rub or 
evidence of pericardial effusion
Pleuritis; record of pleurisy, pleuritic pain, 
effusion or rub
pericarditis: record of pericarditis, 
pericardial effusion or rub
Renal disorder 
Appendix 4 
Table 8
Persistent proteinuria >0.5g/day or 3+ if 
quantification not performed or 
cellular casts; may be red cell, haemoglobin, 
granular, tubular or mixed
Record of lupus nephritis, SLE with renal 
involvement, renal failure /  
haemodialysis, nephritic syndrome or 
glomerulonephritis or 
record of the presence of persistent 
proteinuria >0.5g/day or 3+; record of 
cellular cases
Neurological 
disorder 
Appendix 4 
Table 9
Seizures in the absence of offending drugs or 
known metabolic derangement or 
psychosis in the absence of offending drugs or 
known metabolic derangement
Record of psychosis record of fits, 
convulsions, seizures or epilepsy or 
record or schizophrenia
Haematological 
disorder 
Appendix 4 
Table 10
Haemolytic anaemia with reticulocy tosis or 
leucopeania <4000/mm3on two or more 
occasions or
Lymphopaenia <1500/ mm  ^on two or more 
occasions or
Thrombocytopenia <100 000/ mm  ^in the 
absence of offending drugs
Record of haemolytic anaemia or 
record of leucopaenia or leucocytes 
<4,000/rrun3 on two or more occasions 
record of lymphopaenia or lymphocytes 
<1,500/ mm3 on two or more occasions 
record of thrombocytopenia or platelets < 
100,000/mm3
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Table 6.2 continued
Criterion and 
location of OXMIS 
and Read Codes
Immunological 
disorder 
Appendix 4 
Table 11
Antinuclear 
antibodies 
Appendix 4 
Table 12
ACR definition
Anti-DNA: antibody to native DNA in 
abnormal titre or
Anti-SM: presence of antibody to SM nuclear 
antigen or
Positive finding of antiphospholipid 
antibodies based on (1) an abnormal serum 
IgG or IgM anticardiolipin antibodies or (2) a 
positive test for lupus anticoagulant 
antibodies or (3) a false-positive serological 
test for syphilis known to be positive for at 
least 6 months and confirmed
An abnormal titre of ANA by 
immunofluorescence or by equivalent assay at 
any point in time and in the absence of drugs 
known to be associated with drug induced 
lupus syndrome
Adapted GPRD definition
Record of the presence of antibodies to ds- 
DNA or DNA binding antibodies 
presence of anti-SM antibody (only 
available in the comments field) 
record of antiphospholipid antibodies 
(anticardiolipin), presence of LE cells, 
presence of circulating lupus 
anticoagulant, or a false-positive VDRL 
test.
Record of the presence of ANA.
6.2.3 Case definition
In the initial search of the GPRD, I identified 4615 potential cases of SLE, this 
reduced to 4014 after taking account of censoring dates outside 1992 -1998. A 
full description of these cases can be found in section 6.3. The original 
sample of 4615 potential cases were classified using the ACR criteria and I 
found that 115 of the cases (2.5%) fulfilled 4 or more of the criteria; a further 
274 (6.0%) fulfilled 3 criteria. A longer discussion of the issues surrounding 
the classification of the cases using the ACR criteria can be found in the 
discussion of this chapter (section 6.4) however, I decided that using the ACR 
criteria with the data available in the GPRD was not a sensitive or specific 
method of case identification. For this reason, an alternative case definition
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was developed using the available data and following a discussion with Dr 
Hughes and Dr Khamashta (Consultant Rheumatologists) from St Thomas' 
Hospital Lupus Unit, London in 2001. During this discussion, we raised the 
issues of the validity of 'hospital' diagnosed SLE. They agreed that if a 
patient had been diagnosed in hospital then it was likely that this diagnosis 
was accurate; however meeting the ACR criteria for the classification of SLE 
could not be determined from a clinical diagnosis of SLE.
In order to be accepted as a case of clinically diagnosed SLE cases must have 
fulfilled at least one of the following criteria;
■ Four or more of the adapted definitions of the ACR criteria (Table 6.2) 
recorded in the medical records or
■ Evidence of the diagnosis or treatment of SLE as a hospital in- or out­
patient. This evidence was taken from a diagnosis of SLE or medication 
changes recorded with an outcome field of 'hospital letter' or 'inpatient 
discharge summary'; referral for symptoms of SLE with a subsequent 
record of diagnosis of SLE or records of outpatient attendance to 
rheumatology, haematology or dermatology departments in the absence 
of any other indication being recorded for these visits. This was taken as 
the patient having had a diagnosis of SLE that had been confirmed by a 
rheumatologist or
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■ At least one prescription for azathioprine, cyclophosphamide, 
cyclosporine or methotrexate following diagnosis and in the absence of an 
alternative indication (for example other autoimmune diseases) or
■ At least three prescriptions for systemic corticosteroids (mainly 
prednisolone), hydroxychloroquine, chloroquine, mepacrine or NSAIDs 
following diagnosis and in the absence of an alternative indication or
■ At least three prescriptions for potent topical corticosteroids or 
medications commonly used for refractory lupus-specific skin disease 
(e.g. dapsone, clofazimine or systemic retinoids) following diagnosis, with 
evidence of severe systemic involvement (renal, cerebral or 
haematological) at any time in the medical record and in the absence of an 
alternative indication.
If a diagnosis for more than one coimective tissue or autoimmune disease 
(e.g. rheumatoid arthritis) was recorded in the medical records and where it 
was not possible to distinguish whether treatment was for SLE or for the 
other diagnosis, cases were included as having clinically diagnosed SLE. If 
the other diagnosis dominated the medical records, it was taken that the 
diagnosis had been changed from SLE and therefore the case was excluded.
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Cases of drug-induced lupus (DIL) were excluded because this is an 
aetiologicaUy and pathologically a different disease to SLE and symptoms 
disappear on cessation of treatment with the drug that has caused the 
reaction (Lunec 2000). Drugs that are known to be associated with DIL are 
hydralazine, chlorpromazine, penicillamine, isoniazid, a-methyldopa and 
procainamide (Lunec 2000). Cases of DIL were defined as those where the 
GP had attributed the patients symptoms to an adverse drug reaction. In the 
absence of long-term therapy of SLE, I suspect that most cases of DIL would 
have not fulfilled the inclusion criteria.
The method of case identification used for the 2002 database was 
identical to that of the 1998 database but was somewhat more difficult 
because the free text 'comments' field of the medical records was not 
available. Many symptoms and test results are recorded in this field leading 
to a lower proportion of cases fulfilling the ACR criteria. The 2002 database 
was used in the presentation of SLE study (Chapter 10) and therefore the 
only cases identified were incident cases with at least five years of data 
between their left censoring date and date of first SLE diagnosis.
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6.3 Results
6.3.1 1998 database
Four thousand and fourteen potential cases of SLE were identified from the 
1998 database of whom 1860 (46.3%) fulfilled the inclusion criteria and were 
classified as cases of clinically diagnosed SLE. 870 cases were excluded for 
apparently having isolated LE-specific skin disease, 1003 were excluded 
because they had insufficient evidence in their medical record to support 
their diagnosis. Other reasons for exclusion were: change in diagnosis after 
investigation (221 cases) and drug-induced lupus (60 cases).
One hundred and seven 107 of the cases had 4 or more of the criteria 
recorded in their medical records and a further 214 had 3 criteria. Table 6.2 is 
a summary of the characteristics of the cases partitioned by the number of 
ACR criteria that could be extracted from the medical records. Generally, 
patients who contributed more data (i.e. who had been registered on the 
GRRD for longer) to the GPRD had more ACR criteria in their medical 
records. I searched the medical records for diagnoses that were not used for 
the ACR classification but might be records of symptoms associated with 
SLE. Of the cases with no ACR criteria in their medical records, 6.6% had a 
record of "lupus" rash and a further 18.6% had a record of "rash" without 
further information regarding the nature of the rash. Moreover, 22.8% of 
these cases had "arthralgia" without a diagnosis of arthritis, joint effusion or
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swelling. When the medical records for all cases were reviewed, 28.9% of 
cases had "rash" with no further information of the nature of the rash and 
17.2% had "arthralgia" without a record of arthritis, joint swelling or 
effusion.
1473 (79.2%) of the cases had a record of hospital attendance for SLE, 
25 of these had a record of positive skin biopsy and 8 had a record of positive 
renal biopsy. Of those with no record of hospital attendance (n = 387), 10 had 
at least 4 ACR criteria in their records and 86 had been prescribed 
immunosuppressants (median number of scripts 9, range 1-105, mean 18.8). 
Of the remaining cases without a record of hospital attendance, 289 had at 
least 3 prescriptions for systemic steroids (median number of scripts 21, 
range 3-132, mean 27.5), antimalarials (median number of scripts 8.5, range 3- 
113, mean 18) or NSAIDS (median number of scripts 10, range 3-112, mean 
18.2) and 29 also had a record of SLE 'flare'. The two remaining cases who 
received potent topical steroids only were both prevalent and had a record of 
cerebral involvement in their medical histories.
In Chapter 5 I calculated, from the published Hterature, the number of 
cases of SLE I should have expected to identify from the GPRD population in 
1992, 1994, 1996 and 1998. Table 6.4 shows the number of expected cases 
calculated from the literature as well as the number of cases identified from 
the 1998 version of the GPRD.
The number of cases identified from the 1998 version of the GPRD 
was higher than might have been expected from the prevalence estimates in
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the hterature. This is discussed in more detail in Chapter 8 but one of the 
major differences between the method of case identification in this thesis and 
that used by the majority of studies of SLE is that we could not use the ACR 
criteria to define our cases because of the incomplete symptom records, and 
lack of blood and urine test results on the GPRD, even with the availability of 
the free text comments field in this version of the database. It is hkely that a 
proportion of the cases included as cases of SLE identified from the GPRD 
had a clinical diagnosis but would not fulfil the ACR criteria and would not 
have been included in a study where these criteria were used to define the 
cases.
It would have been useful to have been able to validate our method of 
case identification by sending questiormaires to general practitioners 
contributing to the GPRD to determine whether or not the patient did have a 
confirmed diagnosis of SLE, to have copies of the relevant hospital letters 
and ascertain the completeness of recording of the ACR criteria in the 
medical records compared with their presence from a more detailed 
questiormaire. However, we did not have the funding available for this study 
and therefore, currently, our method of case identification is unverified. 
Moreover, such a verification exercise would be limited to GPs who have 
agreed to complete questiormaires and send further information and to 
women still contributing to the GPRD at the time that these studies were 
conducted.
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Table 6-3 Symptoms and drug prescriptions in patients with clinically 
diagnosed SLE from the 1998 version of the GPRD, stratified by number of 
ACR criteria in the medical records. ___
Number of Criteria Identified from Medical Records
0 1 2 3 4+ Total
n = 500 n = 599 n = 440 n = 214 n = 107 n = 1860
Males (%) 80 (16.0) 73 (12.2) 56 (12.7) 20 (9.4) 10 (9.4) 239 (12.9)
Females (%) 420 (84.0) 526 (87.8) 384 (87.3) 194 (90.6) 97 (90.6) 1621 (87.1)
Hospital diagnosis (%) 341 (68.2) 469 (78.3) 376 (85.5) 190 (88.8) 97(90.6) 1473(79.2)
Record of 'flare' (%) 11 18.4 23.0 31.8 40.2 20.3
Data available in medical record
Mean Months (SO) 61.8 (32.4) 68.5 (30.0) 74.5 (29.5) 79.0 (26.2) 84.8(23.6) 70.3 (30.6)
Median Months 63 72 79.5 84 90 74
Range (months) 1-142 3-134 1-142 8-130 21 -142 1-142
ACR criteria in medical records (% of cases)
Malar rash - 3.0 9.1 20.1 35.5 7.5
Discoid rash - 4.7 19.6 24.8 34.5 11.0
Photosensitivity - 5.8 8.6 27.6 42.1 9.5
Oral ulcers - 3.5 9.8 22.4 33.6 8.0
Arthritis - 35.6 53.9 62.2 67.3 35.2
Serositis - 6.5 14.8 22.9 40.2 10.5
Renal disorder - 13.0 18.0 19.6 29.0 12.4
Neurologic disorder - - 7.2 15.9 20.1 25.2 9.8
Haematologic
disorder
- 6.5 12.3 29.4 31.8 10.2
Immunologic disorder - 8.9 23.4 32.2 61.7 15.7
Antinuclear
antibodies
- 5.3 14.8 18.7 31.8 9.2
Prescriptions fo llow ing diagnosis (% of cases)
Immunosuppressants 21.0 27.7 33.4 33.6 38.3 28.6
Systemic steroids 54.8 63.1 63.6 63.1 73.8 61.6
Antimalarials 31.4 41.2 42.5 44.4 56.1 40.1
NSAlDs 61.2 61.9 69.6 72.0 77.6 65.6
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Table 6-4 Number of cases of SLE identified from the 1998 version of the 
GPRD compared with the number of expected cases calculated from 
published estimates of SLE prevalence.
1992 1994 1996 1998
Number of cases identified 1152 1235 1215 842
from the 1998 database
Number of cases expected 825 - 901 833 - 911 632 - 690 375- 410
to be identified
6.3.2 2002 database
The 2002 version of the GPRD was searched using the OXMIS and Read 
codes listed in table 6.1 who were registered as permanent, left practice or 
dead patients and who contributed at least five years of data to the GPRD 
before their first record of a diagnosis of SLE. There were 656 potential cases 
of SLE. The records of all of these cases were reviewed in detail using the 
Coding Browser software. Three hundred and forty-five cases were classified 
as incident cases of SLE, these cases are discussed in more detail in Chapter 
10.
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6.4 Discussion
Although I attempted to classify cases according to the ACR criteria, it was 
not feasible to define our cases using these criteria. The main reason for this 
was that the GPRD is comprised of records that have been recorded during 
the day-to-day clinical management of patients by their GPs. Symptoms that 
are under treatment, those that are not reported to the GP, or which the GP 
does not deem to be of sufficient importance to record do not appear in the 
medical record. In the two versions of the GPRD that I have used in this 
thesis, blood test results were not consistently recorded or were recorded in 
the free text comments field of the medical records. There comments were 
not available for the 2002 version. The ability to classify cases using the ACR 
criteria is dependent on the availability of the results of specific 
haematological and immunological tests, some of which may not be 
initialised by GPs. I believe that it is unlikely that results of tests conducted 
in secondary care are recorded with any consistency on the GPRD. 
Moreover, GPs are not required to record every symptom of a chronic 
disease (Hollowell 1997) such as SLE so that once a patient had the diagnosis 
of SLE in their record further clinical manifestations may or may not have 
been recorded depending on their relevance to the clinical management of 
the patients care.
The length of time contributed to the GPRD by individuals varies 
from a few months to a maximum of just under 15 years. As has been 
previously discussed in Chapter 2, the ACR criteria (Tan 1982, Hochberg
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1997) were developed using prevalent case of SLE and criteria can be fulfilled 
at any time during that individual's life. It can take many years for patients 
with a new clinical diagnosis of SLE to obtain 'criteria diagnosis'. In the 
GPRD there is only a snap-shot of a person's medical records and therefore it 
is not possible to determine the hfe-time medical history and consequently 
the presence of absence of all the ACR criteria. Therefore, it was necessary to 
develop an algorithm by which we defined our cases of SLE.
I identified 1860 cases of clinically diagnosed SLE in the 1998 version 
of the GPRD that had evidence in their medical record to support their 
diagnosis. I have discussed the incidence and prevalence of SLE in the GPRD 
population compared with that reported previously for the UK in Chapters 7 
and 8. With the exception of discoid rash, the prevalence of aU of the ACR 
classification criteria in the GPRD population was substantially lower than 
that reported by Hopkinson (1994) for Nottingham (Chapter 2, Table 2.3). It 
could be argued that cases with none of the ACR criteria recorded in their 
medical record should not be included in a study of SLE, however, all of 
these cases have some supporting evidence of diagnosis either from evidence 
of hospital diagnosis or long term therapy with drugs such as azathioprine, 
cyclophosphamide and the antimalarials chloroquine or 
hydroxychloroquine. These drugs in particular are unlikely to be prescribed 
by a GP without direction from a hospital specialist (Glazier 2002).
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In order to establish whether our method of case identification resulted in an 
incidence and prevalence of SLE that was comparable to published incidence 
and prevalence of SLE for the UK population, we calculated the annual, age- 
and sex-specific incidence and prevalence of SLE for the GPRD population. 
These studies are presented in Chapters 7 and 8. Although we did not 
originally plan to calculate mortality rates in patients with SLE, it was 
necessary to do so in order to investigate our finding of increased prevalence 
of SLE in the GPRD between 1992 and 1998. Mortality in SLE is presented in 
Chapter 9.
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Chapter 7
Incidence of Systemic Lupus Erythematosus 
in the Population of the General Practice 
Research Database
Nightingale AL, Farmer RDT, de Vries CS. Incidence of clinically diagnosed 
systemic lupus erythematosus 1992 -1998 using the UK General Practice 
Research Database. Pharmacoepidemiology and Drug Safety 2006; 15: 656- 
661 (see Appendix 1)
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7 Incidence of Systemic Lupus Erythematosus
In this chapter I describe my investigation of the incidence of SLE in the 
population of the GPRD between 1992 and 1998.
7,1 Methods
The study period ran from 1®^ January 1992 to 31®^ December 1998,1 used the 
1998 version of the GPRD. The study population consisted of all patients 
registered on the GPRD who had contributed at least three years of data to 
the GPRD and who were registered as permanent, left practice or dead 
patients. The method of case identification has been described in Chapter 6. 
In their study of SLE disease activity using the Hopkins Lupus cohort (Barr 
1999), the mean length of a period of long quiescence was 2.3 years (SD 1.1). 
Additionally, Lewis et al (2005) investigated the effect of the length of lead- 
time used in studies of disease incidence and recommended that the 
minimum lead-time for chronic diseases should be at least 12 months. For 
this reason I defined incident cases as those with at least three years of data 
between their left-censoring date and the date of their first record of SLE 
diagnosis.
I calculated the annual and age- and sex-specific number of person- 
years of observation contributed to the GPRD by all people in the study 
population. This was calculated by summing the number of days of data 
contribution during each year of the study period between their left and right
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censoring dates. The first three years of each person's registration period was 
excluded from the denominator because they were not deemed to be 'at risk' 
of being diagnosed with SLE during this period. The number of person- 
years of observation was the denominator for the incidence rate calculation.
I calculated the annual and age- and sex-specific incidence rates of 
SLE for the population of the GPRD and calculated 95% confidence intervals 
using STATA statistical software [iri] (StataCorp 2001, Stata Statistical 
Software, Release 7.0 College Station, TX: Stata Corporation).
7.2 Results
In the restricted study population of those with at least three years of data in 
their record there were 390 incident cases of SLE; 41 males and 349 females. 
The median age at diagnosis for the males was 54 years (mean 52.2 SD 16.3), 
range 8 to 81 years). The median age at diagnosis for the females was 46 
years (mean 46.1 (SD 15.9), range 12-82 years). Table 7.1 shows the 
supporting evidence of diagnosis for all cases.
There were 12,911,216 person-years of observation during the study 
period yielding an overall incidence rate of 3.02/100,000/year (CI95 2.72, 
3.32). There was a record of diagnosis confirmed in hospital for 341 (87.4%) 
of the cases. The incidence rate calculated using only these cases was 
2.64/100,000/year (CI95 2.36, 2.92). Of the 49 cases without a record of 
hospital attendance, two had four ACR criteria in their records, 11 had at
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least 1 prescription for an immunosuppressant following diagnosis, 20 had at 
least 3 prescriptions for prednisolone, 24 had at least 3 prescriptions for 
antimalarials and 18 had at least 3 prescriptions for NSAIDs following 
diagnosis.
The sex-specific incidence rates for males and females were 
0.65/100,000/year (CI95 0.45, 0.85) and 5.30/100,000/year (CI95 4.75, 5.86) 
respectively. The incidence rate ratio for females compared to males was 8.15 
(CI95 5.9, 11.6). Table 7.2 shows the age- and sex-specific incidence rates of 
SLE. Figures 7.1 and 7.2 illustrate the age and sex-specific patterns of 
incidence rates more clearly. The annual sex-specific incidence rates 
remained stable throughout the study period (Table 7.3)
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Table 7-1. Supporting evidence of diagnosis and ACR symptoms recorded in 
the medical records_______________________________________________ __
Males n = 41 Females n = 349
n % n %
Hospital confirmed diagnosis 34 83 307 88.0
Number of ACR criteria
0 10 24.4 71 20.3
1 13 31.7 115 33.0
2 10 24.4 90 25.8
3 6 14.6 50 14.3
4 or more 2 4.9 23 6.6
Therapy following diagnosis
Immunsuppressants 14 34.1 76 21.8
Prednisolone (>2 prescriptions) 18 43.9 133 38.1
Antimalarials (>2 prescriptions) 10 24.4 134 38.4
NSAIDs (>2 prescriptions) 7 17.1 135 38.7
ACR symptom recording
Malar rash 2 4.9 36 10.3
Discoid rash 4 9.8 30 8.6
Photosensitivity 4 9.8 38 10.9
Oral ulcers 4 9.8 32 9.2
Non-erosive arthritis 10 24.4 149 42.7
Serositis (pleuritis /  pericarditis) 5 12.2 30 8.6
Renal disorder t 9 22.0 35 10.0
Neurologic disorder (psychosis /  seizures) 4 9.8 34 9.7
Haematologic disorder* 3 7.3 40 11.5
Immunologic disorder* 8 19.5 57 16.3
Antinuclear antibodies present 6 14.6 61 17.5
t Record of renal involvement, lupus nephritis or membranous /  proliferative glomerulonephritis 
t Record of haemolytic anaemia or thrombocytopaenia, leucopenia or lymphopenia 
*Record of diagnosis of antiphospholipid syndrome, record of antiphospholipid antibodies, LE cells, 
anti-dsDNA antibodies or anti-Sm antibodies
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Figure 7-l.Age-specific incidence rates (95% confidence intervals) of systemic 
lupus erythematosus 1992 to 1998 in males
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Figure 7-2 Age-specific incidence rates (95% confidence intervals) of systemic 
lupus erythematosus 1992 to 1998 in females
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7.3 Discussion
This is the first study of the incidence of SLE using the GPRD. Incidence rates 
were stable between 1992 and 1998 and the rates of clinically diagnosed 
disease were consistent with those reported for ACR classified cases in 
Nottingham and Birmingham (Hopkinson 1993, Johnson 1995). The peak 
incidence rates were amongst women aged 30-69 and this is also consistent 
with that found in Nottingham (Hopkinson 1993) and in other largely 
Caucasian populations such as Sweden and Iceland (Stahl-Hallengren 2000, 
Gudmundsson 1990, Jonsson 1990). The classical view of SLE as a disease of 
"women of childbearing age' is somewhat challenged by the trends in peak 
incidence rates in these largely Caucasian populations. Although women up 
to the age of 50 might be considered to be of 'childbearing age', incidence 
rates in women between the ages of 50 and 69 are equally as high. In order to 
reduce delay in diagnosis of SLE, the traditional view of SLE predominantly 
affecting women in their 30s and 40s might have to be addressed and 
updated to include women of menopausal age. It was not possible to 
calculate race-specific incidence rates of SLE in as this information is not 
recorded on the database.
The prevalence of the ACR symptoms, particularly those that are 
dependent on the recording of haematology test results (such as the presence 
and titre of autoantibodies) were significantly lower than reported
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previously for SLE patient populations (Tan 1982, Hopkinson 1994, Voss
1998). The GPRD contains data that are collected from day-to-day clinical 
practice and GPs are tmlikely to record every symptom of a chronic disease 
such as SLE. Moreover, the ACR criteria were developed using prevalent 
rather than incident cases of SLE (1) where cases have had a longer period of 
time in which to develop symptoms. Additionally, it is possible that some of 
the cases included in my study would not fulfil four of the ACR criteria and 
might be milder cases of clinically diagnosed SLE. However, the incidence 
rates calculated using the GPRD are consistent with previous studies and this 
would suggest that incident cases may be successfully and correctly 
identified using primary care data alone from the GPRD.
The possibility that some cases of SLE were misclassified as 'incident' 
in this study that might have, in fact, been cases of long-standing but 
quiescent disease experiencing an exacerbation cannot be entirely excluded. 
All males and females had to have had at least 3 years of research standard 
data before entry into the study population, this was based on the average 
length of a period of long quiescence (2.3 years SD 1.1) (Barr 1999). It is after 
a period of long quiescence that cases could be misclassified as incident.
In conclusion, the incidence of SLE in the GPRD population of 
3.02/100,000/year and the female to male ratio of incidence was 8:15. This 
study shows that in the UK population, incidence of SLE is highest in women 
aged 30-69 years and that incident cases may be successfully identified from 
the GPRD.
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Chapter 8
Prevalence of Systemic Lupus 
Erythematosus in the Population of the 
General Practice Research Database
Nightingale AL, Farmer RDT, de Vries CS. Systemic lupus erythematosus 
prevalence in the UK: methodological issues when using the General Practice 
Research Database to estimate frequency of chronic relapsing-remitting 
disease. Pharmacoepidemiology and Drug Safety 2006, In Press, published 
online, (see Appendix 1)
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8 Prevalence of Systemic Lupus Erythematosus
8.1 Introduction
I calculated the prevalence of SLE in women aged 15-40 years as part of my 
study of hormonal contraception in women with SLE (Chapter 11). 1 found 
that the prevalence of SLE increased significantly between 1992 and 1998. 
Increasing prevalence of a chronic disease over time is attributed either to 
increasing incidence or improved survival or both. In the GPRD population 
between 1992 and 1998, incidence of SLE remained stable (Chapter 7) as did 
the mortality rates (Chapter 9). 1 made a number of hypotheses regarding the 
reason for this apparent increase in prevalence. In this chapter 1 describe the 
methods we used to calculated annual age- and sex-specific prevalence of 
SLE. 1 then go on to discuss the hypotheses that were developed to explain 
the apparent increase in prevalence, the methods used to test them and my 
final conclusions on the reasons for this apparent increase. These issues are 
relevant to the estimation of temporal trends in disease prevalence of any 
chronic disease using data from longitudinal observational databases of 
medical records, particularly chronic diseases that have a relapsing-remitting 
pattern of activity.
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8.2 Methods
8.2.1 Study population
The study period ran from 1st January 1992 to 31st December 1998. We used 
the 1998 version of the GPRD. The study population consisted of aU 
individuals (male and female) who had contributed at least three years of 
research standard data to the GRPD during the study period and our method 
of case identification has been described in detail in Chapter 6.
8.2.2 Calculation of annual age- and sex-specific prevalence
SLE is a chronic disease without a known cure; once a patient had been 
identified as a case of clinically diagnosed SLE, they were considered to be a 
prevalent case of SLE from their date of diagnosis to the point that they left 
the study population. Cases must have had a previous diagnosis of SLE and 
have been contributing to the GPRD on 1®* July in any year of the study 
period in order to be considered a prevalent case during that year. The 
denominators used to calculate prevalence were the numbers of individuals 
(in gender and age category) contributing to the GPRD on 1®* July in each 
year of the study period. I calculated the age- and sex-specific prevalence for 
each year of the study period; 95% confidence intervals for the prevalence 
estimates were calculated using exact methods: Cl = p -  (1.96 x s,e.) to p + 
(1.96 X s.e.). I conducted a sensitivity analysis by calculating the armual sex-
142
specific prevalence of SLE using only those cases with a record of diagnosis 
confirmed in hospital.
8.3 Results
8.3.1 Annual age- and sex-specific prevalence of SLE
I have described the characteristics of the 1860 cases of SLE that were 
identified from the GPRD population in Chapter 6 (Section 6.3.1). Of these, 
1538 contributed at least three years of research standard data to the GPRD 
and were used for this study. There were 210 males and 1328 females. 158 
(75.2%) of the males and 1081 (81.4%) of the females had evidence of hospital 
treatment for SLE in their medical records. 55 (26.2%) of the males and 387 
(29.1%) of the females had more than one prescription for azathioprine, 
cyclophosphamide, cyclosporin or methotrexate after diagnosis; 138 (65.7%) 
of males and 841 (63.3%) had more than two prescriptions for prednisolone 
after diagnosis; 65 (31.0%) of males and 577 (43.4%) of females had at least 
two prescriptions for hydroxychloroquine or chloroquine and 124 (59.0%) of 
males and 938 (70.6%) of females had at least two prescriptions for NSAIDS 
after diagnosis. I used symptoms and diagnoses recorded on the database to 
estimate the number of ACR criteria recorded for each case. Table 8.1 shows 
the symptoms recorded and number of cases receiving medical therapy after 
diagnosis, stratified by the total number of ACR criteria symptoms in their 
medical records.
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The crude annual prevalence of SLE increased from 25.0/100,000 (CI95 23.4, 
26.7) in 1992 to 40.7/100,000 (CI95 37.6,43.8) in 1998. The annual age-specific 
prevalence for males and females are shown in Tables 8.2 and 8.3 
respectively. In males, the prevalence increased from 7.52/100,000 (CI95 6.26, 
8.78) in 1992 to 10.01/100,000 (CI95 7.83, 12.19) in 1998. Although the 
confidence intervals for these estimates overlapped, they were wide and the 
point estimate increased by 33%. In women, the prevalence increased from 
42.60 /  100,000 (CI95 39.60, 45.60) in 1992 to 70.82/100,000 (CI95 65.08, 76.55) 
in 1998. The increase in prevalence was most substantial in women aged 50- 
79 years (Table 8.3). Prevalence estimates for cases that had evidence of 
hospital treatment for their SLE were between 71.5% and 79.0% of all cases in 
males and between 77.4% and 84.8% of all cases in females. Armual 
prevalence of SLE is illustrated in Figure 8.1. Although this graph is not 
strictly correct in terms of its presentation, it gives a useful view of the 
temporal trends in prevalence.
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Table 8-1 Symptoms recorded on the GPRD that could be mapped to the 
ACR classification criteria and prescribing after diagnosis
Number of criteria in medical record 0 1 2 3 4 +
Number of cases (n) 371 487 387 190 103
Malar rash - 16 37 38 37
Discoid rash - 28 77 53 36
'Lupus' rash 30 23 20 11 7
'Rash' (no details given) 81 137 147 89 57
Photosensitivity - 30 36 512 43
Oral ulcers - 17 37 42 36
Non-erosive arthritis - 168 209 121 68
'Arthralgia' * 93 86 62 26 16
Serositis - 31 61 43 43
Renal involvement - 64 65 36 29
Neurologic disorder - 31 58 38 25
Haematalogic disorder - 30 47 51 32
Immunologic disorder - 43 92 64 64
Antinuclear antibodies - 29 55 33 34
Record of disease 'flare' 42 100 88 60 43
Prescribing after diagnosis 
Immunosuppressants f 76 137 128 63 38
Prednisolone^ 190 280 217 114 61
Antimalarials$ 100 178 140 71 48
NSAIDS* 167 223 208 105 65
*with no record of joint swelling or effusion
t  At least 1 prescription for azathioprine, cyclophosphamide, cyclosporine or methotrexate 
$ At least 3 prescriptions for prednisolone, hydroxychloroquine, chloroquine or NSAIDS
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Figure 8-1 Sex-specific prevalence of SLE /  100,000 between 1992 and 1998
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8.3.2 Investigation of the increasing prevalence
In the absence of an increase in incidence rates and /  or a decrease in 
mortality rates I realised that the increase in prevalence was likely to be an 
artefact that had been produced partly from the way in which we identified 
and defined our cases and partly from the fact that the GPRD is a dynamic 
cohort within which patients contribute different amounts of data. 
Treatment or hospital attendance for SLE was the criteria by which most 
cases were confirmed as cases of clinically diagnosed SLE. Inevitably this 
meant that I would identify patients whose disease was active at some point 
during their contribution of data to the GPRD and were likely to nüss
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patients with quiescent disease unless there was a record of hospital 
attendance for their SLE. After a telephone conversation with Brian Hanner, 
the former director of Lupus UK (a patient support charity) I found out that a 
lupus awareness campaign had started in the UK 1994. This campaign, 
according to the GRPD data, had not changed the diagnosis rate of SLE 
before 1998 because incidence was stable. I hypothesised that there might be 
a number of scenarios whereby I would be more likely to identify cases 
towards the end of the study period. Combined with an under-identification 
of cases at the start of the study period, this would lead to an apparent 
increase in prevalence. These scenarios would be:
(a) Patients with SLE might be less geographically mobile than the healthy 
population, leading to a difference between the population remaining in the 
GPRD and that leaving the GPRD during the study period.
(b) Patients with SLE might have been reminded by the awareness campaign 
that started in 1994 to have a check-up for their SLE with their GP or hospital 
consultant.
I hypothesised that if either of these scenarios was leading to an increase in 
case identification towards the end of the study period that we would also 
observe a change in the proportion of cases being treated for their SLE or 
consulting their GP for SLE between 1992 and 1998. If patients had been
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reminded to see their GP for a check-up at which their SLE was recorded but 
did not have active disease, we might have expected to see a lower 
proportion of cases being treated for their SLE at the end of the study period.
I calculated the proportion of cases receiving any of the standard 
treatments for SLE (immunosuppressants, cytotoxics), prednisolone, NSAIDs 
or antimalarials) for each year of the study period and the number of cases 
who had a record of consultation with their GP or hospital consultant that 
could be directly attributed to SLE. Table 8.4 shows the annual proportion of 
patients being treated for their SLE. This proportion did not change during 
the study period.
It seemed reasonable to assume that the increase in prevalence was 
being driven by the fact that patients who contributed more data to the 
GPRD had more time in which to have a disease flare and therefore be 
identified as case. The GPRD was set up in 1987 hence, was a reasonably new 
data source in 1992 when the study period started. Inevitably, by 1998 there 
were a higher proportion of patients contributing more than five years of 
data to the GPRD than there would have been in 1992. Additionally, by 1998, 
some patients could have contributed 11 years of data, whereas the 
maximum time contributed in 1992 would be five years. With a chronic 
relapsing-remitting disease such as SLE, patients contributing less than five 
years of data, who had been diagnosed before their entry onto the database, 
might not flare during this period of contribution. Consequently, although 
their diagnosis of SLE may have been recorded on the database, they might
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have lacked the supporting evidence in the absence of any need for 
treatment.
Table 8-4 Annual proportion of SLE cases receiving treatment for their SLE 
or consulting with their GP or hospital consultant.
Percentage of cases consulting their GP/hospital consultant or receiving > 1 prescription 
N Consultation Immunosuppressants Prednisolone Antimalarials NSAIDs
1992
Males 137 24.8
Females 774 33.9
19.7
22.0
48.9
56.1
18.2
24.3
32.8
43.5
1993
Males
Females
154
880
18.8
29.0
18.2
20.9
51.3
53.4
20.1
25.0
34.4
42.0
1994
Males
Females
130
941
25.4
27.3
20.8
20.1
57.7
50.7
22.3
25.4
36.1
39.2
1995
Males 150 
Females 964
17.3
25.3
20.0
20.5
50.7
50.4
20.0
26.2
29.3
42.2
1996
Males 123 
Females 841
18.7
27.3
19.5
20.5
56.9
53.0
22.0
27.1
30.1
41.1
1997
Males 98 
Females 711
14.3
26.6
18.4
19.1
60.2
51.6
18.4
28.7
30.0
43.9
1998
Males 81 
Females 585
23.5
24.6
18.5
21.5
40.7
48.5
19.8
29.9
30.9
40.0
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In 2003, Farrar et al (Farrar 2003) presented their research on the prevalence 
of gout in the GPRD at the International Conference for 
Pharmacoepidemiology. The also found an increasing prevalence of gout 
from 1990 to 1999 that they stabilised by adjusting the prevalence for the 
number of years each person contributed to the GPRD, I calculated the point 
prevalence of SLE (mid-year) in the GPRD population stratified for the 
number of years of data contribution. For the entire study population I 
calculated the number of years of contribution between each person's left 
and right censoring dates. For each stratum the numerator was the number 
of prevalent cases of SLE in each year who had contributed the specific 
number of years to the GPRD. The denominator was the number of people in 
the study population in each year of the study period. Individuals could only 
appear in one stratum. Figure 8.2 shows the annual prevalence in females 
stratified for the number of years of contribution of data to the GPRD.
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Figure 8-2 Prevalence of SLE in females 1992 -1998 stratified by the number
of years of data contributed to the GPRD
90.00 1
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10.00 -
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Year
It should be noted that for the lower and upper strata numbers of cases were 
small leading to unstable estimates of the prevalence. In order to stabilise the 
estimates and to present the results of this analysis more clearly, we grouped 
the strata into contribution of 3-5 years and 6 or more years. Figure 8.3 shows 
the annual prevalence of SLE in the grouped strata for males and females. 
The number of male cases was small and all of the point estimates have wide 
confidence intervals (data not shown).
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Figure 8-3 Annual prevalence of SLE in males and females stratified by the
number of years of data contribution to the GPRD.
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I attempted to adjust the age-specific prevalence estimates for the number of 
years of data contribution by calculating the standardised prevalence 
estimates which were the weighed average of the prevalence stratified by 
number of years of contribution using STATA Software [dstdize] (StataCorp 
2001, Stata Statistical Software, Release 8.0. College Station, TX: Stata 
Corporation). This adjustment did not significantly change the point 
estimates of the age-specific annual prevalence estimates (Table 8.5)
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Table 8-5 Age-specific annual prevalence of SLE unadjusted, and adjusted
for number of years of data contributed to the GPRD.
Age Group 1992 1993 1994 1995 1996 1997 1998
Unadjusted prevalence /100,000
0 - 9 0.5 0.5 0.5 0 0 0 0
1 0 -1 9 5.9 6.1 6.8 5.4 6.7 8.5 10.6
2 0 -2 9 26.1 28.1 27.2 28.7 32.9 37.5 39.3
3 0 -3 9 48.2 52.2 60.0 65.5 66.6 72.6 76.2
4 0 -4 9 74.6 81.3 85.8 92.5 100.3 103.0 97.5
50 -  59 76.9 85.0 97.1 102.8 110.7 122.1 138.9
6 0 -6 9 79.9 83.6 93.4 96.4 110.7 114.2 119.4
7 0 -7 9 35.6 47.7 52.8 61.2 72.2 80.2 85.2
80+ 22.9 19.7 22.7 21.4 23.2 31.3 34.4
Adjusted prevalence* /100,000
0 - 9 0.5 0.5 0.6 0 0 0 0
1 0 -1 9 5.8 6.1 6.7 5.5 6.5 8.6 10.5
2 0 -2 9 26.2 28.1 28.1 29.9 34.4 37.8 39.7
3 0 -3 9 48.2 52.2 60.2 65.8 66.9 72.6 77.3
40 -  49 74.7 81.3 85.3 92.8 99.9 102.5 99.8
5 0 -5 9 74.9 85.0 97.3 101.6 111.1 124.2 138.1
6 0 -6 9 79.2 83.6 90.5 93.1 108.6 111.2 115.2
7 0 -7 9 35.6 47.7 52.9 60.9 72.6 80.4 86.7
80+ 25.1 19.7 23.2 20.8 22.3 30.3 31.3
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8.4 Discussion
This study of the prevalence of SLE, which is a chronic relapsing-remitting 
inflammatory autoimmune disease, shows an apparent increase in 
prevalence between 1992 and 1998. The increase was most significant in 
those contributing more than five years of data to the GPRD, whereas for 
those contributing fewer data, prevalence remained reasonably stable. 
Incidence of and mortality from SLE in this population remained stable 
during the study period (Chapters 7 and 9), as did the proportion of SLE 
patients that were actively seeking treatment. Therefore, the observed 
increase in prevalence is almost certainly an artefact due to the nature of the 
disease and the limitation of the GPRD for a study such as this. This 
phenomenon has also been reported in a longitudinal study of the prevalence 
of gout in the GPRD population (Farrar 2003).
Epidemiologists using the GPRD to identify cases of disease usually 
require some supporting evidence of diagnosis in the medical records, be it 
in the form of ongoing medication or evidence of hospital attendance for the 
disease in question in order to ensure minimal misclassification of disease 
status. For acute disorders such as myocardial infarction or venous 
thromboembolism, this evidence is normally present in the medical records 
at the time of diagnosis. For diseases such as SLE, the diagnosis might have 
been made many years before the patient's registration with a contributing 
GP. After this time, they may have received treatment and have gone into
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remission for a period of time during which their GP started to contribute to 
the GPRD.
The likelihood of encountering a record of exacerbation of disease, or 
of fulfilling any of the ACR criteria will inevitably increase with increasing 
years of contribution to any database of medical records. The effect this has 
on prevalence estimates over time is that during a 7 year study period, 
prevalence will increase over time due to the fact that more years of data will 
have been contributed by the end of the study period compared with the 
beginning of that period, therefore, increasing the likelihood of detection of 
cases towards the end of the study even if a minimum period of data 
contribution if stipulated for the study population. It is almost certain that 
prevalence in the first half of my study is an underestimate leading to an 
apparent increase over time.
In this study, the prevalence of SLE was higher than that reported 
previously for the UK population (Samanta 1992, Hopkinson 1993, Johnson 
1995, Gourley 1997) by the end of the study period but in 1992 was consistent 
with these reports. Hopkinson (1993) and Johnson (1995) only included cases 
that fulfilled the ACR criteria; Gourley et al (1997) adjusted their prevalence 
for misclassification. Although the ACR criteria are useful in terms of 
providing diagnostically homogeneous populations in clinical and 
epidemiological studies conducted in different world populations, they are 
limited by the fact that they exclude mild cases of SLE and cases of severe 
SLE that are limited to only one organ system, such as the kidneys (Petri
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2004). It is likely that in our study of clinically diagnosed SLE, there are 
patients who would not fulfil the ACR criteria, that they are mild cases of 
SLE or cases where their disease is limited to renal or cerebral involvement. 
Our method of case ascertainment was designed to exclude cases of isolated 
LE-specific skin disease, such as sub acute cutaneous LE and discoid LE but 
it is possible that some cases were included if they had early systemic 
involvement. It is also probable that cases of SLE without active disease 
during their period of data contribution would have not been included.
The question arises whether observational databases of longitudinal 
medical data can be used to calculate temporal patterns of prevalence of 
chronic relapsing-remitting diseases. I would suggest that in any chronic 
disease that shows an increasing prevalence over time, with no concurrent 
increase in incidence or decrease in mortality, data should be stratified, and if 
possible, adjusted for age, sex and the number of years contributed to the 
database. In addition, when identifying cases of these diseases, a minimum 
period of data contribution in line with an established time of disease 
quiescence should be required. I would suggest that until the GPRD is more 
mature, that temporal trends in chronic relapsing-remitting disease are 
unlikely to be accurate.
In conclusion, I found an increasing prevalence, particularly among 
women aged 30 to 79 years and in those contributing more than 5 years of 
data to the GPRD. This increasing prevalence cannot be explained by an 
increase in incidence of SLE, or a decrease in mortality, and is therefore
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almost certainly an artefact caused by the increased likelihood of detecting, 
or confirming disease with increasing time contributed to the database.
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Chapter 9
Mortality in Systemic Lupus Erythematosus
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9 Mortality In Systemic Lupus Erythematosus
9.1 Introduction
Prevalence of disease can increase due to increasing incidence, decreasing 
mortality or a combination of both. When I was investigating the increasing 
prevalence of SLE in the GPRD population (Chapter 8) it was necessary to 
calculate the armual mortality rates and standardised mortality ratios for the 
SLE population. I have reviewed the literature of mortality in SLE in Chater 
2. The aim of this study was to determine the cause of death and calculate the 
mortality rate amongst cases of diagnosed SLE between January 1992 and 
December 1998 using the UK General Practice Research Database (GPRD). 
Additionally, I aimed to calculate the general as well as age- and sex-specific 
mortality ratios of SLE patients compared with those of the general 
population. This chapter describes my investigation of mortality amongst 
patients with SLE in the GPRD population.
9.2 Methods
I used the 1998 version of the GPRD. The. study period ran from l^ t January 
1992 to 31st December 1998. In my calculation of the incidence and 
prevalence of SLE using the GPRD (Chapters 7 and 8) I used a three-year 
run-m period and appHed this period to the calculations of the study 
population denominator. However, for this study of the mortality from SLE,
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I included all cases of SLE that had been identified in the original case 
identification study. I did not exclude those with less than three years of data 
because it was important to identify males and females with SLE who had 
died shortly after their diagnosis. By excluding anyone With less than three 
years of data, I would have excluded early mortality in SLE patients, thereby 
biasing the results of our study. I included all cases of clinically diagnosed 
SLE described in Chapter 6 (1860 cases).
I searched all cases of SLE for those with a record of death during the 
study period and determined, as accurately as possible, their cause of death. 
Where there were multiple causes of death, I took the first recorded cause of 
death. The entire study population of the GPRD was searched for all 
patients with a medical record of death or whose registration status was 
'dead'. I excluded cases of death where the date of death was more than 6 
months before the person's date of leaving the database (as they should have 
been de-registered at time of death) unless it was clear from the medical 
record that they had died (i.e. a cause of death was given and no further 
records followed the record of death)..
Using STATA (STATA Statistical Software 2005 StataCorp version 9.0 
College Station, TX) statistical software, I calculated the annual age- and sex- 
specific mortality rates for SLE and general populations. In addition, I 
calculated the age- and sex-specific mortality rate ratios for SLE patients 
compared with the general GPRD population and calculated the age- and 
sex- adjusted (SMR) mortality ratio using the Mantel-Haenszel combined
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weighted average for the age-stratified data. It was not possible to establish 
the effect of ethnicity on mortality rates in this population because this 
information is not recorded on the GPRD.
9.3 Results
There were 139 deaths amongst the 1860 cases of SLE identified from the 
GPRD between 1992 and 1998. Of these, 104 (74.8%) had a record of their SLE 
being treated at hospital. There were 25 males and 114 females. The mean 
age at death for the males was 69.0 years (SD 10.4, range 49-92 years). The 
mean age at death for the females was 65.7 years (SD 16.8, range 2-102). Table 
9.1 shows the cause of death for the SLE patients by 10 year age groups. 
Active SLE was the main cause of death in males and females under the age 
of 50, after which acute vascular events (acute myocardial infarction (AMI), 
and cerebrovascular accident (CVA)) was the major causes of death. 
Amongst the cases included in this study, 65 died within five years of their 
diagnosis. The main causes of death in these cases were active SLE (n=19) 
and acute vascular events (AMI/CVA n=18). For those in our study 
surviving longer than 5 years (n=75), the main causes of death were vascular 
events (AMI/CVA n=24), active SLE (n=ll) and malignancy (n=ll).
There were 16 deaths recorded in the incident cases of SLE during the 
study period, seven of these had the cause of death recorded as SLE, five 
died from cerebrovascular accident, two from cancer (lung and oesophagus)
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and one from hepatic cirrhosis. One case had no cause of death recorded. The 
mean age at death was 60.1 years (SD 3.37), median 65, range 25 to 74 years.
I identified 230 892 deaths in the general population of the GPRD, 110 
584 deaths amongst the males and 120 308 amongst the females. The mean 
age at death for the males was 72.7 years (SD 14.8, range 0-109). The mean 
age at death in the females was 78.6 years (SD 13.7, range 0-109). The 
mortality rate remained constant during the study period and was consistent 
with published mortality rates for England and Wales between 1992 an 1998 
(ONS). Table 9.2 shows the annual mortality rates for the SLE and GPRD 
populations.
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Table 9.3 shows the age- and sex-specific mortality rate ratios of mortality in the 
SLE population compared with the GPRD population and SMR for the SLE 
population directly standardised to the population of the GRPD. For the male 
population, the SMR was 1.30 (CI95 0.88,1.92). The annual crude mortality ratios 
were constant for males aged 40 and above. There were no deaths in males with 
SLE under the age of 40. For males and females the confidence intervals of the 
mortality rates were wide due to small numbers.
The SMR was 1.83 (CI95 1.52, 2.20) for all females. The age-specific mortality ratios 
were highest (disregarding that in females aged 0-9 as there was only 1 death in 
this age group), in females aged 20-29. In this group, the death rate in females with 
SLE was 17 times higher than that in the general population. The mortality ratio 
in females decreased with increasing age.
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9.4 Discussion
At the time that this study was conducted, there had been no published 
studies calculating the SMR for SLE in the UK population. I found that the 
mortality rate ratio was highest in women aged 20-29 compared with that of 
the general population of the GPRD and the rate ratio decreased with 
increasing age. This is of interest as although the SMR for the female SLE 
population was 1.83 (CI95 1.52, 2.20) this overall summary of the mortality 
provides insufficient insight into the pattern of mortality in patients with SLE 
as young women with SLE are up to 17 times more likely to die than women 
of the same age in the general population. I also found that, on average, 
males with SLE died at a later age than females with SLE. There were no 
deaths in males under the age of 40 and this pattern of mortality is opposite 
to that in the general population of the GPRD where males have a lower 
mean age of death than the females.
Mortality rates for the GPRD population were consistent with those 
published for England and Wales in 1992 -  1998 by the Office of National 
Statistics (ONS). We found a similar pattern of mortality in SLE patients as 
that reported in previous studies (Cervera 2003, Schattner 2003, Borchers 
2004) with early death from active disease and late death from the effects of 
accelerated atherosclerosis.
The mean age at death in males with SLE was higher than for females 
and this is contrast to the findings of Manger (2005) in Germany, where male
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sex was found to be associated with an increased risk of death when 
compared with females with SLE. The age at death in the SLE population 
was lower than that of the general population of the UK. The results of this 
study are consistent with the findings of Alamanos (2003) in Northwest 
Greece in 1982-2001 who calculated an SMR of 1.5 (CI95 1.3,1.8) for patients 
with SLE. In their study of SLE mortality rates and SMRs in Toronto, 
Urowitz (1997) reported a decrease in SMR in each cohort of SLE patients 
from 10.3 in the 1970-1977 cohort to 3.3 in the 1986-1994 cohort. This does 
show an improvement in survival in SLE patients in the Toronto population. 
However, they also reported a decrease in SMR within the 1970 -1979 cohort 
during each period of the study. For the 1970-77 cohort, the SMR was 10.1 
between 1970 and 1977, for 1978-1985 the SMR was 7.9 (compared with 4.8 
for the 1978-85 cohort) and dropped to 4.7 in 1987-1996 (compared with 3.3 
for the 1987-94 cohort). The authors suggest that this was due to 
improvement in survival within the 1970-77 cohort over time. Based on the 
results of the current study of mortality in SLE, I would suggest that this 
decrease in SMR within the cohort was due to the cohort effect, with young 
patients with SLE at a higher risk of dying with that risk decreasing with 
increasing age.
In their international multi-centre study of mortality in SLE, Bernatsky 
et al (2006) calculated the SMR for 9547 SLE patients to be 2.4 (CI95 2.3, 2.5). 
For England, the SMR for SLE was 3.8 and for Scotland it was 3.5 compared 
with an adjusted SMR of 2.2 in the USA. The SMR calculated from this multi-
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centre study is significantly higher than that calculated for the GPRD 
population. It is possible that the estimates reported by Bernatsky are more 
accurate than those calculated from this study of mortaÜty in the GPRD 
population. Theirs was a mixture of retrospective and prospective 
recruitment to cohort study collecting data on SLE mortaUty from 1970 to 
2002. In the UK, two of the three centres assembled their cohorts 
prospectively. However, the SMR might be higher due to the inclusion of on 
average more severe cases of SLE as these cohorts were assembled from 
specialist SLE treatment centres, which might include more severe cases of 
SLE than, for example, cases managed in rheumatology clinics in secondary 
care. In the GPRD study, accuracy of the SMR depends on the accurate 
recording of death in the SLE population, and in the GPRD population as a 
whole. Notwithstanding the differences in SMR estimates, my study of 
mortality in the GPRD population is consistent with the results of the multi­
centre study in terms of demonstrating an increased risk of death in younger 
patients with SLE and a slightly higher SMR in female patients than in males. 
In the study by Bernatsky et al (2006) the SMR for females was 2.5 (CI95 2.3, 
2.7) and in males it was 1.9 (CI951.7,2.2).
I did not calculate the SMRs for cause-specific mortality for the study 
on the GPRD population. Bernatsky et al (2006) reported that patients with 
SLE were statistically significantly more likely to die from diseases of the 
circulatory system (SMR 1.7 (CI95 1.5, 1.9)), particularly heart disease (SMR 
1.7 (CI95 1.4, 2.0)), haematological cancer (SMR 2.1 (CI95 1.2, 3.4)); non-
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Hodgkin's lymphoma (SMR 2.8 (CI9 51.2, 5.6)), lung cancer (SMR 2.3 (CI95I.6 , 
3 .0 )), infections (SMR 5.0 (CI95 3.7, 6.7)), pneumonia (SMR 2.6 (CI9 5 1.6, 4.1)) 
and renal disease (SMR 7.9 (CI95 5.5,11.0)). These increases in specific causes 
of death indicate the short and long-term damage caused by SLE and risks of 
death from treatment-related complications such as infection.
The main limitations of this study are the lack of data on ethnicity as 
this is not recorded on the GPRD and the fact that we could not use the ACR 
criteria (Tan 1982, Hochberg 1997) to define our cases, although these criteria 
were not used in the most recent study of SLE mortality (Bernatsky 2006). In 
conclusion, this is the first study of mortality rates in SLE patients compared 
with those of the general population in the UK using the GRPD. Although 
the SMR for SLE patients was 1.30 (CI95 0.88, 1.92) in males and 1.83 (CI95 
1.52, 2.20) in females, this is lower than reported in many previous studies of 
SLE mortality except that conducted by Alamanos (2003) in Northwest 
Greece, 1982 -  2001. I found that although the overall SMR was less than 
two, females under the age of 30 were at a significantly increased risk of 
death, and cause of death in this group of patients was mainly from active 
SLÉ.
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Chapter 10
Presentation of Systemic Lupus 
Erythematosus in Primary Care in the 
United Kingdom
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10 Presentation of SLE in Primary Care
10.1 Introduction
In Chapter 2 I reviewed the literature on the initial presentation of SLE. 
Studies of the initial presentation of SLE indicate that arthritis and malar rash 
(Hopkinson 1994, Ozbek 2003, Jacobsen 1998a) as well as constitutional and 
psychological symptoms such as fever, weight loss, fatigue, depression and 
anxiety are common presenting symptoms, especially in older-onset SLE 
(Lahita 1999c, Formiga 1999, Hughes 2000). In males, discoid lesions and 
serositis are also often reported to be initial symptoms of SLE (Font 1992, 
Voulgari 2002). To date, none of the studies of the presentation of SLE have 
been conducted using primary care data. All of the studies have been 
conducted in the hospital setting using data collected from patient interviews 
and medical record review without any comparison of the frequency of the 
presenting symptoms reported by patients with SLE to those without. It is 
recognised that the onset of SLE can be insidious and patients may 
experience symptoms for months or years before their diagnosis (Hopkinson 
1994, Maddison 1987, Jacobsen 1998, Ozebek 2003). Insidious onset is more 
common in Caucasians and in older-onset SLE (Maddison 1987, Formiga 
1999, Ozbek 2003) with abrupt onset being more common in Hispanics and 
Afro-Caribbeans (Petri 1991, Alarcôn 1999). Relying on patient recall of the 
timing of their symptoms during this period raises issues regarding the
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reliability of the data due to recall errors. Additionally, recall wül depend on 
whether or not the patient has associated their symptoms with their SLE 
diagnosis.
If early recognition of SLE is important with regards to starting 
treatment in order to prevent irreversible organ damage (Maddison 2002); 
the only way this can be achieved is by its earlier identification and 
subsequent referral from general practitioners. It is only after the GP suspects 
SLE that appropriate tests and /  or referral to rheumatology for confirmation 
of diagnosis can be made (ACR 1999). If a GP has a list of 1500 patients, 
based on an incidence of 4.0/100,000/year, on average, they wül only see one 
new case of SLE every 10 years. When I carried out the case identification 
process, the avaüable medical record of each potential case was reviewed in 
detaü and I noticed that for many patients, symptoms that might be 
attributed to SLE appeared many months, and in some cases, years before 
their diagnosis of SLE.
The aim of the study reported in this chapter was to develop age- and 
sex-specific symptom profÜes that could be used to distinguish between 
patients with and without SLE in the five years before diagnosis using data 
coUected prospectively on the GPRD.
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10.2 Methods
I conducted a nested case-control study of the presentation of SLE in the five 
years before date of diagnosis. The 2002 version of the GPRD was used for 
this study. The study period ran from January 1992 to 30* April 2002. The 
study population consisted of all males and females contributing at least five 
years of data between their left and right censoring dates.
10.2.1 Case definition
For this study, it was more important to use confirmed and truly incident 
cases of SLE rather than to try to identify all potential cases of SLE from the 
database. In order to be accepted as a case of SLE I required that all cases 
must have had their diagnosis confirmed in hospital (as defined in Chapter 
6). I identified all potential cases of SLE from the GPRD who had at least five 
years of data between their left censoring date and the date of their diagnosis 
and reviewed the medical records of each potential case in detail manually.
10.2.2 Control group
Up to four controls without SLE or rheumatoid arthritis were randomly 
selected from the same general practice as each case of SLE. They were 
matched to each case by practice, year of birth and sex and were assigned an 
index date which was the date of diagnosis of their matched case of SLE. All 
of the members of this control group had. at least 5 years of research standard 
data from their left-censoring date to their index date.
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10.2.3 Coding
All coding was carried out using Microsoft Access 2003 and Minitab 
Statistical Software. The medical, therapy and prevention records of the SLE 
cases and the comparison group were coded together, blind to their SLE 
status. All OXMIS and Read Codes that were used in the combined medical 
records were reviewed and classified according to the symptom groups that 
they belonged to. Table 10.1 is a list of the coded symptom clusters, and the 
individual symptoms that were assigned to each group. A full Ust of the 
OXMIS and Read Codes used for coding in this study is in Appendix 5.
The medical records, blood and urine test results were partitioned into 
periods of time before the date of diagnosis. Period 1 was from the date of 
diagnosis to 12 months before the date of diagnosis; period 2 was between 13 
and 24 months before date of diagnosis; period 3 was between 25 and 36 
months before date of diagnosis; period 4 was between 37 and 48 months 
before date of diagnosis and period 5 was between 49 and 60 months before 
date of diagnosis. I also coded the first 12 months before diagnosis into two 
separate time periods -  the first between 0 and 6 months before diagnosis 
and the second between 7 and 12 months before diagnosis. Analysis of these 
time periods separately made no significant impact on the analysis and in 
order to increase the power of the study, I decided to combine the first year 
before diagnosis into one 12-month period.
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Table 10-1 Coding of symptom clusters
Symptom Cluster
Musculoskeletal symptoms
Cutaneous symptoms
Constitutional symptoms
Haematological symptoms 
(these symptoms were coded using medical 
codes and from all blood test results 
recorded in the prevention records)
Gastrointestinal symptoms
Cardiac symptoms
Neurological symptoms
Symptoms Coded within Cluster
Inflanunatory arthritis
Arthralgia
Arthropathies
Joint pain, effusion or swelling 
Myositis
Myalgia (including fibromyalgia)
Tenosynovitis
General aches and pains
Malar (butterfly) rash 
Discoid rash 
Photosensitivity 
Nasopharyngeal ulcers 
Alopecia
Raynauds phenomenon 
Sjogren's syndrome 
Urticaria 
Vasculitis
Rashes /  purpura NOS*
Fatigue and malaise 
Fever of unknown origin 
Weight loss (unexpected)
General /  multiple symptoms
Anaemia (aU types of anaemia included)
Leucopaenia
Lymphopaenia
Thrombocytopaenia
Nausea
Vomiting (where there was a record of 
diarrhoea or viral vomiting, this was not 
included)
Abdominal pain
Pericarditis
Pericardial rub or effusion
Myocarditis
Endocarditis
Migraine
Cluster headaches 
Peripheral neuropathy 
Cranial neuropathy 
Seizures
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Symptom Cluster
Psychiatric symptoms
Pulmonary symptoms
Reticuloendothelial symptoms
Gynaecological symptoms
Thrombotic symptoms
Renal symptoms
Symptoms Coded within Cluster
Psychosis
Depression
Anxiety
Neurosis
Memory loss
Confusion
Pleurisy
Pleural rub or effusion 
Pulmonary fibrosis
Lymphadenopathy
Splenomegaly
Hepatomegaly
Miscarriage (any number)
Habitual miscarriage 
Pre-eclampsia 
Foetal death
Antiphospholipid syndrome 
Acute myocardial infarction 
Cerebrovascular accident 
Other arterial thrombosis 
Deep vein thrombosis 
Pulmonary embolism 
Superficial venous thrombosis
Nephritis (of any pathology)
Nephrotic syndrome 
Haematuria 
Proteinuria 
Cellular casts
For each symptom, in each time period I originally recorded the number of 
consultations for that symptom. At analysis, the numbers of cases and 
controls with differing numbers of visits resulted in a decision to condense 
the coding into three categories. These were -  no current record or historical 
record of the symptom (0); record of the symptom within the 12 month 
period (1) and; a medical history of that symptom (2) in the periods before 
that 12 month period. Figure 10.1 is a graphical example of the way that
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symptoms might have been recorded in the medical record. Table 10.2 shows
how these symptoms would have been coded.
Where arthritis and arthralgia were combined in the analysis as 
"musculoskeletal symptoms", in period 1, the patient would only appear in 
the "current" rather than "history" category of musculoskeletal symptoms. 
There were insufficient cases and controls to allow analysis using cases who 
presented with both a current record and history of the same symptom. I did 
not take into account the presence of symptoms before the beginmng of 
period 5 (i.e. symptoms that occurred more than 60 months before date of 
SLE diagnosis) to ensure that the same time periods were used for the SLE 
and comparison groups. Going back before 60 months would have led to 
issues regarding differing lengths of data contribution.
Figure 10-1A graphical example of the presentation of SLE symptoms
Entry into study SLE diagnosis
r--------------------
Period 5 Period 4 Period 3 Period 2 Period 1
49-60 months 37-48 months 25-36 months 13-24 months 0-12 months
before before before before before
diagnosis diagnosis diagnosis diagnosis diagnosis
Malar rash Arthritis Seizures Arthalgia, fever Rash
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Table 10-2 An example of coding using figure 10.1 as the example medical 
record
Period Coding Meaning of coding
Period 1 Rash = 1
Arthralgia = 2
Fever = 2
Seizures = 2
Arthritis = 2
Malar rash = 2
All other symptoms = 0
Current rash NOS
History of arthralgia, fever, seizures, 
arthritis, malar rash
Period 2 Arthralgia = 1
Fever = 1
Seizures = 2
Arthritis = 2
Malar rash = 2
All other symptoms = 0
Current arthralgia and fever 
History of seizures, arthritis, malar 
rash
P eriods Seizures = 1
Malar rash = 2
Arthritis = 2
A ll other symptoms = 0
Current seizures
History of malar rash and arthritis
Period 4 Malar rash = 2
Arthritis = 2
All other symptoms = 0
History of malar rash and arthritis
Period 5 Malar rash = 1
Arthritis = 1
All other symptoms = 0
Current malar rash and arthritis
10.2.4 Statistical Analysis
All analyses were conducted using STATA statistical software (STATA 
Statistical Software 2005 StataCorp versions 9.0 and 9.2 College Station, XX). 
The frequency of symptoms recorded in the medical records in each period 
of the study in the cases and controls was compared using Chi-square tests. 
The unadjusted odds ratio (OR) for the presence of each symptom or cluster
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of symptoms (as defined in table 10.1) was calculated using univariate 
conditional multiple logistic regressions. Chi-square with p-values and ORs 
were calculated for aU variables regardless of the number of cases and 
controls in each group. Although this meant that in some cases, analyses 
were conducted using a very small number of cases and controls with the 
presence of symptoms, and that no meaningful conclusions could be drawn 
from these estimates, I have presented the OR as it gives an indication of 
how much more likely the cases were to have the symptom recorded in their 
medical records compared with the controls.
The presence of co-linearity between variables was investigated by 
calculating the correlation coefficients. In the absence of significant 
correlation, the following symptom cluster variables (for the period 0-12 
months before SLE diagnosis) were entered as categorical independent 
variables into forward and backward conditional stepwise logistic regression 
models set to accept or reject variables at p = 0.20 and p=0.15: constitutional 
symptoms, cutaneous symptoms, gastrointestinal symptoms, haematological 
symptoms, musculoskeletal symptoms, neurological symptoms, psychiatric 
symptoms, renal symptoms, thrombotic symptoms. Variables selected by the 
stepwise models were entered into a multivariate conditional logistic 
regression model to calculate the adjusted odds ratios. This model was 
applied to the periods before SLE diagnosis: 0-12 months, 13-24 months and 
36-48 months. In order to determine the predictive value and goodness of fit 
for the model for each time period, it was necessary to conduct unmatched
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logistic regression analyses. For the unmatched analysis, sex and age at index 
date were included in the model to adjust for the confounding factors that 
were adjusted for by matching in the conditional model. General practice 
was not included in the model as it caused considerable instability. 
Predictive value of the model was estimated using Hosmer & Lemshow data 
in Stata 9.2 (STATA command [estât class]). Goodness of fit was estimated 
using Hosmer & Lemshow goodness of fit test [STATA command [estât gof, 
group (10)]).
10.3 Results
Three hundred and forty-five incident cases of SLE were identified from the 
GPRD. There were 38 males and 307 females. The mean age at diagnosis for 
the males was 52.2 years (SD 16.6 years, range 8 - 7 5  years). The mean age at 
diagnosis for the females was 46.8 years (SD 16.1 years, range 8 -  86 years). 
Table 10.3 shows the number of cases identified in each year of the study.
Four controls were matched to each case for 321 of the cases, three for 
16 cases, and two for one case. There were seven cases that were not matched 
to any controls ("orphans"). All of the orphans were female; their mean age 
was 55.3 years (range 37 -  76 years). Two were diagnosed in 1993, three in 
1995 and two in 1996. They were aU from practices where the up-to-standard 
date of the practice was five years before their date of diagnosis. In the 
analyses, the orphans were included in the chi-square tests and unmatched
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logistic regression models but they were automatically dropped from the 
conditional logistic regression models as these only analyse discordant 
matched pairs within the dataset.
Table 10.3 Number of cases identified in each year of the study period from 
the 2002 database
Year Cases Year Cases
1992 0 1998 60
1993 4 1999 53
1994 9 2000 40
1995 29 2001 28
1996 50 2002 3
1997 69
Table 10.4 shows the number of cases and controls with a record of each 
symptom cluster for the five years before the date of SLE diagnosis (index 
date for the controls). The frequency of symptoms classically associated with 
SLE, for example musculoskeletal and cutaneous symptoms are relatively 
common in patients who later receive a diagnosis of SLE and relatively 
uncommon in the general population of the same age. As might be expected, 
the proportion of cases with a record of symptoms is higher in the 0-12 
months before diagnosis compared with the previous year. Even with a
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sample size of 345 cases and 1334 controls, the number of cases with a record 
of any of the symptoms within each cluster was relatively small. Figures 10.2 
to 10.11 show the unadjusted odds ratios for the symptom clusters where the 
number of cases and controls with a record of the symptoms exceeded 5 in 
the period 0-12 months before diagnosis.
There was no significant correlation between any of the variables. 
When variables were offered to the forward and backward stepwise logistic 
regression models for the period 0-12 months before SLE diagnosis, the same 
variables (musculoskeletal symptoms, cutaneous symptoms, renal 
symptoms, constitutional symptoms, haematological symptoms, 
neurological symptoms and psychiatric symptoms) were accepted into the 
models with p = 0.20 and p = 0.15 as an entry criteria. Tables 10.5,10.6 and 
10.7 contain the adjusted odds ratios for each symptom cluster for each of the 
three years before SLE diagnosis respectively, calculated using conditional 
and unconditional logistic regressions. The sensitivity, specificity and 
predictive values for each model and the Homer-Lemeshow test (chi-square 
and p-value) for goodness of fit of each model were based on the unmatched 
analysis. In aU tables and figures, "current" refers to the presence of the 
symptom in the medical record during that year; "history" refers to the 
presence of the symptom in the medical record between 5 years before 
diagnosis and that time period but no current record of the symptom.
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Figure 10.2. Unadjusted odds ratios and 95% confidence intervals for
constitutional symptoms calculated using conditional logistic regression
models for the five years before diagnosis
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Figure 10.3. Unadjusted odds ratios and 95% confidence intervals for 
cutaneous symptoms calculated using conditional logistic regression models 
for the five years before diagnosis
1I 1^ 1 t '
49-60 mths 37-48 mths 37-48 mths 25-36 mths 25-36 mths 13-24 mths 13-24 mths 0-12 mths 0-12 mths 
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Figure 10.4 Unadjusted odds ratios and 95% confidence intervals for
gastrointestinal symptoms calculated using conditional logistic regression
models for the five years before diagnosis
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Figure 10.5 Unadjusted odds ratios and 95% confidence intervals for 
haematological symptoms calculated using conditional logistic regression 
models for the five years before diagnosis
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Figure 10.6 Unadjusted odds ratios and 95% confidence intervals for
musculoskeletal symptoms calculated using conditional logistic regression
models for the five years before diagnosis
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Figure 10.7 Unadjusted odds ratios and 95% confidence intervals for 
neurological symptoms calculated using conditional logistic regression 
models for the five years before diagnosis
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Figure 10.8 Unadjusted odds ratios and 95% confidence intervals for
psychiatric symptoms calculated using conditional logistic regression models
for the five years before diagnosis
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Figure 10.9. Unadjusted odds ratios and 95% confidence intervals for renal 
symptoms calculated using conditional logistic regression models for the five 
years before diagnosis
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Table 10.5. Multivariate logistic regression models for symptom presentation
in the 0-12 months before SLE diagnosis.
Symptom cluster Unadjusted OR(Cl9s) Adjusted OR (CI95) Adjusted OR (CI95)
Matched analysis Unmatched analysis
Constitutional
No 1.00 1.00 1.00
Current 4.07(2.62,6.31) 3.37 (1.67, 6.78) 3.34 (1.83,6.09)
History 1.61 (1.09,2.38) 1.03 (0.57,1.86) 1.10 (0.65,1.86)
Cutaneous
No 1.00 1.00 1.00
Current 19.71 (12.51,31.05) 19.74 (11.10,35.11) 14.84 (9.60,22.93)
History 2.78(1.88,4.11) 2.20 (1.27, 3.82) 1.89 (1.16,3.01)
Haematological
No 1.00 1.00 1.00
Current 2.81 (1.61,4.90) 1.92 (0.85,4.37) 1.87 (0.90,3.89)
History 2.21 (1.36,3.62) 1.92 (0.93, 3.97) 1.75 (0.91,3.69)
Musculoskeletal
No 1.00 1.00 1.00
Current 30.58 (19.44,48.09) 32.99 (19.20,56.67) 27.50 (19.02,42.81)
History 4.79 (3.22, 7.12) 4.31 (2.61,7.10) 3.69 (2.44,5.59)
Neurological
No 1.00 1.00 1.00
Current 3.07(1.86,5.06) 1.88 (0.81,4.40) 1.91 (0.96,3.83)
History 1.84(1.09,2.15) 1.01 (0.51,2.00) 1.03 (0.58,1.82)
Psychiatric
No 1.00 1.00 1.00
Current 2.58 (1.77,3.76) 1.67 (0.92,3.00) 1.37(0.84,2.25)
History 1.53(1.09,2.15) 1.03 (0.61,1.75) 1.02 (0.65,1.61)
Renal
No 1.00 1.00 1.00
Current 7.78 (3.77,16.10) 8.13 (2.83,23.08) 8.66 (3.38,22.81)
History 1.01 (0.46,2.23) 1.05 (0.35,3.13) 0.74 (0.27,1.98)
Goodness of fit* Observations = 1679; groups = 10; chi-square = 20.89 p = 0.0076
Sensitivity 62.0%
Specificity 94.1%
Positive predictive value 73.1%
Negative predictive value 90.6
% Correctly classified 87.5
*Hosmer-Lemeshow test (chi-square)
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Table 10.6 Multivariate logistic regression models for symptom presentation
in the 13-24 months before SLE diagnosis.
Symptom duster Unadjusted OR(Cl9s) Adjusted OR (CI95) Adjusted OR (CI95)
Matched analysis Unmatched analysis
Constitutional
No 1.00 1.00 1.00
Current 1.95 (1.12,3.40) 1.43 (0.74, 2.77) 1.31 (0.70,2.46
History 1.36 (0.87,2.12) 1.13 (0.68,1.86) 1.12(0.69,1.81
Cutaneous
No 1.00 1.00 1.00
Current 4.73 (3.06, 7.32) 4.06 (2.48, 6.63) 4.14(2.60,6.59)
History 2.11 (1.41,3.16) 2.11 (1.37,3.26) 1.96 (1.30,2.95)
Haematological
No 1.00 1.00 1.00
Current 1.83 (0.91,3.67) 0.95 (0.41,2.21) 0.98 (0.43,2.20)
History 1.94(1.10,3.40) 2.51 (1.31,4.80) 1.96 (1.06,3.60)
Musculoskeletal
No 1.00 1.00 1.00
Current 8.44 (5.41,13.16) 8.29 (5.18,13.28) 7.15 (4.63,11.05)
History 3.86 (2.69,5.56) 3.70 (2.53,5.41) 3.46(2.42,4.94)
Neurological
No 1.00 1.00 1.00
Current 2.42 (1.32,4.28) 1.93(0.98,3.83) 1.67 (0.84,3.31)
History 1.86 (1.16, 2.98) 1.75 (1.03 (2.96) 1.80(1.09,2.99)
Psychiatric
No 1.00 1.00 1.00
Current 1.71 (1.11,2.65) 1.25 (0.74,2.10) 1.27 (0.80,2.02)
History 1.53(1.07,2.21) 1.28 (0.85,1.94) 1.26 (0.85,1.86)
Renal
No 1.00 1.00 1.00
Current 2.01 (0.74,5.47) 1.80 (0.58, 5.62) 1.79 (0.61,5.31)
History 0.78 (0.30,2.07) 0.42 (0.14,1.28) 0.54 (0.19,1.53)
Goodness of fit* Observations = 1679; groups = 10; chi-square = 8.09 p = 0.4250
Sensitivity 18.6%
Specificity 97.0%
Positive predictive value 61.5%
Negative predictive value 82.2%
% Correctly classified 80.9%
*Hosmer-Lemeshow test (chi-square)
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Table 10.7 Multivariate logistic regression models for symptom presentation
in the 25-36 months before SLE diagnosis.
Symptom cluster Unadjusted OR(Cl9s) Adjusted OR (CI95) Adjusted OR (CI95)
Matched analysis Unmatched analysis
Constitutional
No 1.00 1.00 1.00
Current 2.10 (1.15,3.83) 1.75 (0.91,3.40) 1.80 (0.95,3.45)
History 1.25 (0.74,2.13) 1.09 (0.62,1.93) 1.07 (0.61,1.87)
Cutaneous
No 1.00 1.00 1.00
Current 3.24 (1.99,5.29) 2.43(1.43,4.12) 2.42 (1.46,4.01)
History 2.18 (1.387,3.46) 2.15 (1.33,3.50) 2.23 (1.40,3.56)
Haematological
No 1.00 1.00 1.00
Current 1.95 (0.94,4.03) 1.78 (0.79,4.01) 1.59 (0.72,3.52)
History 2.15 (1.08,4.30) 2.21 (1.01,4.84) 1.90 (0.91,3.97)
Musculoskeletal
No 1.00 1.00 1.00
Current 4.92 (3.19,7.60) 4.42 (2.82, 6.95) 4.47 (2.89,6.92)
History 3.47 (2.31,5.21) 3.45 (2.26, 5.25) 3.09 (2.07,4.62)
Neurological
No 1.00 1.00 1.00
Current 1.58 (0.83,3.01) 1.47 (0.73,2.95) 1.34 (0.68,2.67)
History 1.88 (1.06,3.32) 1.78 (0.79,4.01) 1.78 (0.98,3.22)
Psychiatric
No 1.00 1.00 1.00
Current 1.20 (0.77,1.87) 0.99 (0.61,1.62) 1.01 (0.63,1.62)
History 1.71 (1.12,2.61) 1.56 (0.98, 2.46) 1.44 (0.92,2.26)
Renal
No 1.00 1.00 1.00
Current 1.00 (0.20,4.90) 0.69 (0.13,3.68) 0.90 (0.18,4.52)
History 0.91 (0.30,2.74) 0.70 (0.21,2.34) 0.77 (0.24,2.46)
Goodness of fit* Observations = 1679; groups = 10; chi-square = 5.10 p = 0.7467
Sensitivity 9.0%
Specificity 98.4%
Positive predictive value 59.6%
Negative predictive value 80.7%
% Correctly classified 80.1%
*Hosmer-Lemeshow test (chi-square)
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The results from these analyses indicate that musculoskeletal symptoms are 
the most strongly predictive of a diagnosis of SLE in the three years before 
diagnosis. In table 10.4 it can be seen that patients with an eventual 
diagnosis of SLE are significantly more Hkely to have cutaneous, 
gastrointestinal, haematological, musculoskeletal and reticuloendothelial 
symptoms for the five years before their date of diagnosis compared with the 
general population of the GPRD, indicating that these symptoms, in some 
patients, are apparent for five years before their diagnosis of SLE. The 
frequency of renal symptoms is only significantly different from the general 
population in the 12 months before SLE diagnosis indicating that those with 
severe initial manifestations are diagnosed more quickly than those with 
more generalised symptoms such as arthritis and skin rashes.
It was not possible to conduct logistic regression analyses on more 
specific symptoms because the models became unstable due to the small 
number of controls with records of various symptoms. To describe the 
evolution of the disease I determined the number of symptom clusters 
recorded in the medical records of the cases in the five years before their 
diagnosis. Figure 10.10 shows the percentage of cases with 0 to 5 of the 
symptom clusters included in the multivariate conditional logistic regression 
models for the five years before SLE diagnosis.
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Figure 10.10 Percentage of SLE cases with symptom clusters accepted by the
multivariate conditional logistic regression models recorded in their medical
records in the five years before SLE diagnosis.
Years before SLE diagnosis
Id  No symptom clusters D1 cluster □  2 clusters □  3 clusters B 4  clusters □  5 clusters |
As can be seen from Figure 10.10, the number of cases with none of the 
symptom clusters listed in Tables 10.5,10.6 and 10.7 decreased from five 
years before diagnosis to the year of diagnosis and the proportion of cases 
with one or more of the symptoms from the five symptom clusters increased 
from five years before diagnosis to the year of SLE diagnosis. Of potential 
concern, there were 15 (4%) cases that had two or more symptom clusters 
present in their medical records for at least five years before their diagnosis. 
Although this is a relatively small number of patients in the context of the 
presentation of SLE in the UK, closer examination of their medical histories
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might lead to earlier recognition of SLE in primary care for future patients. 
Table 10.8 shows the symptom clusters present in the medical records of the 
92 (27% of the total) cases who had at least one of the clusters recorded in 
their medical records five years before their SLE diagnosis.
Table 10.8 Symptom clusters recorded in cases five years before their SLE 
diagnosis
Num ber o f cases Sym ptom  clusters recorded in  medical record 5 years 
(total n = 77) before SLE diagnosis
Cases w ith ONE symptom cluster (n=77)
20 Psychiatric symptoms (mostly depression)
19 Cutaneous sym ptom s (mostly rash NOS)
17 Musculoskeletal symptoms ( m ostly arthritis /  arthralgia)
9 Haematological symptoms (mostly anaemia)
8 Neurological symptoms (mostly palsies)
Cases w ith TWO symptom clusters (n=12)
3 Musculoskeletal and psychiatric symptoms
3 Musculoskeletal and cutaneous symptoms
6 Combinations of musculoskeletal, psychiatric, cutaneous,
haematological, neurological, constitutional and renal 
symptoms
Cases w ith THREE symptom clusters (n=3)
1 Musculoskeletal, psychiatric and cutaneous symptoms
1 Musculoskeletal, haematological and cutaneous sym ptom s
1 Musculoskeletal, psychiatric and haematological sym ptom s
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A more detailed examination of the records of the 12 cases with two or more 
symptom clusters revealed that the psychiatric symptoms were, with the 
exception of one case, depression. Epilepsy was present in one patient two 
years before their SLE diagnosis. The depression seemed to be persistent or 
appeared regularly in the five years before diagnosis. Musculoskeletal 
symptoms were generally arthralgia followed by arthritis. In most of the 
cases, referral seemed to be made at the appearance of arthritis. Four of the 
cases had a diagnosis of rheumatoid arthritis before their SLE diagnosis, one 
had a diagnosis of polymyalgia rheumatica and two patients had a diagnosis 
of Raynaud's phenomenon in their medical records. Looking at the medical 
records, the patients with a combination of depression and arthralgia seemed 
to have a longer period of time between the onset of their arthralgia and 
referral to secondary care but it should be emphasized that this is purely 
anecdotal and has not been quantified.
When the multivariate models were tested for goodness of fit, the 
models for 13-24 and 25-36 months pre-diagnosis were accepted. The model 
for 0-12 months was not rejected but was less well fitted to the data. Without 
age and sex in the model, the goodness of fit was improved but not to a point 
where the model could be accepted. Sensitivity of the model is the 
proportion of true positives correctly identified i.e. the number of cases of 
SLE correctly identified from the model. The specificity of the model is the 
proportion of true negatives correctly identified i.e. the proportion of 
controls correctly identified from the model. The specificity of the three
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multivariable models was good meaning that the models correctly classified 
the controls as controls rather than cases. However, the sensitivity of the 
models decreased with increasing time from time of SLE diagnosis and was 
very low for the 13-24 month and 25-36 month models. The positive 
predictive value of the model is the proportion of positives that are truly 
positive, i.e. the proportion of those classified as cases that were truly a case 
of SLE. The negative predictive value is the proportion of negatives that are 
truly negative i.e. the proportion of those classified as controls that were 
truly controls. For the 0-12 month and 13-24 month models, the positive 
predictive value was above 60% indicating that the positive predictive value 
of the model for cases of SLE was reasonable; for the 35-36 month model the 
positive predictive value was sHghtly below 60%. The negative predictive 
values were all in excess of 90% indicating good predictive value of the 
model for the controls.
I conducted chi-square tests to determine differences in the frequency 
of recorded symptoms in the 12 months before SLE diagnosis in the cases by 
age (<20 years, 20-50 years and >50 years) and sex. There were 21 cases in 
the early-onset SLE group, 173 in the adult-onset group and 151 in the late- 
onset group. There were no significant differences in the recording of any of 
the symptom clusters between the three age groups. However, females were 
more likely to have musculoskeletal symptoms recorded before their date of 
SLE diagnosis compared with the males (67.1% in the females compared with 
44.7% in the males p<0.0001). Pulmonary disease (which consisted
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predominantly of pleuritis) was more frequent in males but the difference 
was not statistically significant, perhaps because of a lack of power to detect 
a significant difference. In females, 3.9% had pulmonary symptoms 
compared with 10.5% of the males, p=0.067. There were no other differences 
in the frequency of symptoms in males and females.
10.4 Discussion
In the five years leading up to diagnosis, musculoskeletal and cutaneous 
symptoms, and to a less extent gastrointestinal, haematological and 
reticuloendothehal symptoms were more commonly recorded in the medical 
records of SLE patients compared with the general population. SLE patients 
were 27 times more likely to have a record of musculoskeletal symptoms 
(predominantly arthritis and arthralgia) in their record in the 0-12 months 
before their diagnosis and in the 13-24 months they were 7 times more likely 
to have a record of these symptoms. This is consistent with previous studies 
of the initial presentation of SLE (Hopkinson 1994, Jacobsen 1998, Voulgari 
2002, Font 2002, Ozebek 2003). Constitutional symptoms were significantly 
associated with a diagnosis of SLE in the 12 months before diagnosis but not 
before this period. Renal symptoms and thromboses were recorded 
significantly more frequently in the SLE cases only in the 0-12 months before 
diagnosis. This finding is consistent with the fact that severe disease is more 
hkely to lead to a faster diagnosis of SLE (Ozebek 2003). I found a non­
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significant increase in the risk of pulmonary involvement in males before 
diagnosis of SLE compared with females, which is consistent with previous 
studies (Font 1992, Voulgari 2002).
There were 92 patients who had early symptoms of SLE in their 
medical records for at least five years before their diagnosis, 12 of whom had 
two or more symptoms possibly associated with SLE. It was not possible to 
calculate the mean time from symptom onset to diagnosis using data from 
the GPRD because the data are left-censored. Five of the 12 patients with 
multiple symptoms were under the care of hospital consultants for related 
autoimmune diseases and therefore, it can be concluded that for these 
patients probably, there was insufficient clinical evidence to support a 
diagnosis of SLE.
This is the first study of the initial presentation of SLE that has been 
conducted using prospectively recorded data from primary care and using a 
general population control group. It has the advantage of being free from 
recall bias but is affected by issues surrounding the completeness of 
recording of symptoms by GPs, and perhaps, the reporting of symptoms by 
patients to their GPs. GPs contributing to the GPRD are more likely to 
record only symptoms that they deem to be of importance in their day-to- 
day clinical patient management. Whilst symptoms such as depression, 
arthritis, persistent rashes, and major events such as thrombosis and renal 
disease are Hkely to be deemed of cHnical importance, it is debatable whether 
or not symptoms such as arthralgia, malaise, fatigue and other vague
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symptoms are recorded as consistently. It might be reasonable to suggest that 
these symptoms are more frequently recorded when they are persistent 
rather than relapsing-remitting as might be expected based on the typical 
pattern of disease in SLE (Chapter 2).
The multivariate conditional logistic regression models showed good 
positive and negative predictive values of the models for the first three years 
before diagnosis, suggesting that perhaps these models may have some 
clinical application in primary care but further research into the cost- 
effectiveness of such an intervention needs to be undertaken before this 
possibihty can be addressed. The lack of sensitivity of the multivariate 
logistic regression models to detect SLE confirms the fact that presentation 
varies from patient to patient which makes it difficult to recognise and 
diagnose in primary care, a setting in which it is a relatively uncommon 
disease.
In order to determine the goodness of fit, sensitivity, specificity and 
predictive value of the logistic regression models it was necessary to conduct 
an unmatched analysis in addition to the matched analysis (conditional 
logistic regressions). Matching in case-control studies is designed to 
mmimise confounding by factors such as age and gender. Previous studies of 
SLE have shown that initial presentation varies with age and gender 
(Maddison 1987, Font 1992, Jacobsen 1998, Lahita 1999c) and therefore in this 
study, controls were matched by age and sex to each case. In addition to 
matching by age and sex, I also matched the cases to controls from the same
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general practice. Matching by general practice can be seen as a proxy for 
matching by geographical location (i.e. the controls are from the same local 
population as the cases), to some degree by socioeconomic status and, of 
most importance in this study, to the recording habits of GPs. In a 
conditional logistic regression model, unmatched cases (orphans) and 
concordant pairs are dropped out of the analysis. The odds ratios are 
calculated from the frequency of 'exposure', or in this case, presence of a 
symptom where this is discordant between matched pairs (Greenland 1998). 
In the unmatched analysis, all cases and controls in the study are entered into 
the analysis. This increases the statistical power of the model, and hence 
narrows the confidence intervals of the odds ratio. Whether or not 
unmatched analyses should be conducted using matched data is debatable 
however, the results of this study indicate that there was no significant 
difference between the estimates for the matched and unmatched analyses; 
consequently, it is reasonable to assume that the stabiHty, sensitivity arid 
specificity of the unmatched models is similar to that of the matched models.
In conclusion, this study confirms the protean initial presentation of 
SLE in primary care, making it difficult to diagnose the disease early unless 
severe disease such as renal involvement is the presenting symptom. I was 
unable to develop age- and sex-specific symptom profiles of patients given 
the data in the GPRD. Whilst the early detection of SLE is of interest and of 
importance, it seems that it will be difficult to develop models further due to 
the protean manifestations of this disease. One area of interest might be the
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delay between symptom onset and patients reporting the symptoms to their 
GP. Any delay in diagnosis in older adults might be confounded by a delay 
in reporting symptoms thought by the patient to be attributable to the 
menopause or 'old age'.
From the data presented in this study it is not possible to determine 
how many patients in the general population have arthritis, arthralgia, rashes 
or depression but do not get an eventual diagnosis of SLE. It might be 
suggested that GPs should refer all patients with arthritis plus one other 
symptom suggestive of SLE but this would be costly and would impact on 
waiting list times for rheumatology. Perhaps the 'wait and see' approach is 
the only reasonable course of action with increased awareness of a potential 
diagnosis of SLE. It is important that GPs are aware of the relevance of 
arthritis, arthralgia, depression, rashes and general fatigue, particularly so in 
men and women of peri- or post-menopausal age in the context of 
presentation of SLE. Before further research is conducted to tackle the issue 
of the recognition of SLE in primary care, it is important that, based on the 
epidemiological evidence in Caucasian populations of an equivalent risk of 
diagnosis in women aged from 20 to 60 years of age (Hopkinson 1995, 
Chapter 7), the traditional depiction of SLE affecting only women of 
'childbearing' age should be also be addressed.
207
Chapter 11
Management of Systemic Lupus 
Erythematosus in the General Practice 
Research Database
Nightingale AL,_de Vries CS, Farmer RDT. Contraceptive practice in women 
with lupus erythematosus. Pharmacoepidemiology and Drug Safety, 2000; 9: S46
208
11 Management of systemic lupus erythematosus in 
the GPRD
11.1 Introduction
In Chapter 10 I described the way in which SLE presents in primary care 
using the GPRD. The purpose of this chapter is to describe the management 
of SLE after SLE diagnosis with regards to consultation patterns before and 
after diagnosis, prescribing patterns of drugs commonly used for SLE. I have 
also conducted case study of the use of systemic hormonal contraceptives 
compared with the prescribing guidelines according to the British National 
Formulary at the time ihat the data were collected.
11.2 Methods
I used the 1998 version of the GPRD to conduct this study and all 1860 cases 
that have been described previously with at least 6 months of research 
standard data in their record.
Within the records of the 1860 cases, data were available between 1992 
and 1998, from the time of diagnosis, to many years (over 20 years) post 
diagnosis of SLE. Additionally, there seemed to be no annual change in 
prescribing or consultation patterns (Chapter 8). Therefore, in order to 
combine the data from all cases so that aU available data could be used to 
describe consultation patterns from time of diagnosis forwards, I
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transformed the date of the consultation from a date to a quarter post­
diagnosis. I calculated the number of quarters of the year (3-month periods) 
before or after the date of diagnosis that the consultation took place. This was 
calculated by subtracting the date of consultation /  prescription from the 
date of diagnosis and divided by 3 monthly periods. Table 11.1 shows the 
way in which the transformation into quarters was implemented in the 
medical and therapy records. In this way, consultation data from cases 
diagnosed in 1992 and 1998 could be combined in terms of their consultation 
patterns before and after the date of diagnosis.
I calculated consultation rates for each quarter during the study 
period. The denominator for all of the rate calculations was the number of 
people with SLE contributing to the population during that quarter. The 
numerator for the calculations was the number of people consulting their GP 
in that period. Consultation rates were calculated as follows:
Consultation rate/100 = Number of consultations in the quarter *100
Number of cases of SLE during the period
Cases were considered to be contributing to the denominator from their date 
of diagnosis or left censoring date, whichever was the later until their right 
censoring date.
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Table 11.1. Transformation of consultation date to quarters after diagnosis
Patient Date of 
diagnosis
Consultation
date
Diagnosis Number 
of days 
after 
diagnosis
Number
of
quarters
after
diagnosis
2 11/08/1987 05/10/1994 EMBOLISM PULMONARY 2612 29
3 18/01/1990 07/01/1993 ARTHROPATHY 1085 12
3 18/01/1990 19/03/1993 FIBROMYALGIA 1156 12
4 16/01/1981 14/08/1992 ARTHRinS ACUTE 4228 46
4 16/01/1981 15/07/1993 THERAPY STEROIDS 4563 50
5 07/01/1971 06/01/1994 ANAEMIA 8400 92
5 07/01/1971 20/02/1998 ABDOMINAL COLIC 9906 108
6 05/06/1998 02/07/1998 MYOSITIS 27 1
6 05/06/1998 30/10/1998 DYSPEPSIA 147 2
I identified all prescriptions of drugs commonly used in the treatment of SLE 
(immunosuppressants, cytotoxics, antimalarials, NSAIDs) that were issued to 
patients after their diagnosis from the 'therapy' data table for any indication. 
This table has been described in Chapter 4. From prescribing data available 
within this table, for example, dose (text e.g. BD (twice a day), TDS (three 
times a day)) and number of tablets or capsules prescribed over a given 
period of time, it was possible to calculate the prescribed total daily dose for 
most of the prescriptions for orally administered (tablet or capsule) 
medications. Where possible I calculated the mean, median and standard
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deviation of prescribed daily dose for each drug between 1** January 1992 and 
31®^ December 1998.
11.3 Results
11.3.1 Consultation rates
Consultation rates were calculated per case of SLE from 8 quarters (2 years) 
before the date of diagnosis to 20 quarters (5 years) after date of diagnosis for 
the first 80 quarters (20 years) following date of diagnosis. Figure 11.1 shows 
the consultation rates for each quarter following diagnosis. Consultation 
rates were at their highest at the time of diagnosis (6.3/person in quarter 0) 
and dropped to a rate of approximately 3 /person/ quarter after the first 2.5 
years (10 quarters) following diagnosis.
Figure 11.1 Consultation rates in patients with SLE 2 years before their date 
of diagnosis to 5 years after their date of diagnosis
6
5
S . 4
I
I
I 3
2
Diagnosis^Date of SLE
Year Quarters from SLE Diagnosis (Time 0)
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11.3.2 Prescribing
In table 8.4 (Chapter 8), I presented the proportion of SLE cases receiving 
prescriptions for cytotoxics/ immunosuppressants, corticosteroids, 
antimalarials or NSAIDs for each year of the study period. Table 11.2 shows 
the proportion of SLE cases prescribed these medications at any time from 
1992 to 1998 compared with the proportion of patients treated at any time in 
their disease in other studies. Topical corticosteroids were prescribed to 
48.7% of patients, sunscreens to 17.2% of patients. Antiepileptics and 
antipsychotics were prescribed to 9.1% and 3.1% of patients respectively.
There were 14,101 prescriptions for NSAIDs issued to 1210 patients 
with SLE during the study period. Figure 11.2 shows the proportion of 
patients prescribed different generic NSAIDs. In patients prescribed NSAIDs, 
diclofenac was the most frequently prescribed drug; tiie median daily dose 
prescribed was lOOmg (range 25mg -  300mg). The second most frequently 
prescribed NSAID was ibuprofen at a median dose of 1200mg per day (range 
200mg -  2400mg).
There were 9442 prescriptions for antimalarial agents to 677 SLE 
patients during the study period. 86.1% of these were for 
hydroxychloroquine (median dose 200mg /  day), 9.9% for chloroquine 
(median dose 200mg/day) and 4.0% for mepacrine (median dose 
lOOmg/ day).
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Figure 11.2 Pie chart showing the percentage of all NSAIDs prescribed to 
patients following SLE diagnosis by generic type (for any indication) 
(n=14,101)
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There were 25,218 prescriptions for systemic corticosteroids issued to 1089 
patients with SLE of which 25,055 (99.4%) were for prednisolone. The mean 
prescribed dose of prednisolone was 7.3mg /  day (SD 8.0), median 5mg/day 
(range 0.5mg -  lOOmg). There were 3165 prescriptions for doses of 
prednisolone over lOmg/day issued to 519 patients. Of these, 12.0% were for
doses of 40mg per day or over.
There were 5171 prescriptions for topical corticosteroids issued to 905
patients with SLE during the study period. 25.8% of these were for
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hydrocortisone 0.1% to 2.5%. 16.5% of the prescriptions were for 
betamethasone valerate 0.025% to 0.1% and 12.5% of the prescriptions were 
for clobetasol butyrate 0.05 %.
Four hundred and seventy-nine patients with SLE received 10,369 
prescriptions for immunosuppressive or cytotoxic therapy during the study 
period. 11.4% of these were for cytotoxic agents: 3.4% were for 
cyclophosphamide (mostly oral) and 8.0% for methotrexate. The majority of 
immunosuppressant prescriptions were for azathioprine (79.3% of 
prescriptions). There were 13 prescriptions for mycophenelate mofetil. This 
drug would have been in its experimental stage in treatment of SLE during 
the study period. There were 949 (9.1%) prescriptions for cyclosporin.
11.4 Discussion
11.4.1 Consultation rates
Consultation rates rose in the 2 years before SLE diagnosis to a maximum 
during the three months after the date of diagnosis. Consultations rates 
decreased after date of diagnosis suggesting that over time, patients with 
SLE need less input from the GP as they adjust to their illness. It should be 
noted that this method of calculation of the consultation rates wül be affected 
by the issues of case identification of the prevalent cases that has been 
discussed in detail in Chapter 8. Additionally it is likely to be an 
underestimate of the overall consultation rates for SLE that includes
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consultations in outpatient clinics. Patients with severe disease are more 
likely to be managed in specialist centres (AGR guidelines 2000) and 
therefore their consultations for SLE will not be taken into account in this 
calculation. Moreover, GPs are not required to record all consultations for a 
chronic disease (HoUowell 1997) increasing the likelihood that the 
consultation rates reported in this study wiU be an underestimate.
11.4.2 Prescribing
The proportion of patients receiving NSAIDs in the GPRD population was 
higher than that reported for the EuroLupus cohort (Cervera 2003). It is 
possible that this is because for the present study, the indication for the 
NSAID prescription was not taken into account whereas for the EuroLupus 
cohort, it is more likely that the proportion of those treated with NSAIDs 
were treated specifically for SLE rather than for other indications.
The proportion of patients treated with prednisolone is similar to that 
previously reported for SLE populations (Uramoto 1998, Stahl-Hallengren 
2000, Cervera 2003) and most of the prescriptions were in line with the 
recommendation of doses less than lOmg/ day (Petri 1998). The mean dose of 
prednisolone was slightly lower than the mean for the LUMINA cohort 
(7.3mg/ day compared with llm g/day) (Alarcon 1999).
The proportion of patients treated with antimalarial agents was lower 
for the GPRD population than it has been in other pubHshed series (Barr 
1999, Uramoto 1999, Stahl-Hallengren 2000, Cervera 2003). It is unclear why
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this is the case and may indicate physician preference in the UK. It is also 
possible that the widespread use of antimalarial agents for the treatment of 
SLE in preference to NSAIDs has changed over the last decade.
There were a similar proportion of SLE patients in the GPRD treated 
with azathioprine to that for other populations (Uramoto 1999, Stahl- 
Hallengren 2000, Cervera 2003). Cyclophosphamide prescribing was sHghtly 
lower than reported for the EuroLupus cohort (Cervera 2003) and was 
mainly for orally administered rather than intravenous (pulse) therapy. It is 
highly hkely that patients receiving pulse cyclophosphamide, and, in 
general, those receiving cyclophosphamide treatment would be managed in 
secondary rather than primary care for their disease (ACR 1999). Bearing in 
mind that cyclosporine is reserved for those with severe and /  or refractory 
disease (Ruiz-lrastorza 2001), it was surprising that 9.1% of the 
immunosuppressant prescriptions were for cyclosporine but the 
prescriptions were for only 38 patients.
When 1 started this thesis, 1 conducted a study of prescribing of 
systemic hormonal contraceptives in women with SLE to investigate 
utihsation patterns before and after diagnosis in the context of the fact that 
within the BNF SLE is Hsted as a contraindication to their use but in practice, 
most specialists treating patients with SLE prescribe combined oral 
contraceptives to women for whom the benefits would outweigh any 
theoretical an anecdotal risks of an increase in risk of disease flare or
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thrombosis (Arden 1993, personal communication Dr Graham Hughes 2001, 
Dr Chris Edwards 2007,).
11.5 Case study of systemic lupus erythematosus 
management: the use of systemic hormonal 
contraceptives before and after diagnosis of SLE
11.5.1 Introduction
According to the prescribing guidelines in the British National Formulary, 
combined oral contraceptives (COCs) are contra-indicated in women with 
SLE (British National Formulary 1998). However, in 1993 it was suggested 
that in women with stable disease, COCs may be a suitable method of 
contraception (Arden 1993) and many clinicians continued to prescribe COCs 
to women with SLE (personal communication. Dr Chris Edwards 2007). In 
the 1990s, some experts advised against the use of COCs in women with SLE 
before definitive data became available from the double-blind, placebo- 
controlled randomised controlled clinical trial (RCT) SELENA (Safety of 
Estrogens in Lupus Erythematosus National Assessment) became available 
(Lahita 1999b). In the Hopkins Lupus Cohort at this time, it was standard 
practice to stop the use of COCs in women at the time of their diagnosis 
(Petri 1997). However, some researchers suggest that with careful monitoring 
and assessment, women with SLE without active renal disease or 
antiphospholipid antibodies in raised titre might benefit from COCs, which 
are a relatively safe and effective method of contraception (Buyon 1996, Petri
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1997, Bruce 1997). The reason for this guideline is that women with 
antiphosphoHpid antibodies in raised titre may be at increased risk of 
thrombosis (Asherson 1999), and combined oral contraceptives are also 
associated with an increased risk of venous thrombosis, and in some studies, 
arterial thrombosis (Lewis 1998).
11.5.1.1 SLE and COCs
It is accepted that exogenous oestrogen exacerbates some clinical 
manifestations of murine lupus as that oestrogen is implicated in the 
pathogenesis of SLE through the predominance of SLE in women, evidence 
of an increased risk of SLE in males with Klinefelter's syndrome and the 
presence of altered oestradiol and androgen metabolism in patients with SLE 
(see Chapter 2).
Studies of contraceptive practice in women with SLE have shown a lower use 
of COCs compared with women of the same age in the general population. 
Julkunen (1993) found that in Finland, 10.0% of sexually active women with 
SLE (n=85) used COCs compared with 23.0% of women in the general 
population (n=834) aged 18-44 years (p<0.05). This analysis was based on 
five women with SLE, there of whom were using COCs and two were using 
progestogen-only contraceptives. Buyon (1995) investigated the use of COCs 
in 404 women with SLE. Fifty-five percent (n=224) of the women had used 
COC in the past and 13.0% and 14.0% used COCs after their diagnosis. The 
study was based on the patient's recall of their COC use and did not report
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the formulations of COCs used. The use of COCs in women aged 35 years or 
less with SLE was 10.0% compared with 25.0% of women not using COCs at 
the same time. In the Hopkins Lupus Cohort only 4.0% of women were 
reported to be using COCs (Petri 1997).
There have been several case reports of the onset of SLE and of disease 
exacerbation associated with the use of COCs (Chapel 1971, Travers 1978, 
Garovich 1980, Todd 1985, Miller 1987, Julkimen 1991, Julkimen 1991b). Most 
of these reports were published before the introduction of the newer COCs 
containing <50pg oestrogen (as ethinyloestradiol or mestranol). Three studies 
have been published investigating the effect of COCs on the frequency of 
exacerbation of SLE. Two of these studies (Julktmen 1993, Buyon 1995) found 
a low incidence of flare among women with SLE using COCs. Julkunen 
(1993) round no statistically significant difference between the incidence of 
flare in current COC users compared with never users of COCs. Buyon 
(1995) reported that in COC users with SLE, only 13% had self-reported flare 
which is consistent with the findings of Julkunen. An earlier study of women 
with SLE by Jungers (1982) found that 43% of women using COCs 
experienced flares compared with no women using progestogen-only 
contraceptives. In that study, all 20 women using COCs had renal 
involvement and 14 of them were using COCs containing 50pg of oestrogen.
A small proportion of women in the general population use 
progestogen-only contraceptives (Farmer 1996). Jungers (1982) reported that 
no clinical flares occurred in 11 women using progestogen-only
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contraceptives in their study of contraceptive practice. Julkimen (1993) 
reported that although 32 women (n=85) in their study had used 
progestogen-only contraceptives, 23 had discontinued use because of 
gynaecological side-effects. Mintz (1984) studied the safety and tolerability of 
progestogen-only contraceptives in women with SLE compared with non­
users; 50% and 80% in users of norethisterone and levonorgestrel-based 
progestogen-only contraceptives, respectively, experienced side effects and 
had poor gynaecological tolerance.
The aim of this study was to determine the use of hormonal 
contraceptives in women with SLE in the UK population using the GPRD, to 
compare use with the general female population of the same age and to 
investigate whether the use of systemic hormonal contraceptives changed 
following diagnosis of SLE.
11.5.2 Methods
The 1999 version of the GPRD was used. The study period ran from 1»* 
January 1992 to 31s‘ December 1998. The study population consisted of all 
women contributing to the GPRD during the study period aged 15-40 years. 
The method of case definition for SLE has been described in detail in Chapter 
6. In this study, I defined incident cases of SLE as those with a new diagnosis 
of SLE during the study period who had at least six months of research 
standard data in their record before their date of diagnosis. Women who had 
a diagnosis of SLE before the study period or their left-censoring date or
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during the study period but who had less than six months of data before 
their date of diagnosis were considered prevalent cases of SLE.
The product-specific utiHsation patterns of COCs and progestogen-only 
contraceptives had been described and mapped previously by members of 
staff in our department (Farmer 1996). Overlapping prescriptions for the 
same product were concatenated to give periods of continuous 'exposure'. 
When a woman switched from one product to another it was assumed that 
she started using the new product immediately and any unused product was 
discounted. For women with SLE I calculated the use of COCs and 
progestogen-only contraceptives before and after their date of SLE diagnosis. 
Where a prescription straddled the date of diagnosis it was spHt on that date 
into two separate periods of utilisation.
The utilisation rate ratios and their 95% confidence intervals were 
calculated, adjusted by year of age using Poisson regression. All statistical 
analyses were conducted using STATA statistical software (STATA Statistical 
Software 2005 StataCorp version 9.0 College Station, TX). I compared the use 
of COCs and progestogen-only contraceptives before and after diagnosis as 
well as comparing utiHsation rates amongst women with SLE with those of 
the female population of the GPRD of the same age.
11.5.3 Results
Two hundred and forty-six women were classified as incident cases of SLE 
aged 15-40 years during the study period. Before their date of diagnosis 98 
(39.8%) of women with SLE used COCs, 10 (4.0%) used progestogen-only
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contraceptives and 18 (17.0%) used both types of hormonal contraception. 
After diagnosis 64 (26.0%) of the women with SLE used COCs, 17 (7.0%) 
used progestogen-only contraceptives and 17 (7.0%) used both types of 
hormonal contraceptives. Most of the women with SLE were using COCs 
containing ^ 35pg ethinyloestradiol. Only one woman had used a COC 
containing 50pg mestranol and this was before her date of diagnosis. 40 
women with SLE used phased COCs containing 30pg to 40pg of 
ethinyloestradiol. The utiHsation rates of COCs and progestogen-only 
contraceptives in women with SLE before and after diagnosis are shown in 
Table 11.3. There was no statisticaUy significant change in the use of COCs 
before and after diagnosis of SLE (age-adjusted RR 1.01 (CI95 0.78, 1.31)). 
There was a statisticaUy significant increase in the use of progestogen-only 
contraceptives after SLE diagnosis (age-adjusted RR 2.47 (CI9 51.28,4.43)).
Table 11.3. UtiHsation rates of hormonal contraceptives in women with SLE 
before and after date of diagnosis.
Before SLE 
diagnosis
After SLE 
diagnosis
Total observed woman-years in wom en  
with SLE
637.6 534.5
Total woman-years of utilisation of 
COCs
137.4 106.1
UtiHsation rate of COCs 21.5 /  100 OWY 1 9 .9 /1 0 0  OWY
Total woman-years of utilisation of 
POCs
15.8 31.2
UtiHsation rate of POCs 2.5 /1 0 0  OWY 5.8 /  100 OWY
OWY, observed woman-years
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There was no difference in the use of COCs between women with SLE and 
women in the general population of the GPRD of the same age (Figure 11.3). 
The age-adjusted utilisation rate ratio comparing use of COCs in women 
after diagnosis of SLE with use in women in the general population of the 
GPRD of the same age was 1.00 (CI95 0.82, 1.20). Women with SLE used 
statistically significantly more progestogen-only contraceptives than women 
in the GPRD general population (Figure 11.3). The age-adjusted utilisation 
rate ratio was 2.62 (CI9 5 1.84,3.72).
Figure 11.3. Utilisation rates of COCs and progestogen-only contraceptives in 
women with SLE and for those in the general population of the GPRD of the 
same age.
50.00 -
4 0 .0 0 -
30.00
S 20.00
10 .0 0 -
0.00 40
Age
■Progestogen-only contraceptives (GRPD population) -« -C o m b in ed  oral contraceptives (GPRD population) 
■Progestogen-only contraceptives (SLE patients) -« -C o m b in e d  oral contraceptives (SLE patients)_____
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11.5.4 Discussion
There was no statistically significant change in the use of COCs after 
diagnosis of SLE or compared with the general female population of the 
GPRD. The apparent peak in utilisation rates of COCs in women with SLE is 
likely to be due to small numbers of cases. This finding is not consistent with 
prescribing guidelines at the time that this study was conducted (BNF 1998) 
or with previous studies of contraceptive practice in women with SLE 
conducted elsewhere (Jungers 1982, Buyon 1995, Julkunen 1991) but is 
consistent with accepted practice amongst UK specialists (Arden 1993, 
personal communication Dr Chris Edwards 2007). These data suggested that 
for women in the GPRD population with SLE, COCs were well tolerated and 
that clinicians in the UK did not necessarily stop COCs at time of SLE 
diagnosis. Subsequently the results of SELENA have been published and 
have concluded that in women with stable disease, COCs do not increase the 
risk of exacerbation or of thrombosis (Petri 2005).
There was a statistically significant increase in the use of progestogen- 
only contraceptives after SLE diagnosis and compared with the general 
female population of the GRPD with a utilisation rate of 10/100/year for 
women in their early 30s. Use of all hormonal contraceptives decreased with 
increasing age after the age of 22 and in women using hormonal 
contraceptives, relative use of the progestogen-only contraceptives increased 
with increasing age. It is possible that when we compared the use of 
progestogen-only contraceptives in women before and after SLE diagnosis,
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there was residual confounding by age. Although I adjusted the rate ratios 
for year of age, this would not have completely controlled for the fact that the 
SLE population was older after diagnosis than they were beforehand.
The major implications in terms of prescribing of COCs from this 
study, and from the results of SELENA are that current prescribing 
guidelines indicating that COCs are contra-indicated in all women with SLE 
should be updated to reflect the fact that in women without 
antiphospholipid antibodies and in women with stable disease without renal 
involvement, COCs do not appear to post an increased risk in women with 
SLE compared with those without SLE.
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Chapter 12
Discussion and Conclusions
228
12 Discussion
The findings of this thesis relate to both methodological issues with the use 
of the GPRD and to the clinical presentation of SLE in primary care, which 
may contribute to the possibility of earlier referral for patients with 
symptoms suggestive of SLE. In Chapter 3 1 presented the hypotheses that 
were formulated for the studies in the thesis. In this chapter 1 will discuss 
each of these hypotheses in the context of the findings from the studies in the 
thesis, further discuss conclusions that can be drawn from them and outline 
areas of potential future research.
12.1 Identifying cases of SLE from the GPRD
I hypothesised that it would be possible to identify cases of SLE from the 
GPRD population.
The GPRD was chosen as the data source to conduct these studies because 
SLE is a rare disease in terms of its incidence, with previous estimates from 
the UK being between 3.8/100,000/year and 4.0/100,000/year (Hopkinson 
1993, Johnson 1995). In order to identify a sufficient number of cases to 
conduct an investigation into the presentation of SLE in primary care it 
would have been necessary to conduct a large multi-centre study involving 
hundreds of general practices throughout the UK. Doing this without using 
a pre-existing database would have been expensive, logistically difficult and 
would have been affected by issues with recall error. Using the GPRD
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provided a population of over four millions patient from practices 
throughout the UK (predominantly from England and Wales). The 
observational nature of the GPRD was an advantage in terms of the study of 
SLE presentation in primary care, but also had some limitations with regards 
to the identification of SLE cases as not all symptoms of SLE and relevant test 
results were recorded on the database.
American College of Rheumatology classification criteria for SLE 
The vast majority of epidemiological studies of SLE define cases according to 
tire ACR classification criteria for SLE (Tan 1982, Hochberg 1997). These 
criteria were developed for use in research, especially clinical trials, so that 
the results of studies from different geographical locations were comparable 
in terms of their disease definition (see Chapter 2). Interestingly, in the most 
recently published study of mortality in SLE, the researchers, including 
many of the most esteemed researchers in SLE, decided to include cases of 
SLE with a clinical diagnosis even if they did not fulfil these criteria 
(Bernatsky 2006).
The ACR criteria were developed on prevalent cases of SLE (Tan 1982) 
and have been criticised for excluding mild cases of SLE and those with 
severe disease limited to one organ system, for example, lupus nephritis 
(Smith 1999, Petri 2004). It has been acknowledged that patients with a 
clinical diagnosis of SLE can take many years to fulfil the ACR criteria (Petri 
2002) and studies of SLE incidence frequently refer to 'incident' cases as
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those who have fulfilled the fourth criterion in that year, rather than those 
who have been newly diagnosed in that year (for example, Hopkinson 1993, 
Johnson 1995). Inevitably there will be some differences in the 
characteristics, and perhaps outcome, of incident patients who are newly 
diagnosed and those who have just fulfilled the 4*^  criterion as the duration 
of their illness might differ dramatically. As SLE is usually diagnosed and 
managed by specialists (Glazier 2002), it seems unlikely that patients who 
have received a diagnosis and consequently receive treatment for SLE have 
received an inaccurate diagnosis from their clinician. Therefore the 
application of criteria developed using prevalent cases to define incident 
cases can be called into question.
The ACR criteria were developed so that when studies of the 
epidemiology and management of SLE were conducted in different clinical 
settings, the study populations would be diagnostically homogeneous. 
However, if they fail to include patients with a clinical diagnosis of SLE, 
sometimes with severe disease manifestations, the value of the results of 
studies including only patients that meet the criteria may be limited in terms 
of their generalisability. In the context of randomised controlled trials 
(RCTs) of the treatment of any disease, inclusion criteria are generally 
specific and can lead to issues with the generalisability of the results from 
RCTs to the general population. The purpose of conducting studies of the 
incidence, prevalence and mortality of disease is to determine the impact of 
that disease on society, to provide information to health service planning and
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to raise hypotheses regarding the causes or triggers of that disease. If studies 
of the incidence and prevalence of disease are limited to a sub-group of 
highly selected patients, they cannot be generalised to the general population 
that will include patients with a clinical diagnosis of SLE who are receiving 
treatment for SLE. The 1982 ACR criteria (Tan 1982) were found to be 96% 
sensitive and specific in the classification of SLE; altering the criteria so that 
they include milder cases or those where disease is limited to one organ 
system will inevitably lead to a decrease in the accuracy of the criteria for the 
classification of SLE. In future, it would be useful for investigators to present 
the incidence and prevalence of clinically diagnosed SLE and incidence and 
prevalence of ACR defined disease so that, for the purposes of health care 
planning, a clearer picture of the true impact of SLE on society may be 
estimated. Additionally, if incidence rates of disease are used to detect 
adverse event signals from randomised clinical trials, it is important that 
incidence rates are accurate so that false signals are not raised.
In their case-control study of the risk of SLE and discoid LE onset 
associated with the use of hormone replacement therapy using the GPRD, 
Meier et al (1998) included only cases where it was possible to obtain copies 
hospital letters and test results from participating GPs so that the presence of 
the ACR criteria could be established. They defined cases fulfilling four or 
more criteria as 'definite' cases of SLE and those fulfilling three criteria as 
'probable' cases of SLE. In terms of a case-control study, it might be argued 
that this was a reasonable method of case definition as it reduces the risk of
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misclassification of disease however, it does have some limitations. Not all 
GPs contributing to the GPRD have agreed to supply further information 
about patients and those that do respond to requests for further information 
cannot provide information for patients who are no longer registered with 
their practice. For example, if a study is conducted in 1998, for example, only 
the records of patients still contributing to these specific practices can be 
accessed. This means that any patients who have died or transferred out of 
their practice would not be eligible for inclusion into the study population. 
This results in an over-representation of survivors in the study population.
In a subsequent case-control study of the risk of SLE onset associated 
with hepatitis B vaccination, Sturkenboom (2000) (who was one of the 
investigators in the Meier study) did not continue to use the method of case 
identification outline above, instead they defined cases of SLE as those with 
at least two records of the diagnosis of LE, one of which must have been 
confirmed in hospital. Further details of the cases have not been made 
available as to date this study has only been published as a conference 
abstract. Although GPs contributing to the GPRD are required to record 
diagnoses that lead to hospital referral or new therapy (Hollowell 1997), they 
are not required to record attendance at hospital per se. Studies of the 
completeness of hospital attendance recording estimate that the rate of 
under-recording is between 10% and 30% of all attendances (Lawrenson 
2000, Lewis 2002) with records of surgery being approximately 90% complete 
(Lewis 2002). This means that a requirement of a record of hospital
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attendance as a case definition will miss between 10% and 30% of aU cases of 
SLE.
In case-control studies, it is important to include only cases where one 
is sure of the disease status in order to avoid the risk of introducing biases to 
the risk estimates. If one includes individuals as cases that do not, in fact, 
have that disease, the results will be generally that the risk estimates for 
exposures of interest will be reduced. Additionally, if an increased risk 
associated with a particular exposure is found, it is important to be sure that 
the method of case definition has been accurate. In the calculation of 
frequency of disease, it is equally as important to minimise the risk of 
misclassification to prevent an overestimation of the incidence, however it is 
important to identify all cases of disease so that the estimated rates are as 
accurate as possible. In studies using the GPRD, limiting case identification 
to those cases where further information is available from GPs in a study of 
the incidence and prevalence of disease would result in an underestimate of 
the true frequency of disease in the population.
I aimed to define cases of SLE identified from the GPRD using an 
adapted version of the ACR criteria (Chapter 6). I expected that this would 
be problematic because of inconsistencies in the recording of blood test 
results and the virtually complete absence of immunological testing and /  or 
recording of test results from secondary care on the GPRD. However, only 
2.4% of the potential cases fulfilled 4 or more of the criteria therefore it was 
necessary to develop an algorithm for the identification of cases (Chapter 6).
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I included cases that had a record of hospital-confirmed diagnosis and /  or 
therapy consistent with a diagnosis of SLE after the date of diagnosis. It is 
weU established that prescribing data on the GPRD are almost 95% complete 
(Walley 1997) and studies of the accuracy of recording of diagnoses recorded 
in hospital in- and out-patient letters and discharge summaries are in the 
region of 90% (Jick 1991, Jick 1992, van Staa 1994, HanseU 1999). An 
algorithm based on a combination of prescribing for and evidence of 
management of SEE in hospital is likely to identify correctly between 80% 
and 90% of all cases of SLE depending on the length of time that the 
individual contributed time to the database. The purpose of the initial case 
identification process was to calculate the incidence and prevalence of SLE 
and therefore limiting the identification of cases to those with hospital- 
confirmed diagnosis would have led to an underestimate of the incidence 
and prevalence as was demonstrated in the sensitivity analyses of the 
incidence and prevalence of SLE restricted only to cases with a record of 
hospital diagnosis or treatment. However, in my study of the presentation of 
SLE in primary care it was essential to include only cases where the 
diagnosis of SLE was definite and for this study, I required that all cases had 
evidence of hospital confirmation of their SLE. The sensitivity of this 
algorithm for identifying cases of SLE was assessed by comparing the 
expected number of cases of SLE from epidemiological studies of SLE in the 
UK population that were defined using the ACR criteria to the number of 
cases identified from the GPRD (Hopkinson 1993, Johnson 1995, Gourley
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1997). The observed number of incident cases of SLE was slightly lower than 
expected but within the confidence intervals of the estimates. In order to 
make a more formal assessment of the accuracy of the recording of SLE 
diagnosis on the GPRD and of the method of case identification used, further 
investigations should take place to validate the diagnosis of SLE on the 
GPRD compared with hospital discharge or outpatient attendance letters. 
This may be especially useful for cases where the sole diagnostic code used is 
for lupus erythematosus without the use of a code for 'systemic lupus 
erythematosus' and where recorded symptoms appear to be limited to 
cutaneous and musculoskeletal or patients with a record of systemic lupus 
erythematosus where the only symptoms recorded are cutaneous.
Identification of incident cases
The identification of incident cases of SLE from the GPRD population was 
more straightforward than the identification of prevalent cases. However, it 
was necessary to take into account the possibility of misclassification of 
prevalent cases as incident cases. This might have occurred where a 
prevalent case of SLE had a long period of quiescence and experienced a 
flare, which might appear to be a new presentation of SLE. In their study of 
SEE disease activity, Barr et al (1999) calculated the mean time of quiescent 
disease in SLE to be 2.3 years. Additionally, Lewis et al (2005) conducted a 
study of the time from left-censoring date on the GPRD to incident diagnosis 
of a range of acute and chronic diseases. They concluded that for chronic
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relapsing-remitting disease, the minimum run-in period should be at least 12 
months. I required at least 3 years of data between the left-censoring date 
and the date of the first record of SLE diagnosis for a case to be defined as 
incident.
I did not attempt to identify cases where prescribing was consistent 
with a diagnosis of SLE but a diagnostic code for lupus did not appear in the 
medical record. It is unlikely that this will have significantly affected the 
incidence and prevalence estimates as GPs are required to record indications 
for all new therapies and referrals to hospital (Garcia Rodriguez 2000). 
Moreover, there are no medications that are entirely specific to the treatment 
of SLE and therefore, the presence of prescriptions for these medications 
could not be directly attributed to SLE, even in the absence of diagnostic 
codes for other autoimmune diseases.
Johnson et al (1996) conducted a prospective questionnaire-based 
study of undiagnosed SLE in the community in Birmingham. Although they 
only identified three additional cases of SLE in their population to those 
already identified in their study of the incidence and prevalence of SEE 
(Johnson 1995), this increased their prevalence estimate in women aged 18-65 
years from 54/100,000 to 200/100,000. It would be interesting to apply the 
model that was developed in Chapter 10 for the presentation of SLE to the 
GPRD population to determine the number of patients with SLE that may 
have been undiagnosed and have not been investigated for any autoimmune 
disease.
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Identification of prevalent cases of SLE
The identification of prevalent cases was not as simple as the identification of 
incident cases. Whilst it was possible to identify prevalent cases of SLE where 
there was a diagnostic code for SLE and ongoing treatment or hospital 
management, for cases with quiescent disease, the likelihood of fulfilling the 
inclusion criteria set out in Chapter 6 was dependent on the length of time 
that they contributed data to the GPRD (Chapter 8).
In Chapter 4 1 outlined the data entry requirements for GPs 
contributing to the GPRD. Once a chronic disease is diagnosed, they are not 
required to record every symptom of that disease. In a patient with long­
standing SLE at the time that they entered the GPRD population, especially 
those who had been registered with their GP for a long time before the GP 
started to contribute data to the GPRD; this lack of recording of symptoms 
might make it difficult to identify prevalent cases of SLE. 1 will discuss this in 
terms of its impact on the calculation of temporal patterns in SLE prevalence, 
in the following section of this chapter. In addition, if one were to conduct a 
study using prevalent cases of SLE identified from the GPRD, it is possible 
that cases of quiescent or very long standing disease would be excluded from 
the population, as would cases that had died early on in their disease 
evolution. Therefore, there would be strong possibility that studies using 
prevalent cases would be affected by selection bias through the differential 
inclusion of (a) patients who had survived from their time of diagnosis to 
their contribution to the GPRD (i.e. patients who had very severe life-
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threatening disease might be excluded) and (b) patients who had active 
disease during the study period. In a study of survival studying a cohort of 
prevalent cases, might artificially increase survival.
In conclusion, it is possible to identify incident cases of SLE from the 
GPRD but not by using the ACR criteria to define the cases. The most 
effective way to identify cases is by detailed review of the complete patient 
record where there is a diagnostic code for SLE combined with supporting 
evidence of diagnosis such as therapy with commonly used medications 
such as immunosuppressants, corticosteroids, antimalarials and NSAlDs in 
the absence of other indications for the prescriptions; and /  or evidence that 
the patient is being managed in a hospital setting for their SLE, indicated by 
the presence of hospital letters with the diagnosis or details of medication 
changes and/or evidence of in- or outpatient attendance for SLE. Studies of 
prevalent cases of SLE should be undertaken with caution in the knowledge 
that patients experiencing a period of quiescent disease are likely to be 
excluded unless they are contributing more than five years of data and such 
studies would also be limited to longer survivors of SLE.
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12.2 Incidence and prevalence of SLE
I hypothesised that the incidence and prevalence of SLE in the GPRD 
population would be consistent with previous estimates for the UK 
population.
In my systematic literature review in Chapter 5, 1 found that in the UK, 
incidence rates of SLE had been reported to be between 3.8/100,000/year 
(Johnson 1995) and 4.0/100,000/year (Hopkinson 1993) and that they were 
around six times higher in females than in males. The peak incidence rates in 
Nottingham (Hopkinson 1993) were in women aged 50-59 years, whilst in 
Birmingham (Johnson 1995), the incidence rates were consistent in women 
aged 30-59 years. Prevalence estimates ranged from 12.0 (Hochberg 1987) to 
27.7/100,000 (Johnson 1995) and were more likely to range from 24.0 to 
27.7/100,000 for ACR defined SLE as the study by Hochberg (1987) is 
certainly an underestimate of the prevalence. The incidence rates presented 
in Chapter 7 were consistent with previous reports from the UK, with the 
point estimates being slightly lower than those reported for Nottingham and 
Birmingham. The method of case identification that 1 used in all of the 
studies required the presence of a SLE or LE diagnosis plus evidence of this 
diagnosis being confirmed in hospital and/ or long-term therapy consistent 
with the diagnosis. The lack of supporting evidence in the medical record 
does not necessarily mean that the case was not a true case of SLE. Therefore 
it is possible that the exclusion of cases without supporting evidence would 
lead to an underestimate of the incidence. For example the exclusion of those
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who left the database shortly after diagnosis and /  or where their disease 
was being managed in hospital.
Incidence and prevalence of SLE is higher in Afro-Caribbeans and 
Asians compared with Caucasians (Samanta 1992, Hopkinson 1993, Johnson 
1995). One major weakness of all of the studies in this thesis is the lack of 
data on ethnicity. Ethnicity is not recorded consistently on the GPRD. In their 
study, Meier (1998) claimed that 90% of their cases were Caucasian, but is 
unclear on what data this claim is based. Without data on the exact locations 
of all practices contributing to the GPRD, it would not be reasonable to 
extrapolate UK-wide race-specific population estimates to the GPRD 
population.
Incidence rates were highest in women aged 30 to 69 years (Chapter 
7). This finding is consistent with reports from Birmingham (Johnson 1995) 
and from other predominantly Caucasian populations in Europe 
(Gudmundsson 1990, Jonsson 1990, Stahl-Hallengren 2000). In Nottingham, 
incidence rates were highest in women aged 50-59 years and were nearly 
four times higher than those in women aged 30-39years (Hopkinson 1993). In 
the hght of the consistency of this finding in predominantly Caucasian 
populations, it is time that the classical description of SLE as a 'disease of 
women of childbearing age' is challenged; its persistence in the UK is 
unhelpful in terms of the recognition of disease in primary care for women of 
peri- and post-menopausal age.
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Prevalence estimates (Chapter 8) were higher than previously 
reported and increased between 1992 and 1998 in the absence of any changes 
to consultation or prescribing patterns, an increase in incidence (Chapter 7), 
or a decrease in mortality rates (Chapter 9). The finding that this increase was 
an artefact caused by a combination of the method of case definition of SLE 
in the GPRD population and the differing lengths of time that individuals 
contribute data has implications for the estimates of prevalence of any 
chronic relapsing-remitting disease in the GPRD and perhaps any chronic 
disease where prevalence rather than cumulative incidence is estimated. 1 
attempted to adjust the prevalence estimates for age and years of 
contribution to the GPRD without success.
Farrar et al (2003) published a conference abstract describing an 
increase in the cumulative incidence of gout in the GPRD population. In the 
abstract they indicated that this was caused by the differences in time 
contributed to the GPRD and that they had developed a statistical method of 
adjusting for this issue. 1 had a number of conversations with Dr Kenneth 
Saag, who was one of the co-investigators in the gout study about this study 
but the method of adjustment remains unclear and to my knowledge, has not 
yet been published. When they published the results of the gout incidence 
and prevalence study in full (Mikuls 2005), they limited their estimation of 
prevalence to one year at the end of the study period (1999) because "data on 
prevalent conditions (those present at time of enrolment into the GPRD) 
were not complete in the early 1990s" (p268). In their study of the effect of
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time since registration on the GPRD on incidence rate measurements, Lewis 
et al (2005) reported that the effect of the time from the left-censoring date to 
identification of an incident case varied according to the type of disease and 
was longest in those with chronic relapsing-remitting diseases.
An area of future methodological research on the GPRD, and indeed 
on any longitudinal database of medical records is to develop a statistical 
model of this issue and to investigate ways in which it can be overcome. In 
the meantime, the interpretation of temporal trends of chronic disease 
prevalence should be made with caution and in the case of relapsing- 
remitting diseases, until the GPRD has matured to the state where a higher 
proportion of practices have at least 10 years of data contribution in their 
record, temporal patterns of disease prevalence cannot be reliably calculated.
Mortality in SLE
During my investigation of the increasing prevalence of SLE, 1 calculated the 
annual mortality rates for the SLE population, armual mortality rate ratios 
compared with those of the GPRD population and the SMR for the entire 
study period (Chapter 9). Bernatsky (2006) published a prospective 
international multi-centre study of mortality in SLE. In their study the 
overall SMR for all centres was 2.4 (CI95 2.3, 2.5) which was a higher point 
estimate than the SMR for females with SLE in the GPRD population which 
was 1.83 (CI95 1.52, 2.20) (Chapter 9). The differences between the SMR from 
the study by Bernatsky and my study of mortality using the GPRD might be
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attributed to inaccurate recording of death on the GPRD, censoring issues or 
by the potential inclusion of more severe cases of SLE in the study by 
Bernatsky, which was conducted in specialist SLE centres. The most 
important finding of my study of mortality in SLE, which was consistent 
with the findings of Bernatsky, was the significantly increased risk of 
mortality in younger patients with SLE.
Studies of survival in SLE have demonstrated an improvement in 
survival over the last 50 years and this has been attributed to improvements 
in the management of active disease as well as complications of treatment 
(e.g. infections) and the earlier diagnosis of SEE (Borchers 2004). However, 
there remains a lack of data regarding the age-specific changes in mortality 
from SLE over time. It is possible that increased awareness of SLE has 
resulted in the diagnosis of patients with milder disease, perhaps at an older 
age that are at decreased risk of dying from the SLE. Until the publication of 
the study by Bernatsky et al (2006), survival statistics for SLE were given for 
SLE populations as a whole. My study of mortality in SLE and the study by 
Bernatsky (2006) highlight the sobering fact that these generalised 
representations of mortality and survival do not reflect the true pattern of 
mortality where young patients are at a greatly increased risk of death from 
their disease. In order to claim steps forward in survival from SLE, temporal 
trends in the age-specific mortality rates should be examined to determine 
whether the battles is being won across aU patient groups, or only amongst 
those with the best prognosis at their time of diagnosis.
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12.3 Presentation of SLE in primary care
I hypothesised that SLE patients would be significantly different from 
members of the general population without SLE in terms of their reported 
symptoms, use of medication and GP consultation rates for at least 12 
months before their date of clinical diagnosis and probably for up to three 
years before diagnosis and that it would be possible to develop age- and 
sex-specific profiles of the clinical presentation of SLE in primary care. 
Patients with SLE were significantly more likely to have cutaneous and 
musculoskeletal symptoms recorded in their medical records in the five 
years before diagnosis (Chapter 10). The positive predictive value of the 
multivariate conditional logistic regression model of constitutional, 
cutaneous, haematological, musculoskeletal, neurological, psychiatric and 
renal symptoms was 59.6% in the third year before diagnosis indicating that 
with some refining based on more accurate recording of test results, this 
model may be implemented as a flagging program within GPs computer 
systems for the identification of SLE.
Ozebek (2003) et al suggested that all young patients with arthritis 
should be carefully screened for SLE. Whilst it seems unlikely that arthritis in 
women of childbearing age would not go iminvestigated if it were reported 
to the GP, it is more likely that perhaps for older patients, especially women 
of menopausal age, arthritis or arthralgia might be considered a symptom 
that is attributed to other causes and therefore not investigated. The 
implication of the study of the SLE presentation is that all patients with
245
arthritis, and certainly those with arthritis and other symptoms suggestive of 
SLE, should be screened for the possibility for SLE whether or not they fit 
into the classical ^women of childbearing age, Afro-Caribbean' patient 
profile. However, screening tests and unnecessary referrals to 
rheumatologists are not only time consuming for the patient and GP but they 
are also are costly. Currently, many National Health Service Trusts are under 
financial pressure. Whilst it is important that the earlier recognition of SLE 
would prevent irreversible organ damage and premature mortaUty 
(Maddison 2002), screening all patients with arthritis would need to be 
carefully evaluated in terms of both its costs and benefits.
Lahita (1999a) and Hughes (2000) have both indicated that the 
pathway to diagnosis for some patients with SLE is made difficult by the fact 
that these patients are led to beHeve that their symptoms are psychosomatic 
and the tendency for some patients, especially those with insidious onset, to 
be labelled as hypochondriacs. Of particular concern was the significant 
difference between cases with SLE and the general population of the GPRD 
in the frequency of recorded of psychiatric symptoms in the five years before 
diagnosis. Although the study lacked sufficient power to investigate this 
issue statistically, anecdotally, most of these patients had depression rather 
than epilepsy or psychosis recorded in their records, some repeatedly so 
before their diagnosis. The examination of 15 of the medical records of 
patients with at least two of the symptom clusters recorded in their records 
for five years before diagnosis revealed that many of these patients had
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depressive disorder recorded before any other physical symptoms associated 
with SLE. Depression in SLE is known to be a neuropsychiatrie manifestation 
rather than solely a reaction to diagnosis (Moore 1999). It could be that in 
patients with depression, the likelihood of their physical symptoms being 
attributed to causes other than their depression might be lower than in those 
without depression. It is essential that patients with depressive disorders 
who develop symptoms such as arthritis and /  or other symptoms related to 
SLE are investigated for the possibility of SLE and are not led to believe that 
their physical symptoms are attributable only to their mood disorder.
Further research in this area may be directed firstly to determine the 
proportion of patients with a record of arthritis and cutaneous symptoms 
that are eventually diagnosed with SLE. Using these data, combined with the 
model developed in my study of the presentation of SLE it may be possible 
to determine whether the implementation of early warning flags built into 
GP computer software would be of potential benefit. Additionally, it would 
be important to determine the value to patients in terms of receiving a 
diagnosis of SLE or to being referred for further investigation by way of 
acknowledging the presence of their symptoms.
Whilst it was possible to confirm that patients with SLE are 
significantly different from members of the general population of the GPRD 
without SLE or rheumatoid arthritis with regards to recording of symptoms 
suggestive of SLE in the five years before diagnosis, it was not possible to 
evaluate the predictive value of prescribing or consultation patterns within
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this model because these variables were positively correlated with symptom 
variables. Additionally, it was not possible to develop age- and sex-specific 
models as there were insufficient cases and, more usually, controls with 
symptoms recorded in their medical records to allow meaningful analyses of 
the data.
12.4 Management of SLE
I hypothesised that management of SLE in primary care would be consistent 
with prescribing patterns for SLE from hospital-based studies.
In Chapter 11 I described consultation and prescribing patterns for patients 
with SLE between 1992 and 1998. Consultation rates increased in the year 
before SLE diagnosis and decreased over the 3 years after diagnosis, perhaps 
indicating the time needed to estabhsh an optimal treatment regimen. 
Prescribing patterns in SLE were generally consistent with those reported in 
the published literature (Barr 1999, Uramoto 1999, Stahl-Hallengren 2000, 
Cervera 2003) with regards to prescribing of corticosteroids, antimalarials, 
immunosuppressants and cytotoxic agents. Prescribing rates for NSAIDs 
were higher in the GPRD population than in the EuroLupus cohort (Cervera 
2003). This difference is almost certainly caused by the fact that in the GPRD 
study I did not differentiate between NSAIDs prescribed for SLE and those 
prescribed for other indications. Prescribing data have been found to be 95% 
complete (Walley 1997) on the GPRD and although it is likely that changes in
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medical therapy of SLE wiU be made by the specialist (Glazier 2002), 
prescriptions are issued by the GP rather than the hospital specialist.
12.5 Use of oral contraceptives in women with SLE
I hypothesised that, as a case study of adherence to oral contraceptive 
prescribing guidelines, the use of combined oral contraceptives would 
decline in women after their date of SLE diagnosis and than overall use 
would be significantly lower than that of the female population of the 
same age who did not have a diagnosis of SLE.
In my study of prescribing patterns of systemic hormonal contraceptives in 
women with SLE I found that, despite their contraindication (BNF 1992), 
utilisation rates of combined oral contraceptives (COG) did not decrease 
following SLE diagnosis and they were the same as utihsation rates of the 
general population of the GPRD in women of the same age. Use of systemic 
progestogen-only contraceptives increased following diagnosis of SLE. 
Since this study was conducted, the results of SELENA have been published 
(Petri 2005). The oral contraceptive arm of SELENA was a randomised 
controlled trial of the safety of a triphasic combined oral contraceptives 
compared with placebo in women with SLE with stable disease. Non- 
smokers under the age of 40 and smokers under the age of 36 were eligible 
for inclusion into the study if they had stable or inactive disease (according 
to the SLE Disease Activity Index (SLEDAl), with or without maintenance 
doses of prednisolone or immunosuppressants and without evidence of
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antiphospholipid antibodies. This study concluded that in women with 
"stable" SLE, combined oral contraceptives were not associated with an 
increased risk of flare or of thrombosis. Prescribing guidelines for COCs 
should now be altered to reflect these findings.
12.6 Conclusions
The conclusions from this investigation of the epidemiology of SLE in the UK 
using the General Practice Research Database are that:
(a) It is not possible to use the ACR criteria for the classification of cases of 
SLE from the GPRD population because symptoms and test results are 
not consistently recorded in the medical records. An algorithm to 
identify cases of SLE was developed for the GPRD population that 
required cases to have a record of diagnosis of SLE (or LE plus evidence 
of systemic disease) plus evidence of the diagnosis being confirmed in 
hospital and /  or long-term therapy consistent with a diagnosis of SLE.
(b) Incident cases of SLE may be rehably identified from the GPRD using a 
combination of the presence of a diagnostic code for SLE or lupus 
erythematosus and evidence of the diagnosis being confirmed in 
hospital or long-term therapy with immunosuppressants, systemic 
corticosteroids or antimalarial agents.
(c) The peak incidence of SLE is in women not only of childbearing age but 
in women of peri- and post-menopausal age, up to 69 years. This is 
consistent with previous studies from predominantly Caucasian
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populations and therefore the classical description of SLE as a "disease 
of women of childbearing age" must be challenged and altered in order 
for the current delay in diagnosis of SLE in older women to be 
rninhnised in the future.
(d) Increasing prevalence of SLE in the GPRD population from 1992 to 1998 
was an artefact caused by a combination of the relapsing-remitting 
nature of the disease and the differing lengths of time that individuals 
contribute data to the GPRD. Based on this finding, researchers using 
observational databases longitudinal medical records should not 
calculate temporal changes in the prevalence of relapsing-remitting 
diseases until a method by which this phenomenon can be controlled 
for statistically has been developed. The calculation of the prevalence of 
chronic relapsing-remitting disease over time using the GPRD should 
be conducted with caution.
(e) SLE remains a disease that is difficult to diagnose but this study may 
contribute to earlier recognition of SLE by GPs for some patients. 
Individuals with an eventual diagnosis of SLE have significantly more 
records of musculoskeletal, cutaneous and psychiatric symptoms 
(mostly depression) than those in the general population of the same 
age in the three years before diagnosis, and for some, for five years 
before diagnosis. The model developed in the study of the presentation 
of SLE may have some clinical application to decrease the delay in 
diagnosis of SLE in primary care. Further research is required to
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determine the proportion of patients with musculoskeletal and 
cutaneous symptoms that develop SLE and the cost effectiveness of the 
implication screening all patients with arthritis for SLE.
(f) The study of mortality in SLE found an SMR for SLE of 1.83. However, 
age-specific mortahty rate ratios indicate a significantly increased risk of 
death in patients under the age of 30 years.
(g) Prescribing guidelines for combined oral contraceptives remain to list 
SLE as a contra-indication for their use. Utilisation rates of COCs in the 
GPRD population show that these prescribing guidelines are not 
adhered to in the majority of cases. In the light of this finding, and 
alongside definitive evidence from SELENA of the safety of COCs in 
women with stable SLE, prescribing guidelines should be altered to 
reflect clinical practice and evidence that COCs are not unsafe in 
women with stable SLE.
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Appendix 2
Example of a Patient Record
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This is an exam ple of the w ay that a patient record from the GPRD looks in the 
Browser software. I h ave annotated this to highlight features of the record of interest 
in terms of the patient's diagnosis of SLE. I have rem oved all of the registration data 
to preserve anonymity.
12 /02 /1970
1 2 /02 /1970
09 /03 /1971
29/07 /1971
08 /09 /1981
0 1 /0 1 /1 9 8 4
2 4 /0 2 /1989
0 1 /0 1 /1990
26 /09 /1991  
Left Censor
20 /1 0 /1992
Dt
20 /1 0 /1 9 9 2
2 7 /10 /1992
27 /10 /1992
2 7 /10 /1992
2 7 /1 0 /1992
2 7 /1 0 /1992
27 /10 /1992
2 8 /1 0 /1992
28 /10 /1992
04 /02 /1993
04/02 /1993
04 /02 /1993
0 4 /0 2 /1993
04/02/1993
Smallpox ( 2120000) fl] » 1000 = First 
Typhoid ( 2130000) [1] » 1000 = First
Diphtheria Tetanus Pertussis & Polio ( 2010111) [2] » 3000 = Third 
Measles ( 2020000) [2] » 1000 = First 
Rubella Vaccine ( 2040200) [12] » 1000 = First 
POLYMYALGIA ( 7179P) [15]
Outcome=Inpatient, hospital discharge summary; Episode=; 
MedFlag=OXMIS code in m edcode field  
Cervical ( 8050000) [20]
IRRITABLE COLON ( 5641RC) [21]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in 
m edcode field  
Cervical ( 8050000) [22]
CO-CODAMOL (96753997) [23]
D osage 8.00 2QDS
Quantity = 40; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
TORTICOLLIS ( 7172) [23]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
Investigations URINE ALBUMIN TRACE ( 13000000) [23]
Alcohol ALCOHOL OCCASIONALLY ( 3050000) [23] » 0 = Units 
Drunk Per W eek
Smoking SMOKER N O N  ( 3040000) [23] » 0 = Number Of Cigarettes 
Smoked per Day
H eight ( 5010100) [23] » 154.94 = Height In ms » 0 = H eight Centile 
Blood Pressure ( 5010500) [23] » 100.00 = Systolic Pressure » 70.00 = 
Diastolic Pressure
W eight ( 5010200) [23] » 61.70 = W eight In Kgs 
MSU (L7891MS) [23]
Outcome=; Episode=; MedFlag=OXMIS code in m edcode field  
Investigations MSU ( 13000000) [23]
Contraception ORAL CONTRACEPTIVE PRESCRIBED ( 2550000)
[24] » 0 = Drug Code Of Contraceptive » 940204 = Date LUCD Fitted 
MEBEVERINE HYDROCHLORIDE (95924998) [24]
Dosage -1.00 ITDSACPRN
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
Blood Pressure ( 5010500) [24] » 125.00 = Systolic Pressure » 85.00 = 
Diastolic Pressure
SYNDROME IRRITABLE BOWEL ( 5641) [24]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field 
SKIN MOLE(S) ( 7571C) [24]
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Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field 
0 4 /0 2 /1993  ETHINYLESTRADIOL+ GESTODENE (96922998) [24]
Dosage -1.00
Quantity= -6; Days= 0; Type=l; NoOrigPacks= 6; PkSize= 0.00 
1 8 /02 /1993  LIGNOCAINE HYDROCHLORIDE (96016998) [24]
Dosage -1.00 EVANS 2ml
Quantity = -1; Days= 0; Type=l; NoOrigPacks= 1; PkSize= 0.00 
18 /02 /1993  Surgicalbraided silk non-abs (99732994) [24]
Dosage -1.00
Quantity= -1; Days= 0; Type=l; NoOrigPacks= 1; PkSize= 0.00 
18 /02 /1993  MOLE REMOVED (K913 EM) [24]
Outcome=Minor Surgery*; Episode=; MedFlag=OXMIS code in 
m edcode field  
1 8 /0 2 /1993  HISTOLOGY (L 161) [24]
Outcome=; Episode=; MedFlag=OXMIS code in m edcode field  
18/0 2 /1 9 9 3  REQUESTS MEDICATION (T3100) [24]
Outcome=Other; Episode=; MedFIag=OXMIS code in m edcode field  
18 /02 /1993  Investigations HISTOLOGY ( 13000000) [24]
18 /02 /1993  MEBEVERINE HYDROCHLORIDE (99816998) [24]
Dosage -1.00 ITDSACPRN
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
05/0 8 /1 9 9 3  ETFHNYLESTRADIOL+ GESTODENE (96922998) [24]
Dosage -1.00 MDS
Quantity= -6; Days= 0; Type=l; NoOrigPacks= 6; PkSize= 0.00 
05 /0 8 /1993  MEBEVERINE FIYDROCHLORIDE (99816998) [24]
Dosage -1.00 ITDSACPRN
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 5 /08 /1993  Blood Pressure ( 5010500) [24] » 120.00 = Systolic Pressure » 80.00 = 
Diastolic Pressure 
1 6 /0 8 /1993  CLEMASTINE (99072998) [24]
Dosage 2.00 IBD
Quantity= 30; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
1 6 /0 8 /1 9 9 3  SKIN RASH ( 7882) [24]
Outcome=Other; Episode=; MedElag=OXMIS code in m edcode field  
2 3 /0 8 /1993  NO  CHANGE (T993) [24]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
2 3 /0 8 /1993  MICONAZOLE+ HYDROCORTISONE (99794998) [24]
Dosage -1.00 APLBD
Quantity= 60; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
18 /0 1 /1 9 9 4  ETHINYLESTRADIOL+ GESTODENE (96922998) [25]
Dosage -1.00
Quantity= 147; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
18/01 /1994 Contraception ORAL CONTRACEIH’iVE PRESCRIBED ( 2550000)
[25] » 0 = Drug Code Of Contraceptive » 950204 = Date LUCD Fitted 
1 8 /0 1 /1994  MEBEVERINE HYDROCHLORIDE (99816998) [25]
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Dosage -1.00 ITDSACPRN
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
18 /01 /1994  Blood Pressure ( 5010500) [25] » 125.00 = Systolic Pressure » 80.00 = 
Diastolic Pressure 
1 9 /0 7 /1994  MEBEVERINE HYDROCHLORIDE (99816998) [25]
Dosage -1.00 ITDSACPRN
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 9 /0 7 /1994  ETHINYLESTRADIOL+ GESTODENE (96922998) [25]
Dosage -1.00
Quantity= -7; Days= 0; Type=l; NoOrigPacks= 7; PkSize= 0.00 
1 9 /0 7 /1994  TERFENADINE (95208998) [25]
Dosage 2.00 IBD
Quantity= 28; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
1 9 /0 7 /1 9 9 4  AMPICILLIN+ FLUCLOXACILLIN (95031998) [25]
Dosage 4.00 IQDS
Quantity= 20; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
19 /07 /1994  Blood Pressure ( 5010500) [25] » 120.00 = Systolic Pressure » 88.00 = 
Diastolic Pressure 
19 /07 /1994  W eight ( 5010200) [25] » 63.06 = W eight In Kgs 
2 4 /0 8 /1 9 9 4  SKIN MOLE(S) ( 7571C) [25]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
2 4 /0 8 /1994  VAGINITIS ( 6221C) [25]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
2 4 /0 8 /1 9 9 4  PERIODS IRREGULAR ( 6265P) [25]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
2 4 /0 8 /1 9 9 4  CLOTRIMAZOLE (96623996) [25]
Dosage -1.00 IPVON
Quantity = 3; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
0 4 /1 0 /1 9 9 4  URGENCY MICTURITION/URINATION ( 7863C) [25]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
0 4 /1 0 /1 9 9 4  STOOLS LOOSE ( 0091AB) [25]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
0 6 /1 0 /1994  Investigations FAECES TEST ( 13000000) [25]
0 6 /1 0 /1 9 9 4  FAECES TEST (L2630F) [25]
Outcome=; Episode=; MedFlag=OXMIS code in m edcode field  
0 6 /1 0 /1 9 9 4  URINE CULTURE (L 133) [25]
Outcome=; Episode=; MedFlag=OXMIS code in m edcode field 
0 6 /1 0 /1994  Investigations URINE CULTURE ( 13000000) [25]
0 9 /1 2 /1 9 9 4  STOOLS LOOSE ( 0091AB) [25]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
0 9 /1 2 /1 9 9 4  URGENCY MICTURITION/URINATION ( 7863C) [25]
Outcome=Outpatient referral; Episode=; MedFlag=OXMIS code in 
m edcode field
2 0 /02 /1995  Contraception ORAL CONTRACEPTIVE PRESCRIBED ( 2550000) 
[26] » 0 = Drug Code Of Contraceptive » 960204 = Date LUCD Fitted
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20/02 /1995  Blood Pressure ( 5010500) [26] » 120.00 = Systolic Pressure » 75.00 = 
Diastolic Pressure 
2 0 /02 /1995  ETHINYLESTRADIOL+ GESTODENE (96922998) [26]
Dosage -1.00
Quantity= -7; Days= 0; Type=l; NoOrigPacks= 7; PkSize= 0.00 
2 0 /02 /1995  MEBEVERINE HYDROCHLORIDE (99816998) [26]
Dosage -1.00 ITDSACPRN
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
20 /02 /1995  MEBEVERINE HYDROCHLORIDE (99816998) [26]
Dosage -1.00 ITDSACPRN
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
2 7 /0 2 /1995  URETHRAL STENOSIS ( 598 N) [26]
Outcom e=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field  
2 2 /03 /1995  CYSTOSCOPY (K608) [26]
Outcome=Inpatient, hospital discharge summary; Episode=; 
MedFlag=OXMIS code in m edcode field  
23/0 3 /1 9 9 5  NITROFURANTOIN (95716996) [26]
Dosage 2.00 IBD
Quantity= 28; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
2 3 /0 3 /1995  REQUESTS MEDICATION (T3100) [26]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 8 /05 /1995  MEDICATION NEW  ADDED (L2021NA) [26]
O utcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field  
0 5 /06 /1995  REQUESTS MEDICATION (T3100) [26]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
0 5 /06 /1995  FLAVOXATE (96536997) [26]
Dosage 2.00 IBD
Quantity = 56; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
2 2 /0 6 /1995  MICTURITION FREQUENCY OF ( 7863A) [26]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field  
10 /07 /1995  OXYBUTYNTN (98043996) [26]
Dosage 2.00 IBD
Quantity= 56; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
14/07 /1995  Cervical ( 8050000) [26] » 2000 = Candida
2 9 /0 8 /1995  MICTURITION FREQUENCY OF ( 7863A) [26]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
2 9 /0 8 /1 9 9 5  FLAVOXATE (96536997) [26]
Dosage 2.00 IBD
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
2 9 /0 8 /1995  ETHINYLESTRADIOL+ GESTODENE (96922998) [26]
Dosage -1.00
Quantity= -7; Days= 0; Type=l; NoOrigPacks= 7; PkSize= 0.00
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2 9 /08 /1995  Blood Pressure ( 5010500) [26] » 120.00 = Systolic Pressure » 80.00 = 
Diastolic Pressure
2 9 /08 /1995  Contraception ORAL CONTRACEPTIVE PRESCRIBED ( 2550000)
[26] » 0 = Drug Code Of Contraceptive » 960220 = Date LUCD Fitted
2 9 /08 /1995  W eight ( 5010200) [26] » 72.81 = W eight In Kgs
1 0 /1 0 /1 9 9 5  SYNDROME CARPAL TUNNEL ( 357 C) [26]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
10 /10 /1995  VAGINITIS ( 6221C) [26]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
10 /10 /1995  CLOTRIMAZOLE (96623996) [26]
Dosage -1.00 IPVO N
Quantity^ 3; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
12/10 /1995  Investigations THYROID FUNCTION TEST ( 13000000) [26]
1 2 /10 /1995  THYROID FUNCTION TEST (L4033F) [26]
Outcome=; Episode=; MedFlag=OXMIS code in m edcode field 
0 1 /11 /1995  SKIN MOLE(S) ( 7571C) [26]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
0 1 /1 1 /1 9 9 5  MEBEVERINE HYDROCHLORIDE (99816998) [26]
Dosage -1.00 ITDSACPRN
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
01 /I I /1 9 9 5  ETHINYLESTRADIOL+ NORETHISTERONE (98207998) [26]
Dosage -1.00
Quantity= 126; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
0 8 /1 1 /1995 LIGNOCAINE HYDROCHLORIDE (98512998) [26]
Dosage -1.00 MARTINDALE
Quantity= -4; Days= 0; Type=l; NoOrigPacks= 4; PkSize= 0.00 
08 /11 /1995  Surgicalbraided silk non-abs (97326994) [26]
Dosage -1.00
Quantity= -2; Days= 0; Type=l; NoOrigPacks= 2; PkSize= 0.00 
0 8 /1 1 /1995  FUSTOLOGY (L 161) [26]
Outcome=; Episode=; MedFlag=OXMIS code in m edcode field  
0 8 /1 1 /1995  MOLE REMOVED (K913 EM) [26]
Outcome=Minor Surgery*; Episode=; MedFlag=OXMIS code in  
m edcode field
08 /11 /1995  Investigations HISTOLOGY ( 13000000) [26]
07/01/1996 NECK PAIN ( 7280AC) [27]
Outcome=Outpatient, Self referral to Accident & Emergency; 
Episode=; MedFlag=OXMIS code in m edcode field  
18/01 /1996  Cervical ( 8050000) [27]
09 /0 4 /1 9 9 6  ETHINYLESTRADIOL+ LEVONORGESTREL (97464998) [27] 
Dosage -1.00
Quantity= -4; Days= 0; Type=l; NoOrigPacks= 4; PkSize= 0.00 
0 9 /0 4 /1996  Smoking SMOKER NO N ( 3040000) [27] » 0 = Number Of Cigarettes 
Smoked per Day
0 9 /0 4 /1996  Blood Pressure ( 5010500) [27] » 125.00 = Systolic Pressure » 85.00 = 
Diastolic Pressure
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0 9 /0 4 /1 9 9 6  Contraception ORAL CONTRACEPTIVE PRESCRIBED ( 2550000)
[27] » 0 = Drug Code Of Contraceptive » 970220 = Date LUCD Fitted 
09 /0 4 /1 9 9 6  AMENORRHOEA ( 6260A) [27]
Outcome=Other; Episode=; MedFIag=OXMIS code in m edcode field 
2 9 /0 4 /1 9 9 6  OXYBUTYNTN (98043996) [27]
Dosage 1.00 lO D M D S
Quantity= 56; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
2 2 /0 7 /1 9 9 6  ETHINYLESTRADIOL+ LEVONORGESTREL (97464998) [27] 
Dosage -1.00
Quantity= -7; Days= 0; Type=l; NoOrigPacks= 7; PkSize= 0.00
2 4 /0 7 /1 9 9 6  Blood Pressure ( 5010500) [27] » 110.00 = Systolic Pressure » 60.00 =
Diastolic Pressure 
2 4 /0 7 /1996  W eight ( 5010200) [27] » 64.42 = W eight In Kgs
24 /0 7 /1 9 9 6  Contraception PILL CHECK ( 2550000) [27] » 0 = Drug Code Of
Contraceptive » 970220 = Date LUCD Eitted 
2 7 /0 1 /1997  ETHINYLESTRADIOL+ LEVONORGESTREL (97464998) [28] 
Dosage -1.00
Quantity = -6; Days= 0; Type=l; NoOrigPacks= 6; PkSize= 0.00 
2 9 /0 1 /1 9 9 7  W eight ( 5010200) [28] » 69.86 = W eight In Kgs
2 9 /0 1 / 1 997 Blood Pressure ( 5010500) [28] » 110.00 = Systolic Pressure » 60.00 =
Diastolic Pressure
2 9 /0 1 /1 9 9 7  Contraception PILL CHECK ( 2550000) [28] » 0 = Drug Code Of 
Contraceptive » 980204 = Date LUCD Fitted 
2 9 /0 1 /1 9 9 7  Cervical ( 8050000) [28] » 16000 = N o Inflammation
1 2 /0 2 /1 9 9 7  PAIN LOW BACK ( 7287A) [28]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 2 /0 2 /1 9 9 7  RHEUMATISM PALINDROMIC ( 7122A) [28]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 4 /0 2 /1 9 9 7  X-RAY LUMBO-SACRAL SPINE (X1040LL) [28]
Outcome=; Episode=; MedFlag=OXMIS code in m edcode field  
14 /0 2 /1 9 9 7  Investigations X-RAY LUMBO-SACRAL SPINE ( 13000000) [28] 
1 4 /0 7 /1 9 9 7  BLISTER SKIN TRAUMATIC ( 9180D) [28]
Outcome=Other; Episode=; MedElag=OXMIS code in m edcode field  
1 4 /0 7 /1997  Blood Pressure ( 5010500) [28] » 110.00 = Systolic Pressure » 76.00 = 
Diastolic Pressure
1 4 /0 7 /1 9 9 7  ETHINYLESTRADIOL+ LEVONORGESTREL (97464998) [28] 
Dosage -1.00
Quantity= -7; Days= 0; Type=l; NoOrigPacks= 7; PkSize= 0.00
18 /0 8 /1 9 9 7  W eight ( 5010200) [28] » 71.68 = W eight In Kgs
1 8 /0 8 /1 9 9 7  POLYARTHRITIS ( 715 B) [28]
Outcome=Other; Episode=; MedElag=OXMIS code in m edcode field 
1 8 /0 8 /1 9 9 7  DICLOFENAC SODIUM (96400998) [28]
Dosage 4.50 U2TDSPC
Quantity= 100; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 4 /0 9 /1 9 9 7  Investigations X-RAY H A N D  (S) ( 13000000) [28]
0 4 /0 9 /1 9 9 7  X-RAY H A N D  (S) (X115) [28]
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Outcome=; Episode=; MedFlag=OXMlS code in m edcode field 
2 4 /1 0 /1 9 9 7  FOLIC ACID (97579998) [28]
Dosage 1.00 lO D
Quantity= 84; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
2 4 /1 0 /1 9 9 7  PRECONCEPTION ADVICE (L6286PR) [28]
Outcome=Other; Episode=; MedElag=OXMIS code in m edcode field  
2 4 /1 0 /1 9 9 7  VERTIGO ( 7805A) [28]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 9 /1 1 /1 997  SCANTY PERIODS ( 6261P) [28]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 1 /1 2 /1 9 9 7  RHEUMATISM PALINDROMIC ( 7122A) [28]
Outcom e=Hospital letter*; Episode=; MedFlag=OXMIS code in 
m edcode field  
30 /1 2 /1 9 9 7  DICLOFENAC SODIUM (96399996) [28]
Dosage 2.00 IBDPC
Quantity = 56; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
3 0 /1 2 /1 9 9 7  POLYARTHRITIS ( 715 B) [28]
Outcome=Other; Episode=C; MedFlag=OXMIS code in m edcode 
field
0 8 /0 1 /1 9 9 8  RHEUMATISM PALINDROMIC ( 7122A) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field
2 8 /0 1 /1998  DICLOFENAC SODIUM& MISOPROSTOL (93085998) [29]
Dosage 3.00 ITDSPC
Quantity= 60; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
2 8 /0 1 /1998 OESOPHAGITIS ( 5309A) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 0 /0 2 /1998  POLYARTHRITIS ( 715 B) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 0 /02 /1998  DYSPEPSIA ( 5369CD) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
10 /02 /1998  OMEPRAZOLE (94411998) [29]
Dosage 2.00 IBD
Quantity = 56; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
11 /02 /1998  DYSPEPSIA ( 5369CD) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field 
2 4 /0 2 /1998  THROAT SORENESS ( 462 AR) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
24 /02 /1998  DICLOFENAC SODIUM& MISOPROSTOL (93085998) [29]
Dosage -1.00 ITDSPRN
Quantity= 60; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
24/02 /1998  CO-CODAMOL (96753998) [29]
Dosage -1.00 2QDSPRN
Quantity= 100; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00
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0 6 /0 3 /1 9 9 8  REACTION ALLERGIC ( 6929G) [29]
Outcome=Outpatient, Doctor referral to Accident & Emergency; 
Episode=; MedFlag=OXMIS code in m edcode field 
17 /0 3 /1998  DIHYDROCODEINE (96379998) [29]
Dosage -1.00 1-2QDSPRN
Quantity= 100; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
1 7 /0 3 /1998  OMEPRAZOLE (94411998) [29]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
1 7 /0 3 /1998  PREDNISOLONE (97155997) [29]
Dosage -1.00 AD
Quantity = 100; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
1 7 /0 3 /1998  TRAMADOL (92677998) [29]
Dosage -1.00 1-2QDSPRN
Quantity = 100; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
1 7 /0 3 /1998 PRESCRIPTION CHANGE (L2021MC) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 9 /0 3 /1 9 9 8  SYSTEMIC LUPUS ERYTHEMATOSUS ( 6954) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field  
1 9 /0 3 /1998  ANGIO-OEDEMA ( 7080AO) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field  
2 5 /0 3 /1 9 9 8  DYSPEPSIA ( 5369CD) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
2 5 /0 3 /1998  TRIPOTASSIUMDICITRATOBISMUTHATE (94084997) [29]
Dosage 4.00 2BD
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
3 0 /0 3 /1 9 9 8  SYSTEMIC LUPUS ERYTFIEMATOSUS ( 6954) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in 
m edcode field  
30 /0 3 /1 9 9 8  PROTEINURIA (L2020PV) [29]
Outcome=Hospital letter*; Episode=C; MedFlag=OXMIS code in  
m edcode field  
02 /04 /1998  OMEPRAZOLE (94411998) [29]
Dosage 1 .5 0 1-20D
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
02 /0 4 /1998  MAGNESIUM HYDROXIDE+OXETACAINE&ALHYDRO 
(99394998) [29]
Dosage 30.00 5-lOMLQDS
Quantity= 400; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 2 /0 4 /1998  METOCLOPRAMIDE (95837998) [29]
Dosage 3.00 ITDS
Quantity = 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 2 /0 4 /1998  MEDICAL CERTIFICATE INTERMEDIATE (T304) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field
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02 /0 4 /1998  METOCLOPRAMIDE (95837998) [29]
Dosage 3.00 ITDS
Quantity = 60; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
0 2 /0 4 /1 9 9 8  HYDROXYCHLOROQUINE SULPHATE (96192998) [29]
Dosage 2.00 IBD
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 2 /0 4 /1998  TRIPOTASSIUMDICITRATOBISMUTHATE (94084997) [29]
Dosage 4.00 2BD
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 2 /0 4 /1 9 9 8  SYSTEMIC LUPUS ERYTHEMATOSUS ( 6954) [29]
Outcome=Other; Episode=; MedPlag=OXMIS code in m edcode field  
0 2 /0 4 /1998  HEARTBURN ( 7843) [29]
Outcome=Other; Episode=; MedPlag=OXMIS code in m edcode field  
0 2 /0 4 /1 9 9 8  PREDNISOLONE (95417996) [29]
Dosage 6.00 60D PC
Quantity= 168; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
2 0 /0 4 /1998  MEDICATION NEW  ADDED (L2021NA) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in 
m edcode field  
28/0 4 /1 9 9 8  OMEPRAZOLE (94411998) [29]
Dosage 1 .501-20D
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
2 9 /04 /1998  DIHYDROCODEINE (96379998) [29]
Dosage -1 .001EV3*6HRPRN
Quantity= 100; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
3 0 /0 4 /1 9 9 8  NEPHRITIS ( 583 A) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in 
m edcode field  
0 1 /0 5 /1998  STOPPED MEDICATION (T914) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field 
0 7 /0 5 /1 9 9 8  BIOPSY (K959 B) [29]
Outcome=Inpatient, hospital discharge summary; Episode=; 
MedFlag=0)bv4IS code in m edcode field  
11/05 /1998  BENDROFLUAZIDE (97217997) [29]
Dosage -1.00 MDS
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
11/05 /1998  DIHYDROCODEINE (96379998) [29]
Dosage -1.00 1EV3*6HRPRN
Quantity= 100; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 1 /05 /1998  PREDNISOLONE (95417996) [29]
Dosage 6.00 60D P C
Quantity= 168; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 1 /05 /1998  METOCLOPRAMIDE (95837998) [29]
Dosage 3.00 ITDS
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Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 4 /0 6 /1 9 9 8  PREDNISOLONE (95417996) [29]
Dosage 6.00 60D P C
Quantity= 168; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
01 /0 7 /1998  HYDROXYCHLOROQUINE SULPHATE (96192998) [29]
Dosage 2.00 IBD
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
01/0 7 /1 9 9 8  BENDROFLUAZIDE (97217997) [29]
Dosage -1.00 MDS
Quantity = 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
13 /07 /1998  PREDNISOLONE (95417996) [29]
Dosage 6.00 60D P C
Quantity= 168; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
01/0 9 /1 9 9 8  HYPOKALAEMIA ( 7887K) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field  
01/0 9 /1 9 9 8  POTASSIUM CHLORIDE (99157998) [29]
Dosage 3.00 ITDSAQ
Quantity = 15; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
0 7 /09 /1998  BENDROFLUAZIDE (97217997) [29]
Dosage -1.00 MDS
Quantity = 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
07 /09 /1998  PREDNISOLONE (95417996) [29]
Dosage 6.00 60D PC
Quantity= 168; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 5 /0 9 /1998  HYPERTENSION ( 401 A) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
1 5 /09 /1998  VISION DISTURBANCE ( 7810) [29]
Outcome=Other; Episode=; MedFlag=OXMIS code in m edcode field  
15/09 /1998  Blood Pressure ( 5010500) [29] » 154.00 = Systolic Pressure » 106.00 = 
Diastolic Pressure 
15/09 /1998  METRONIDAZOLE (95823998) [29]
Dosage 3.00 ITDSPC
Quantity= 21; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
1 2 /10 /1998  OSTEOPOROSIS ( 7230A) [29]
Outcome=Hospital letter*; Episode=; MedFlag=OXMIS code in  
m edcode field 
0 4 /1 1 /1998  PREDNISOLONE (95417996) [29]
Dosage 6.00 60D P C
Quantity= 168; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
04 /11 /1998  BENDROFLUAZIDE (97217997) [29]
Dosage -1.00 MDS
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 9 /11 /1998  CLOPIDOGREL (89385998) [29]
Dosage 1.00 lO D
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Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 9 /1 1 /1998  AZATHIOPRINE (97036998) [29]
Dosage 3.00 ITDS
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 9 /1 1 /1998 PROPHYLACTIC DRUG THERAPY ANTIDOTE (Y44 C) [29]
Outcome=Other; Episode=; MedPlag=OXMIS code in m edcode field  
1 9 /1 1 /1998 CALCITRIOL (96903998) [29]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 4 /1 2 /1998  AZATHIOPRINE (97036998) [29]
Dosage 3.00 ITDS
Quantity= 84; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 4 /12 /1998  CALCITRIOL (96903998) [29]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 4 /1 2 /1998  CLOPIDOGREL (89385998) [29]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
3 1 /1 2 /1998  AZATHIOPRINE (97036998) [29]
Dosage -1.00 MDS
Quantity= 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
31/1 2 /1 9 9 8  BENDROFLUAZIDE (97217997) [29]
Dosage -1.00 MDS
Quantity = 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
31/1 2 /1 9 9 8  CALCITRIOL (96903998) [29]
Dosage 1.00 lO D
Quantity = 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
3 1 /1 2 /1998  PREDNISOLONE (97155998) [29]
Dosage -1.00 MDS
Quantity = 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
31/1 2 /1 9 9 8  CLOPIDOGREL (89385998) [29]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
08/0 2 /1 9 9 9  AZATHIOPRINE (97036998) [30]
Dosage -1.00 MDS
Quantity = 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
08 /0 2 /1 9 9 9  CLOPIDOGREL (89385998) [30]
Dosage 1.00 lO D
Quantity = 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 8 /0 2 /1 9 9 9  CALCITRIOL (96903998) [30]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 1 /0 3 /1 9 9 9  BENDROFLUAZIDE (97217997) [30]
Dosage -1.00 MDS
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00
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0 1 /0 3 /1 9 9 9  CALCITRIOL (96903998) [30]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
01/0 3 /1 9 9 9  PREDNISOLONE (97155998) [30]
Dosage -1.00 MDS
Quantity= 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 1 /0 3 /1 9 9 9  CLOPIDOGREL (89385998) [30]
Dosage 1.00 lO D
Quantity = 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
01 /0 3 /1 9 9 9  AZATHIOPRINE (97036998) [30]
Dosage -1.00 MDS
Quantity= 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
06 /0 4 /1 9 9 9  AZATHIOPRINE (97036998) [30]
Dosage -1.00 MDS
Quantity = 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 6 /0 4 /1 9 9 9  BENDROFLUAZIDE (97217997) [30]
Dosage -1.00 MDS
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 6 /0 4 /1 9 9 9  CALCITRIOL (96903998) [30]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 6 /0 4 /1 9 9 9  PREDNISOLONE (97155998) [30]
Dosage -1.00 MDS
Quantity= 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 6 /0 4 /1 9 9 9  CLOPIDOGREL (89385998) [30]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 6 /0 4 /1 9 9 9  PREDNISOLONE (95417996) [30]
Dosage -1.00 MDS
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
1 6 /0 4 /1 9 9 9  THERAPY REDUCED (L2021MR) [30]
Outcome=Hospital letter*; Episode=; MedFIag=OXMIS code in  
m edcode field  
0 4 /0 5 /1 9 9 9  AZATHIOPRINE (97036998) [30]
Dosage -1.00 MDS
Quantity= 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 4 /0 5 /1 9 9 9  CLOPIDOGREL (89385998) [30]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 4 /0 5 /1 9 9 9  CALCITRIOL (96903998) [30]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 4 /0 5 /1 9 9 9  PREDNISOLONE (97155998) [30]
Dosage -1.00 MDS
Quantity= 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00
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0 6 /0 5 /1 9 9 9  AMITRIPTYLINE FIYDROCHLORIDE (97223998) [30]
Dosage 1.00 INOCTE
Quantity= 56; Days= 0; Type=l; NoOrigPacks= 0; PkSize= 0.00 
0 6 /0 5 /1 9 9 9  PAIN BACK ( 7289CH) [30]
Outcome=Hospital letter*; Episode=; MedFIag=OXMIS code in  
m edcode field  
0 1 /0 6 /1 9 9 9  AZATHIOPRINE (97036998) [30]
Dosage -1.00 MDS
Quantity= 112; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
01/0 6 /1 9 9 9  BENDROFLUAZIDE (97217997) [30]
Dosage -1.00 MDS
Quantity= 56; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
01/0 6 /1 9 9 9  CALCITRIOL (96903998) [30]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00 
0 1 /0 6 /1 9 9 9  CLOPIDOGREL (89385998) [30]
Dosage 1.00 lO D
Quantity= 28; Days= 0; Type=0; NoOrigPacks= 0; PkSize= 0.00
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o
Excellence In Public Health Research
RESTRICTED-COMMERCIAL
Scientific & Ethical Advisory Group
SEAG EVALUATION OF PROTOCOLS
FEED-BACK TO APPLICANTS
CONFIDENTIAL 
PROTOCOL NO: 583
PROTOCOL TITLE: 
APPLICANT:
b y  e - m a i l
Alison Nightingale, Postgraduate Medical School, University of 
Surrey
APPROVED □ APPROVED WITH COMMENTS/ 
RECOMMENDATIONS M
REJECTED/NEEDS REVIEW □
COMMENTS:
It would be useful to know the anicipated size o f Lupus cases to be studies to ensure that sufScient 
number o f cases will be available to carry out the multivariate analysis.
DATE: 22/12/2003
GPRDO
Excellence In Public Health Research
RESTRICTED-COMMERCIAL
Scientific & Ethical Advisory Group
SEAG EVALUATION OF PROTOCOLS 
FEED-BACK TO APPLICANTS
CONFIDENTIAL 
PROTOCOL NO: 762
PROTOCOL TITLE:
APPLICANT:
by e-mail
Alison Nightingale, Department of Pharmacoepidemiology, Post 
Graduate Medical School, University of Surrey
APPROVED
□
APPROVED SUBJECT TO 
MINOR AMENDMENT 
(resubmission not required) ^
REVISION/ 
RESUBMISSION 
REQUESTED □
REJECTED
□
COMMENTS Protocol number 762 is approved with minor amendments. Re submission is 
not required.
The researchers should take note of these comments. The increasing 
prevalence of SLE between 1992 and 1998 may be due to improvements in 
treatment so it would be valuable to collect information on trends in treatment 
over the period.
The list of codes in appendix 2 is very long and covers a very broad range 
including such things as syphilis, epilepsy and requests for strong analgesics 
so there may be many false casés of SLE identified.
DATE: 9 December 20b5..
C:\Documents and Settings\pgms\Local Settings\Temporary Internet Files\OLK8\762_feedback.doc
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Appendix 4a: Adapted critical appraisal questionnaire
Critical appraisal questionnaire adapted from the cohort study and survey critical 
appraisal questionnaires in Crombie's pocket guide to critical appraisal (12).
1. Who was studied?
2. What was the study period?
3. How was the sample obtained?
4. How was the denominator calculated?
5. Are the aims clearly stated?
6. Are the measurements likely to be valid and reliable?
7. Are the statistical methods described?
8. Were the basic data adequately described?
9. Do the numbers add up?
10. What do the main findings mean /  what are the main findings?
11. How could selection bias arise?
12. Can the results be generalised?
13. How do the results compare with previous reports?
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Appendix 4b. Data extraction form
DATA EXTRACTION: EPIDEMIOLOGY OF 
SEE
AUTHOR 
COUNTRY 
STUDY PERIOD 
DENOMINATOR N 
CASES N MALES FEMALES
AGE AT DIAGNOSIS/INITIAL 
MANIFESTATION
CASE DEFINITION
CASE IDENTIFICATION
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COULD CASES HAVE BEEN MISSED?
DENOMINATOR
INCIDENCE
308
PREVALENCE
COMMENTS
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Appendix 4c. Papers excluded from the review at abstract assessment for not
fulfilling the inclusion criteria of the review.
1. Bakimer, R., et al.. The frequency of a common anti-DNA antibody idiotype 
(16/6) in different populations of patients with systemic lupus 
erythematosus. J Rheumatol 1991; 18(7); 1035-7.
2. Bernatsky, S., et al.. Hormonal exposures and breast cancer in a sample of 
women with systemic lupus erythematosus. Rheumatol 2004; 43(9): 1178-81.
3. Bertolaccini, M.L., et al.. Antiprothrombin antibodies detected in two 
different assay systems. Prevalence and clinical significance in systemic 
lupus erythematosus. Thromb Haemost 2005; 93(2): 289.
4. Bessant, R., et al.. Risk of coronary heart disease and stroke in a large British 
cohort of patients with systemic lupus erythematosus. Rheumatol, 2004;
43(7): 924-9.
5. Bruce, I.N., Cardiovascular disease in lupus patients: Should all patients be 
treated with statins and aspirin? Best Prac Res Clin Rheumatol 2005; 19(5 
SPEC. ISS.): 823.
6. Butcher, G.A., Malaria and macrophage function in Africans: a possible link 
with autoimmune disease? Medical Hypotheses 1996; 47(2): 97-100.
7. Cameron, H.A. and L.E. Ramsay, The lupus syndrome induced by 
hydralazine: a common complication with low dose treatment. BMJClin Res 
Ed 1984; 289(6442):410-2.
8. Clark, T.J., et al.. Increased prevalence of dialysis-dependent renal failure in 
ethnic minorities in the west Midlands. Nephrology Dialysis Transplantation 
1993; 8(2):146-8.
9. Courtney, P.A., et al.. Systemic lupus erythematosus and coeliac 
disease.[comment]. Lupus 2004; 13(3):214.
10. El-Magadmi, M., et al. Association of the A561C E-selectin polymorphism 
with systemic lupus erythematosus in 2 independent populations. J 
Rheumatol 2001; 28(12): 2650-2.
11. Evans, D.A., Survey of the human acetylator polymorphism in spontaneous 
disorders. J Med Genet 1984; 21(4): 243-53.
12. Ferreira, S., C.D.P. D, and G.R.V. Hughes, Multiple sclerosis, 
neuropsychiatrie lupus and antiphospholipid syndrome: Where do we 
stand? Rheumatol 2005; 44(4): 434.
13. Gardner-Medwin, J.M., et al. Incidence of Henoch-Schonlein purpura, 
Kawasaki disease, and rare vasculitides in children of different ethnic 
origins. Lancet 2002; 360(9341): 1197-202.
14. Giles, 1. and D. Isenberg, Fatigue in primary Sjogren's syndrome: is there a 
link with the fibromyalgia syndrome? Ann Rheum Dis 2000; 59(11): 875-8.
15. Gill, J.M., et al. Diagnosis of systemic lupus erythematosus. Am Fam Phys 
2003; 68(11): 2179-86.
16. Greenwood, B. and T. Corrah, Systemic lupus erythematosus in African 
immigrants.[comment]. Lancet 2001; 358(9288): 1182.
17. Grennan, D.M. and D. Bossingham, Systemic lupus erythematosus (SLE): 
different prevalences in different populations of Australian aboriginals.[see 
comment]. Aust NZ J Med 1995; 25(2):182-3.
18. Huggins, M.L., I. Todd, and R.J. Powell, Reactivation of Epstein-Barr virus in 
patients with systemic lupus erythematosus. Rheumatol Int 2005; 25(3): 183.
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19. Isenberg, D., Making sure the treatment of myositis does not get "lost in 
translation". Curr Opin Rheumatol 2004; 16(6): 665.
20. Isenberg, D., M. Ehrenstein, and A. Rahman, 'Oh, Come All Ye Faithful': 
acquiring and maintaining a cohort. Rheumatol
21. 2002; 41(1): 5-6.
22. Kamel, M.H., et al.. Rabbit antithymocyte globulin as induction 
immunotherapy for pediatric deceased donor kidney transplantation. J Urol 
2005; 174(2):703.
23. Keat, A., et al., BSR guidelines for prescribing TNF-(alpha) blockers in adults 
with ankylosing spondylitis. Report of a working party of the British Society 
for Rheumatology. Rheumatol 2005; 44(7):939.
24. K h u r a n a ,  R .  and S.M. Bemey, Clinical aspects of rheumatoid arthritis. 
Pathophysiology 2005; 12(3):153.
25. Lakasing, L. and M. Khamashta, Contraceptive practices in women with 
systemic lupus erythematosus and/or antiphospholipid syndrome: what 
advice should we be giving? J Fam Plan Repro Health Care 2001; 27(1):7-12.
26. Lampropoulos, C.E., et al.. Electroencephalography in the assessment of 
neuropsychiatrie manifestations in antiphospholipid syndrome and systemic 
lupus erythematosus. Arthritis Rheum 2005; 52(3): 841.
27. McAlindon, T., et al.. Environmental factors predicting nephritis in systemic 
lupus erythematosus. Ann Rheum Dis 1993; 52(10): 720-4.
28. Minaur, N., et al.. Rheumatic Disease in an Australian Aboriginal 
Community in North Queensland, Australia. A WHO-ILAR COPCORD 
Survey. J Rheumatol 2004; 31(5):965.
29. Moses, N., et al.. Prevalence and correlates of perceived unmet needs of 
people with systemic lupus erythematosus. Patient Education & Counselling 
2005; 57(1): 30-8.
30. Napier, S.S., et al.. Potentially malignant oral lesions in Northern Ireland: 
size (extent) matters. Oral Diseases 2003; 9(3): 129-37.
31. Ong, S.H., SLE and psychiatric morbidity, [see comment] [comment]. Br J 
Psych 1992; 160:420.
32. Pankhurst, T., et al.. Malignancy is increased in ANCA-associated vasculitis. 
Rheumatol 2004; 43(12): 1532-5.
33. Pyne, D. and D.A. Isenberg, Autoimmune thyroid disease in systemic lupus 
erythematosus. Ann Rheum Dis 2002; 61(1): 70-2.
34. Rai, T., et al.. Expression of human glucocorticoid receptor in lymphocytes of 
patients with autoimmune hepatitis. Hepatology Res 2004; 29(3):148.
35. Rankin, E.C. and D.A. Isenberg, IgA deficiency and SLE: prevalence in a 
clinic population and a review of the literature. Lupus 1997; 6(4):390-4.
36. Schattner, A. and Y. Naparstek, The future of the treatment of systemic 
lupus erythematosus. Clin Exp Rheumatol 2005; 23(2):254.
37. Stevens, R.J., et al.. Flares of systemic disease in primary Sjogren's syndrome 
(1). Rheumatol 2005; 44(3):402.
38. Stoll, T., et al.. Association of the Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology Damage Index with measures of 
disease activity and health status in patients with systemic lupus 
erythematosus. J Rheumatol 1997; 24(2):309-13.
39. Sultan, S.M., S. Begum, and D.A. Isenberg, Prevalence, patterns of disease 
and outcome in patients with systemic lupus erythematosus who develop 
severe haematological problems. Rheumatol 2003; 42(2): 230-4.
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40. Sultan, S.M., Y. loannou, and D.A. Isenberg, Is there an association of 
malignancy with systemic lupus erythematosus? An analysis of 276 patients 
under long-term review. Rheumatol 2000; 39(10): 1147-52.
41. Sutcliffe, N., et al.. The association of socio-economic status, race, 
psychosocial factors and outcome in patients with systemic lupus 
erythematosus. Rheumatol 1999; 38(11): 1130-7.
42. Tam, L.S., et al.. Increased prevalence of squamous intraepithélial lesions in 
systemic lupus erythematosus: Association with human papillomavirus 
infection. Arthritis Rheum 2004; 50(11): 3619.
43. Tansey, D., et al.. Variations in histological patterns of interstitial pneumonia 
between connective tissue disorders and their relationship to prognosis. 
Histopathology 2004; 44(6): 585.
44. Thomas, T.D.C., et al.. The impact of infection on the incidence of 
autoimmune disease. Current Topics in Medicinal Chemistry 2004; 4(5): 521.
45. Vasoo, S. and G.R.V. Hughes, Perspectives on the changing face of lupus 
mortality. Autoimmunity Rev 2004; 3(6): 415.
46. Yee, C.S., et al. Prevalence and predictors of fragility fractures in systemic 
lupus erythematosus. Ann Rheum Dis 2005; 64(1): 111-3.
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Appendix 4d Studies excluded after assessment of the full text.
1. Feehally, J., et al.. Disease variations in Asians in Leicester. QJM1993; 86(4): 
263-9.
This paper was excluded because it did not report incidence or prevalence rates of 
SLE.
2. Hopkinson, N., Epidemiology of systemic lupus erythematosus. Ann Rhuem 
Dis 1992; 51(12): 1292-4.
This paper was excluded because it is a review of the literature
3. Hopkinson, N.D., et al.. Distribution of cases of systemic lupus 
erythematosus at time of first symptom in an urban area. Ann Rheum Dis 
1995; 54(11): 891-5.
This paper was excluded because it is a study of the geographical distribution of 
incident cases of SLE rather than a report of the incidence rates in Nottingham.
4. Johnson, A.E., et al.. Cross-sectional analysis of the differences between 
patients with systemic lupus erythematosus in England, Brazil and Sweden. 
Lupus 1994; 3(6): 501-6.
This paper was excluded as it reports the difference in characteristics of lupus 
patients rather than incidence or prevalence of SLE.
5. Johnson, A.E., et al.. Undiagnosed systemic lupus erythematosus in the 
community. Lancet 1996; 347(8998): 367-9.
This paper was excluded as it is a survey of undiagnosed SLE in the community, it 
is a pilot study of 3 cases with poor response rate.
6. Samanta, A., et al.. High prevalence of systemic disease and mortality in 
Asian subjects with systemic lupus erythematosus. Ann Rheum Dis 1991; 
50(7): 490-2.
This paper was excluded as it reports on the clinical manifestations and mortality 
rates in Asians with SLE in Leicester rather than incidence or prevalence of SLE
7. Symmons, D.P., Review of UK data on the rheumatic diseases-8. SLE. Br J 
Rheumatol 1991; 30(4): 288-90.
This paper was excluded because it is a review of the literature
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Table 1. Codes for which the comments fields were reviewed but that were not used 
directly for classification purposes.
Codes to check conmients
OXMSCODE
2759P PARAPROTEIN AEMIA
280 A ANAEMIA HYPOCHROMIC
280 B ANAEMIA IRON-DEFIOENCY
280 D ANAEMIA ACHLORHYDRIC
280 F ANAEMIA MICROCYTIC
2810 PA (PERNICIOUS ANAEMIA)
2810A ANAEMIA COMBINED SYSTEM DISEAS
2810DB ANAEMIA B12-DEFICIENCY
2819 ANAEMIA DEFICIENCY
2819MC MACROCYTIC ANAEMIA
2826A ANAEMIA SIDEROBLASTIC
284 ANAEMIA APLASTIC
284 HC ANAEMIA HYPOPLASTIC
2859 ANAEMIA
2859C ANAEMIA SECONDARY
2859H CHRONIC ANAEMIA
2859NM ANAEMIA NORMOCYTIC
2859RF ANAEMIA OF RENAL FAILURE
2869C DEFECT COAGULATION
2869CA PLATELET AUTO AGGLUTINATION
2870B PURPURA IDIOPATHIC
2879D BRUISING SPONTANEOUS
2899 BLOOD DISORDER
2899LC LEUCOCYTOSIS
2899MD IMMUNE DISORDER
2982 MENTAL CONFUSION PSYCHOTIC/REA
3009A PSYCHIATRIC DISORDER
3009AM MENTAL DISTURBANCE
3009F MENTAL DISORDER
3019PC PSYCHOPATHIC PERSONALITY
3059AA PSYCHOPHYSIOLOGICAL DISORDER
315 H MENTAL DEFECTIVE
344 BR HEMIPLEGIA RIGHT
3919CN CARDITIS RHEUMATIC
398 RHEUMATIC HEART DISEASE CHRONI
420 RL PERICARDITIS VIRAL
422 N MYOCARDITIS UNKNOWN ORIGIN
423 TM PERICARDIAL TAMPONADE
428 B MYOCARDHIS
4464TP PURPURA THROMBOTIC
5110FB PLEURISY FIBRINOUS
5192D LUNG DISEASE
581N NEPHROSIS
5900P PYELITIS CHRONIC
5900PN CHRONIC PYELONEPHRITIS
5901 PYELITIS
5901NA PYELONEPHRITIS ACUTE
5901PN PYELONEPHRITIS
5901PR PYONEPHROSIS
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Codes to check comments
OXMSCODE TEXT
592 RT RENAL/URETERIC STONE
5932 ABNORMALITY RENAL
5932A RENAL DISEASE
5932AK KIDNEY DISEASE
5932AP NEPHROPATHY
5932AT KIDNEY TROUBLE
5932EA IMPAIRMENT RENAL
5932L RENAL THRESHOLD LOW
5932NF NON-FUNCnONING KIDNEY
5932RN RENAL INSUFFICIENCY
6349 COMPUCATION PREGNANCY
6439HB ABORHON HABITUAL
6449A ABORTION INEVHABLE
6449B ABORTION INCOMPLETE
6449C ABORTION
6928AB SUNBURN
6928AE SUNLIGHT ADVERSE EFFECT
6928AM ERYTHEMA SOLARE
6928AR RASH LIGHT ERUPTION
6929EA SKIN ALLERGY
6929FN SENSITIVITY
6929H ECZEMA DISCOID
6929MR MACULAR RASH
6950A ERYTHEMA ANNULARE
6951 ERYTHEMA MULTIFORME
6952 ERYTHEMA NODOSUM
6953 ROSACEA
6954 Il u p u s  e r y t h e m a t o su s
6954C SLE CELLS
6954EL LUPUS ERYTHEMATOSUS LOCAL
6959B ERYTHRODERMA
6959E Ie r y t h e m a
6960 ARTHROPATHY PSORIATIC
6960T ARTHRITIS PSORIATIC
6989RT ITCH WITH RASH
702 A IsKIN DERMATOSIS
709 [d iso r d e r  SKIN
709 P SKIN LESION
710 JI jlNFLAMMATION JOINT
7123 1 ARTHRITIS RHEUMATOID
7150SN j ARTHRITIS SERO NEGATIVE
7179PR jpOLYMYALGIA RHEUMATICA
7179T jpAIN
7179TG {GENERALISED PAIN
7179TM MULTIPLE PAINS
718 {RHEUMATISM
718 AH HAND(S) RHEUMATISM
718 BH RHEUMATISM HANDS ACUTE
718 C fRHEUMATICS
729 ND {d ise a se  JOINT
7339D {MUSCULOSKELETAL DISORDER ILL-D
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Codes to check comments
OXMSCODE TEXT
7339WH HANDS WEAK
7341 O LE (DISSEMINATED LUPUS ERYT
7341A SYSTEMIC LUPUS ERYTHEMATOSUS W
7341AA LUPUS ERYTHEMATOSUS SYSTEMIC
7341AC ACUTE SYSTEMIC LUPUS ERYTHEMAT
7341AD LUPUS ERYTHEMATOSUS ACUTE
7531 POLYCYSTIC DISEASE KIDNEY
7531PA POLYCYSTIC DISEASE KIDNEY ADUL
7571ED ERYTHEMA ANNULARE CENTRIFUGUM
780 NEUROLOGICAL SYMPTOMS
7837AT CHEST PAIN ATYPICAL
7837B CHEST PAIN
7837BM CHEST PAIN MUSCULAR
7837C RIB PAIN
7860K PAIN KIDNEY
7860KA PAIN RENAL
7871RH RHEUMATIC PAIN
7873A PAIN JOINT
7873AH JOINT ACHE
7873DH ACHE JOINTS
7874 JOINT SWELLING
7882 RASH (SKIN)
7882E SKIN ERUPTION
7882ND RASH NOT YET DIAGNOSED
9779 ABNORMAL REACTION DRUG
9894BI BITES INFECTED
9977KT KIDNEY TRANSPLANT REJECTION
145..00 H/O: blood disorder
14F..00 H/O; skin disorder
14P200 H/O: steroid therapy
14V2.00 H/O: renal dialysis
16B2.00 Bruises easily
16B3.00 Spontaneous bruising
182..00 Chest pain
182B.00 Rib pain
1012.00 C/O: stiffness
1013.11 Pain
1014.00 C/O: a rash
2127.00 Patient's condition worsened
2227.00 O /E  - rash present
2227.11 O/E - allergic rash
2C2..00 O /E - anaemia
2H6..00 O /E - joint stiffness
2114.00 O /E - a rash
337..00 Lung function testing
337..11 Lung function tests
4....00 Laboratory procedures
4....12 Test - laboratory
41...11 Investigation - lab.,general
41...13 Result, lab.- general
4142.00 Blood sample > Haematol Lab
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Codes to check comments
4143.00 {Blood sample -> Biochem Lab j
4145.00 Blood sample > Lab NOS |
419..00 Lab. test result abnormal
424..00 Full blood count - FBC
4241.00 Full blood count normal
424200 Full blood count borderline
4243.00 Full blood count abnormal
42P..00 Platelet count
42Q..12 Clotting tests
42Q2.00 Coag./bleeding tests abnormal
42QE000 INR - international normal ratio normal
42QS.00 Clotting screen
43...00 Immunology
437..11 Coombs test
4382.00 Syphilis titre test positive
43G..00 AutOantibody titres
43G1.00 Anti-nuclear factor
43G1.11 Anti-nuclear antibody
43G8.00 Serum IgM anticardiolipins level
43GD.00 Lupus circulating anticoagulant index
43GE.00 Lupus anticoagulant screen
43GT.00 Serum anti-cardiolipin level
43I..00 Complement test
4311.00 Complement -third component-C3
4312.00 Complement-fourth component-C4
43Z..00 Immunology NOS
43Z6.00 Antibody studies
4512.00 Renal function tests abnormal
461..11 MSU - general
4617.00 MSU = abnormal
4674.00 Urine protein test = +
4675.00 Urine protein test = ++
4J...00 Microbiology
4K1..00 Histology
4K11.00 Tissue sent for histology
4K13.00 Histology normal
4K1Z.00 Histology NOS
5675.00 CAT scan - brain
66H..12 Rheumatism monitoring
66H2.00 Rheumat. follow-up assessment
66H3.00 |Rheumat.dis.- joints affected
66R5.11 {Prescription dose change
69C2.00 {individual psych, exam.
6A1..11 {Reviewed at hospital
7065200 {Nerve conduction studies
7B00.00 |Transplantation of kidney
7B00100 {Transplantation of kidney from live don*
7B00z00 {Transplantation of kidney NOS
7B04000 {other open pyeloplasty
7B06000 {Open renal biopsy
7G09.00 {other destruction of lesion of skin of *
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Codes to check comments
o x M s t .o n i TEXT
7G0C.00 Other biopsy of skin
7G0Cz00 Other biopsy of skin NOS
7L17.00 Blood withdrawal
7L17200 Blood withdrawal for testing
8A2..00 Psychiatric monitoring
8A6..11 Kidney function monitoring
8B31100 Medication given
8B31300 Medication commenced
8B31311 Medication started
8B31400 Medication review
8B31600 Medication changed
8B3A100 Medication increased
8B3A200 Medication decreased
8B3A300 New medication commenced
8B3A311 New medication added
8H4B.00 Referred to rheumatologist
9EV2.00 Medical report received from hospital
9Nlh.OO Seen in haematology clinic
9N lm .ll Seen in renal clinic
9N10.00 Seen in rheumatology clinic
9N1S.00 Seen in dermatology clinic
9N36.00 Letter from specialist
9N36.11 Letter from consultant
9ND..OO Incoming mail processing
9ND..11 Incoming mail
9ND1.00 Haematology report received
9ND3.00 Microbiology report received
9ND7.00 Histopathology report received
9NDZ.00 Incoming mail NOS
A742100 Coxsackie pericarditis
A97..11 Syphilis
C39..00 Disorders of the immune mechanism
D20..00 Aplastic anaemia
D21..00 Other and unspecified anaemias
D214.00 Chronic anaemia
D21Z.00 Anaemia unspecified
D30Z.00 Coagulation defect NOS
D312z00 Nonthrombocytopenic purpura NOS
D3630N EMGNORMAL (ELECTROMYOGRAPHY
D9912 NEUROLOGICAL INVESTIGATION
E....00 Mental disorders
E210.00 Paranoid personality disorder
F22Z.00 Hemiplegia NOS
F253.il Status epilepticus
G22z.ll Renal hypertension
G41z.ll Chronic cor pulmonale
G80..00 Phlebitis and thrombophlebitis
G802.00 Phlebitis and thrombophlebitis of the 1*
G80y.ll Phlebitis and/or thrombophlebitis of il*
G80yz00 Other phlebitis and thrombophlebitis NOS
G80Z.00 Phlebitis and thrombophlebitis NOS
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Codes to check comments
OXMSCODE
H51..00 Pleurisy
H58Z.00 Lung disease NOS
HSyy.OO Other diseases of respiratory system NEC
H5yz.00 Other diseases of respiratory system NOS
K06..00 Renal failure unspecified
KIOO.OO Chronic pyelonephritis
KlOyOOO Pyelonephritis unspecified
KlOylOO Pyelitis unspecified
K138z00 Renal vascular disorders NOS
K13Z.00 Kidney and ureter disease NOS
K5602 BIOPSY KIDNEY
K561 NEPHROSTOMY
K5632AA PYELOLHHOTOMY
K565 • NEPHRECTOMY
K566 KIDNEY TRANSPLANT
K566AA RENAL TRANSPLANT
K5671 NEPHRECTOMY PARTIAL
K568P PYELOPLASTY
K568PL PYELOPLASTY LEFT
K579 KIDNEY OPERATION
K5871K RENAL CATHETERISATION
K5875 PYELOGRAM RETROGRADE
K771 ABORHON INCOMPLETE CURETTAGE
K920 BIOPSY SKIN
K959B BIOPSY
K959BA BIOPSY ABNORMAL
K981 CEREBRAL SCANNING
K986K SCANNING KIDNEY
L2MR MICROBIOLOGY REPORT
L3HA HISTOLOGY REPORT ABNORMAL
L3HN HISTOLOGY REPORT NORMAL
L3HR HISTOLOGY REPORT
L19TA INVESHGATION (ABNORMALTTY FOU
L19TN INVESTIGAHON NORMAL
LIOIAA BLOOD PROHLE
LIOIAC BLOOD PROFILE ABNORMAL
L116 DIRECT COOMBS TEST
L116D INDIRECT COOMBS TEST ABNORMAL
L116N DIRECT COOMBS TEST NORMAL
L126A RENAL FUNCHON TEST
L126B RENAL FUNCTION TEST NORMAL
L126C RENAL FUNCHON TEST ABNORMAL
L126G CREATININE CLEARANCE TEST
L126I CREATININE CLEARANCE TEST ABNO
L127B VDRLTESTPOSmVE
L127FA SYPHILIS TEST POSIHVE
L131AA URINE INVESTIGAHONS
L131AC URINE INVESHGAHONS ABNORMAL
L133MA MSU ABNORMAL
L146N PLATELET COUNT
L146NA PLATELET COUNT ABNORMAL
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Codes to check comments
o x M S c o n i: TEXT
L147AB LEUCOCYTES TOTAL ABNORMAL
L147AN LEUCOCYTES TOTAL NORMAL
L147GA LYMPHOCYTE COUNT
L147GC LYMPHOCYTE COUNT ABNORMAL
L147SA FULL BLOOD COUNT ABNORMAL
L147SN FULL BLOOD COUNT NORMAL
L147T BLOOD COUNT
L147TA BLOOD COUNT ABNORMAL
L148 LUPUS ERYTHEMATOSUS CELLS
L149C COAGULATION TIME
L149CP CLOTTING SCREEN
L149CR CLOTTING SCREEN ABNORMAL
L149F CLOTTING TIME
L149QA INR NORMAL
L149QB INR ABNORMAL
L151E SERO NEGATIVE RHEUMATOID ARTHR
L151EA RHEUMATOID FACTOR
L151F RHEUMATOID FACTOR POSITIVE
L155NA AUTOANTIBODY HTRE
L155P AUTOANTIBODY TTTRE POSITIVE
L155SM ANTIBODIES SMOOTH MUSCLE PRESE
L161 HISTOLOGY
L161N HISTOLOGY NORMAL
L166B PYELOGRAM INTRAVENOUS NORMAL
L167PG ABNORMALITY SEEN
L177A LUNG FUNCTION TEST
L177AA LUNG FUNCHON TEST ABNORMAL
L177AN LUNG FUNCHON TEST NORMAL
L185C ANHCONVULSANT LEVEL HIGH .
L185CC CARBAMAZEPINE LEVEL HIGH
L185CP PHENYTOIN LEVEL HIGH
L185LC CARBAMAZEPINE LEVEL
L185LP PHENYTOIN LEVEL
L185VA VALPROATE LEVEL LOW
L185VB VALPROATE LEVEL THERAPEUHC
L185VC VALPROATE LEVEL HIGH
L917CL REPORT RECEIVED FROM CLINIC
L917HR LETTER RECEIVED FROM HOSPITAL
L9170R REPORT RECEIVED FROM OUTPAHEN
L917R LETTER RECEIVED
LOOOl TEST LABORATORY
LOOOIAB ABNORMAL TEST RESULT
L0002A RESULTS GIVEN
LOOIOAA SEEN IN DERMATOLOGY CUNIC
LOOIOAL SEEN IN RENAL CUNIC
LOOIOAW SEEN IN RHEUMATOLOGY CLINIC
LOOIOBB SEEN IN HAEMATOLOGY CLINIC
LOOIOBX SEEN IN SPECIAL CLINIC
LOOIOEA REFERRED TO DERMATOLOGY CUNIC
LOOIOEL REFERRED TO RENAL CLINIC
LOOIOEU REFERRED TO PSYCHOLOGICAL MEDI
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.  ^Codes to check comments .  ' _ ,
OXMSCODE
LOOIOEW REFERRED TO RHEUMATOLOGY CLINI
LOIOOAI REVIEWED AT HOSPHAL
LOIOOAS REFERRED TO SPECIALIST
L1090 ABNORMAL RESULT OF INVESTIGATI
L1141N CREATININE BLOOD LEVEL
L1510A RA SCREEN
L1510N RA SCREEN NEGATIVE
L1510P RA SCREEN POSITIVE
L2020PV PROTEINURIA
L2021A MEDICATION GIVEN
L2021AC MEDICATION TO BE CONTINUED
L2021AR MEDICATION GIVEN REDUCING COUR
L2021MC MEDICATION CHANGED
L2021MI MEDICATION INCREASED
L2021NA MEDICATION NEW ADDED
L2021PC PRESCRIPTION CHANGES
L2021TC THERAPY CHANGED
L2401DU URINE TEST 24 HOURS
L2892AB ABNORMAL RESULT BLOOD CHEMISTR
L2979D PARANOID DELUSIONS
L3579S NERVE CONDUCTION STUDY
L6290A SEROLOGY
L6290FP SEROLOGY FALSE POSITIVE
L6290NG SEROLOGY NEGATIVE
L6651N ANTINUCLEAR ANTIBODIES
L6651NA ANF (ANTINUCLEAR FACTOR)
L6652AA ANTIBODY TEST
L6652AE ANTIBODY STUDIES
L6652AG ANTIBODY STUDIES ABNORMAL
L6652AH AUTO-IMMUNE PROFILE
L6652DB ANTIBODIES AGGLUTINATING PRESE
L6652DQ ANTIBODIES ANTI-SMOOTH MUSCLE
L6652EG ANTIBODIES AUTO-IMMUNE PRESENT
L7873JP JOINT PROBLEM
L7890T URINE TEST
L8691AB COAGULATION TEST RESULT ABNORM
L8691B CLOTTING TEST
L8899 BLOOD TEST
L8899AB HAEMATOLOGY ABNORMAL
M0...00 Skin and subcutaneous tissue infections
M 12zlll Discoid eczema
M15..00 Erythematous conditions
M151.00 Erythema multiforme
M151000 Erythema armulare
M152.00 Erythema nodosum
M153.00 Rosacea
M154.00 Lupus erythematosus
M154400 Lupus erythematosus profundus
M154700 Subacute cutaneous lupus erythematosus
M154z00 Lupus erythematosus NOS
MlSyzOO Other erythematous conditions NOS
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Codes to check comments
OXMSCODE TEXT
M15Z.00 Erythematous conditions NOS
M1Z..00 Skin and subcutaneous tissue inflammato*
M22Z.00 Other dermatoses NOS
M2y4z00 Other specified skin disorder NOS
MZyz.OO Other skin and subcut tissue disease NOS
M 2yz.ll Skin lesion
M2z0.00 Skin lesion
Mz...00 Skin and subcutaneous tissue disease NOS
Connective tissue diseases
NOOO.OO Systemic lupus erythematosus
NOOOOOO Disseminated lupus erythematosus
N000300 Systemic lupus erythematosus with organ*
NOOOzOO Systemic lupus erythematosus NOS
N04..11 Inflammatory polyarthropathy
N040.00 Rheumatoid arthritis
N040P00 Seronegative rheumatoid arthritis
N040T00 Flare of rheumatoid arthritis
N053512 Hip osteoarthitis NOS
N090400 Joint effusion of the hand
N094.00 Pain in joint - arthralgia
N2...00 Rheumatism, excluding the back
N20..00 Polymyalgia rheumatica
N240000 Rheumatism unspecified
N240300 Rheumatic pain
Nz...00 Musculoskeletal and cormective tissue d*
R065.00 [DJChest pain
R065000 [DJChest pain, unspecified
R065z00 [DJChest pain NOS
S5y3.00 Rib sprain
T3101 REQUESTS POWERFUL ANALGESICS
T539 CHRONIC DISEASE
T914C MEDICATION REVIEW
T914RS MEDICATION RESTARTED
T922R MEDICAL REPORT RECEIVED
T9231 WORSENED GENERAL CONDITION
T9231AW WORSE
T9262 VERY ILL
T927MT ADMITTED MENTAL HOSPITAL
X960 CT SCAN
X960A CT SCAN ABNORMAL
X960N CT SCAN NORMAL
X9601 CATSCAN
X9601AB CAT SCAN ABNORMAL
Y060JQ LUNG FUNCTION CLINIC
YIOOOMR MEDICAL REVIEW
Y119PA PSYCHIATRIC ASSESSMENT
Y1190AC HOSPITAL ADMISSION MENTAL HEAL
Y19A LABORATORY TEST
Y1900AA LABORATORY TEST ABNORMAL
Y1900AD LABORATORY TEST DUE
Y1900AN LABORATORY TEST NORMAL
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Codes to check comments
OXMSC 01)1 TEXT
Y1900AS LABORATORY TEST SENT
Y1900DO LABORATORY TEST DONE
Table 2. Malar rash
Materish ___________
IMALARRASH
Malar rash was mainly coded from the comments field.
Table 3. Discoid rash
Discoid rash
jOXMSCODL TEXT
16954ED LUPUS ERYTHEMATOSUS DISCOID
|6954ND DISCOID LUPUS
|L7882D DISCOID RASH
IM154100 Discoid lupus erythematosus
Table 4. Photosensitivity
Phutobensithilv
OXMSCODE TEXr
6928AD PHOTODERMATOSIS
6928AG DERMATITIS SUNLIGHT
6928AL ALLERGY LIGHT
6928AP PHOTOSENSITIVITY
M127300 Photodermatitis
M127400 Photosensitiveness
Table 5. Oral ulcers
Ulcers
OXMSCODE TEXT
508 TC ULCER THROAT
5282L ULCER APHTHOUS ORAL
5282M ULCER APHTHOUS MOUTH
5289C MOUTH ULCER
5289LP ULCER PALATE
5290LT ULCER TONGUE
J08211 Mouth ulcer
L5289U ULCER GUM
Table 6. Arthritis
TEXT
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Non-erosive arthritis
OXMSCODE
711 ARTHRITIS SPINE ACUTE
711 F ARTHRITIS ACUTE HNGER
7120DA JUVENILE ARTHRITIS
7149A ARTHRITIS RHEUMATIC
715 A ARTHRITIS
715 AG ARTHRITIS GENERAUSED
715 B POLYARTHRITIS
715 C ARTHRHIS CHRONIC
715 W ARTHRITIS WRIST
715 WA ARTHRHIS SHOULDER
7171PA ARTHRHIS PERIARTHRITIS SHOULD
7179PA PERIARTHRHIS
729 J ARTHROPATHY
7873AL ARTHRALGIA
7873DM POLYARTHRALGIA
14G..11 H/O: arthritis
66H..11 Arthritis monitoring
N042z00 Rheumatoid arthropathy + visceral/syste*
N044.00 Chronic post-rheumatic arthropathy
N04yl00 Sero negative arthritis
N065.il Polyarthropathy NEC
N065zll Polyarthritis
N066100 Unspecified monoarthritis of the should*
N06Z.00 Arthropathy NOS
N 06z.ll Arthritis
N094000 Arthralgia of unspecified site
N094100 Arthralgia of the shoulder region
N094400 Arthralgia of the hand
N094500 Arthralgia of the pelvic region and thi*
N094600 Arthralgia of the lower leg
N094700 Arthralgia of the ankle and foot
N094900 Arthralgia of multiple joints
N094K00 Arthralgia of hip
N0Z..00 Arthropathies NOS
Cases had to have a diagnosis of arthritis recorded in their records in the absence of 
a code for osteoarthritis. Where a code for arthalgia was used, cases must have also 
had a record of joint swelling or effusion.
Table 7. Serositis
• Serositis .............................
OXMSCODE TEXr
3910AN PERICARDITIS ACUTE
393 R RHEUMATIC PERICARDITIS
420 EF PERICARDIAL EFFUSION
420 NA PERICARDHIS NONSPEOFIC ACUTE
423 A PERICARDHIS
423 Œ PERICARDHIS CHRONIC NONRHEUMA
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Serositis
lOXMSCODi 1 EXT
5110 PLEURISY
15112 EFFUSION PLEURAL
I5199PR RUB PLEURAL
I7837A PAIN PLEURITIC
11825.00 Pleuritic pain
lG50z.00 Other and unspecified acute pericarditis
IH51Z.00 Pleural effusion NOS
Table 8. Renal disorder
Renal disorder
1 OXMSCODE
580 ACUTE NEPHRITIS
580 GD GLOMERULONEPHRHIS DIFFUSE ACU
581 NEPHROTIC SYNDROME
581GN MEMBRANOUS GLOMERULONEPHRITIS
582 NT NEPHRITIS INTERSTITIAL CHRONIC
583 A NEPHRITIS
583 B NEPHRITIS GLOMERULONEPHRITIS
583 PC GLOMERULONEPHRHIS FOCAL
583 FL GLOMERULOSCLEROSIS FOCAL
583 GA GLOMERULONEPHRHIS ACUTE
583 MA MESANGIOCAPILLARY GLOMERULONEP
583 MB GLOMERULONEPHRHIS MEMBRANOUS
583 MN NEPHROPATHY MEMBRANOUS
583 PR GLOMERULONEPHRITIS PROLIFERATI
583 RP GLOMERULONEPHRHIS RAPIDLY PRO
5932E FAILURE RENAL
5932EC CHRONIC RENAL FAILURE
7341AB NEPHRITIS LUPUS
K01..00 Nephrotic syndrome
KOlz.00 Nephrotic syndrome NOS
K02..00 Chronic glomerulonephritis
K02..11 Nephritis - chronic
K030.00 Proliferative nephritis unspecified
K031.00 Membranous nephritis unspecified
K03y000 Other nephritis and nephrosis in diseas*
K03Z.00 Unspecified glomerulonephritis NOS
K05..00 Chronic renal failure
K9503 DIALYSIS ARTERIOVENOUS
K9503AA RENAL DIALYSIS
K9503AB HAEMODIALYSIS
T924HA DIALYSIS
Table 9. Neurologie disorder
o x M s c o n i l
Neurological «lisordoi
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Neurological disorder
OXMSCODJ TEXT
7802 CONVULSION
2953A PARANOID SCHIZOPHRENIA
2959 SCHIZOPHRENIC PSYCHOSIS
2970P PARANOID PSYCHOSIS
299 PSYCHOTIC ILLNESS
3450PM EPILEPSY PETIT MAL
3450T EPILEFHC ABSENCE
3451 GRAND MAL EPILEPSY
3453A JACKSONIAN SEIZURE/FIT/EPILEPS
3453T TEMPORAL LOBE EPILEPSY
3459 EPILEPSY
3459BA IDOPATHIC EPILEPSY
3459F EPILEPTIC ATTACK
7802E SEIZURE
7802FT FH (MEANING SEIZURE)
7818 HALLUCINATIONS
7818A HALLUCINATIONS AUDITORY
7818HC HALLUCINATED BY VOICES BEHAVIO
7818L HALLUCINATIONS VISUAL
1B1E.00 Hallucinations
1B63.00 Had a fit
667..00 Epilepsy monitoring
6675.00 Fit frequency
EOOz.00 Senile or presenile psychoses NOS
E10..00 Schizophrenic disorders
Eu22011 [XJParanoid psychosis
Eu2z.ll [XJPsychosis NOS
F25..00 Epilepsy
F251000 Grand mal (major) epilepsy
F255011 Focal epilepsy
R003.00 [DJConvulsions
R003zll [DJSeizure NOS
T4042 POOR INSIGHT INTO PSYCHOTIC CO
T4044 PSYCHOTIC CONDHION NO INSIGHT
Table 10. Haematologic disorder
Haematological disorder
OXMSCODE
2829 ANAEMIA HAEMOLYTIC
2830 ACUTE HAEMOLYTIC ANAEMIA
2839B AUTOIMMUNE HAEMOLYTIC ANAEMIA
2871 THROMBOCYTOPAENIA
2871A THROMBOCYTOPAENIC PURPURA
2871B THROMBOCYTOPAENIC ANAEMIA
2871C IDIOPATHIC THROMBOCYTOPAENIA
288 A LEUKOPAENIA
2899LL LYMPHOPENIA
D1...GG Haemolytic anaemias
D313012 FTP - idiopathic thrombocytopenic purpu*
D315.00 Thrombocytopenia NOS
D400A00 Leucopenia
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Haematological disorder
GXMSCOOr TEXl’
D40y300 Lymphopenia
Haematologic disorder was mainly coded from the comments field. 
Table 11. Immunologic disorder
43G7.00 DNA binding autoantibodies
43H..00 iL.E. cells
L148P 1LE CELLS PRESENT
L6652DI ANTIBODIES ANTI-DNA PRESENT
Immunologic disorder was mainly coded from the comments field. 
Table 12. Antinuclear antibodies
Antinuclear antibodies
OXMSCODE
L6651H INCREASED ANTINUCLEAR ANTIBODI
L6652EF ANTIBODIES ANTINUCLEAR PRESENT
Antinuclear antibodies were mainly coded from the comments field.
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Appendix 6
OXMIS and Read Codes used for coding in the study of 
Presentation of SLE in Primary Care
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Appendix 6. OXMIS and Read Codes used for coding the study of the 
presentation of SLE in primary care.
The following codes were used to classify symptoms recorded in the medical 
records in the five years before date of SLE diagnosis /  index date.
Key to the table:
Column name Description
Medcode OXMIS /  Read Code
Description Text description of the OXMIS or Read Code
MSKEL Musculoskeletal symptoms
1 = Arthritis
2 = Arthralgia
3 = Other joint symptoms
4 = Myositis
5 = Myalgia (including fibromyalgia)
6 = Tendonitis /  synovitis
7 = General aching
SKIN Cutaneous symptoms
1 = Malar rash
2 = Discoid rash
3 = Photosensitivity
4 = Nasopharangeal and oral ulcers
5 = Alopecia
6 = Raynauds phenomenon
7 = Sjoegren's syndrome
7 = Dry eyes /  dry mouth
8 = Urticaria
9 = Vasculitis
10 = Other rash /  purpura
CONST Constitutional symptoms
1 = Fatigue /  malaise
2 = Fever
3 = Weight loss
4 = General /  multiple symptoms
5 = Postviral fatigue
HAEM Haematological symptoms
1 = Anaemia
2 = Thrombocytopaenia
3 = Leucopenia
4 = Lymphopenia
CASTRO Gastrointestinal symptoms
1 = Nausea
2 = Vomiting
3 = Abdominal pain
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Column name Description
CARDIO Cardiac symptoms
1 = Pericarditis
2 = Pericardial rub
3 = Pericardial effusion
4 = Myocarditis
5 = Endocarditis
NEURO Neurological symptoms
1 = Migraine
2 = Cluster headaches
3 = Peripheral neuropathy
4 = Cranial neuropathy
PSYCH Psychiatric and psychological symptoms
1 = Psychosis
2 = Seizures
3 = Depression
4 = Anxiety
5 = Neurosis (including phobia)
6 = Agoraphobia
7 = Memory loss
8 = Confusion
PULM Pulmonary symptoms
1 = Pleurisy
2 = Pleural rub
3 = Pleural effusion
4 = Pulmonary fibrosis
RET Reticuloendothelial symptoms
1 = Lymphoadenopathy
2 = Splenomegaly
3 = Hepatomegaly
GYNAE Gynaecological symptoms
1 = Miscarriage
2 = Habitual miscarriage
3 = Pre-eclampsia
4 = Foetal death
THROMB Thrombosis
1 = Antiphospholipid syndrome
2 = Acute myocardial infarction
3 = Cerbrovascular accident
4 = Other arterial thrombosis
5 = Deep vein thrombosis /  pulmonary embolism
6 = Superficial venous thrombosis
RENAL Renal symptoms
1 = Nephritis
2 = Nephrotic syndrome
3 = Haematuria
4 = Proteinuria
5 = Cellular casts in urine
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